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ABSTRACT
Calcium (Ca2+) regulates various biological and pathological functions via calcium dynamics and
interacting with key calcium binding proteins such as the calcium sensing receptor (CaSR). In this
dissertation, the first X-ray structure of the extracellular domain of CaSR was determined by
engineering mammalian expression systems. The revealed Ca2+/Mg2+ and Trp derivative L1,2,3,4-tetrahydronorharman-3-carboxylic acid (TNCA) binding sites and key determinants
contribute to the functional cooperativity of CaSR in cells.

Magnesium (Mg2+) acts as a

heterotropic cooperative co-agonist with calcium to co-activate the function of CaSR, including
calcium oscillations. TNCA potentiates CaSR co-activation and recovers a loss of function caused
by mutation at the dimer interface calcium binding site. Several mutations of the main Ca2+/TNCA
binding site at the hinge region eliminate CaSR activity. Mutations S272A and D216N at the hinge
region lead to a loss of Ca2+ binding and complete loss of cooperative binding for Tb3+ using

vi

bacterially expressed protein and Trp-sensitized FRET assay. Efforts in the development of new
CaSR therapeutics using structure-based drug design were also explored.
Next, we aimed to monitor endoplasmic/sarcoplasmic reticulum (ER/SR) mediated subcellular
Ca2+ dynamics using our designed calcium sensors CatchER+ and CatchER+-JP45. Using highly
inclined laminated optical (HILO) microscopy, we report calcium dynamics in the ER/SR with
differential calcium responses to 4-cmc for release and recovery indicating differential Ca2+
signaling from Ca2+ and protein expression subcellular microdomains. We find Ca2+ dynamic
differences between the localized high Ca2+ release region of the junctional SR for E-C coupling
with targeted CatchER+-JP45 to ryanodine receptor over the global Ca2+ ER/SR regulation of
CatchER+ sensor. To understand ER Ca2+ dynamics in neurons, we utilized our sensor CatchER+
and high-resolution HILO imaging to show that 100 µM DHPG induced mGluR1/5 activation
leads to IP3R Ca2+ release as well as Ca2+ uptake throughout the soma and dendrites. The
differential release and uptake for the ER Ca2+ dynamics in response to DHPG indicates subcellular
microdomains throughout the neurons as well. These sensors will significantly impact Ca2+
dynamics research and molecular basis of ER Ca2+ related diseases by exposing Ca2+ dynamics,
function, mobility, and trafficking in the ER/SR.

INDEX WORDS: Calcium sensing receptor, CaSR, G-protein coupled receptor, GPCR,
Genetically encoded calcium indicator, GECI, Calcium, Green fluorescence protein, GFP,
CatchER, CatchER+, Calcium signaling, Protein crystallization, ER, SR, HILO, JP45, CatchER+JP45, STORM, Calcium dynamics
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1.1

Introduction

Calcium as a Critical Physiological Ion

Calcium (Ca2+) is the most prevalent metal ion in the human body. Ca2+ is a critical ion for cell
function and signaling, not only for complex eukaryotic multicellular organisms, but also in
unicellular organisms as Ca2+ is the messenger for life and death[1, 2]. Ca2+ is a first messenger
binding to proteins on the plasma membrane such as the calcium sensing receptor (CaSR) in order
to induce intracellular Ca2+ release from the ER in oscillations. Ca2+ oscillations with different
frequencies communicate many biological functions [1].

Figure 1.1 – Calcium oscillations signal processes inside the cell.
Ca2+ oscillations inside the cell relate to the function of cell-based oscillation
frequency where high frequency oscillations (red) do fast processes, and slower
frequency oscillations (black) do slower processes.
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The rate of Ca2+ oscillations depends on cell type and expressed proteins present (Figure 1.1). Low
frequency intracellular Ca2+ oscillations signal slower processes such as fertilization or cell growth
and fast processes such as dendritic growth or insulin secretion are signaled by fast frequency
intracellular Ca2+ oscillations (Figure 1.1).

The dynamics of Ca2+ from extracellularly to

intracellularly and to cellular organelles is an intricate and complex system.

1.2

Calcium Dynamics and Cellular Signaling

Calcium is a critical ion in the body for a plethora of cellular functions such as muscle contraction,
fertilization, activating of enzymes, and gene regulation. A fluctuation in cell concentrations may
also have dire consequences where high Ca2+ levels in the cell are toxic and results in apoptosis.
Intracellular calcium concentration, [Ca2+]i, is found at low levels ~100 nM, whereas extracellular
calcium concentration, [Ca2+]o, is much higher at 1.1-1.8 mM, and even up to 40 mM in the bone
environment. Organelle Ca2+ concentration can vary with the endoplasmic/sarcoplasmic reticulum
(ER/SR) being the major intracellular Ca2+ storage organelle with ER [Ca2+] at 0.5-1.0 mM Ca2+
concentrations vary throughout the whole cell system. Extracellular calcium changes from 1.1 to
1.8 mM, intracellular calcium fluctuates from 0.1 μM to 10 μM depending on if in the resting or
excited states, respectively (Figure 1.2).
Since Ca2+ is such a critical cellular messenger, the [Ca2+] extracellularly, intracellularly, and in
organelles is tightly regulated. Changes in [Ca2+] from 1.1-1.8 mM to 2-3 mM can trigger
intracellular and extracellular signaling cascades and as such the Ca2+ homeostasis within the cell
is tightly regulated. While these are the general [Ca2+] found in most cell types, there is differential
[Ca2+] found in specific cell types, such as cells in the bone have [Ca2+]o up to 40 mM and [Ca2+]SR
of skeletal muscle cells have up to 50 mM stores[3]. These levels initially came in to play when
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Ca2+ was naturally selected as a critical cellular messenger and phosphate became the energy
standard. The formation of insoluble Ca2+ phosphate reduces the bioavailability of phosphate and
calcium for intracellular signaling. Cytosolic [Ca2+] is kept in the μM range, or lower[2], and
fluctuations outside of these concentrations can lead to an increased [Ca2+]i which will lead to
apoptosis[1].
Ca2+ binds to various types of calcium binding proteins (CaBPs) including calsequestrin (CaSQ),
to buffer Ca2+ concentration, or the Ca2+ sensing receptor (CaSR) to read the changes in [Ca2+]o to
initiate downstream intracellular signaling cascades. The Ca2+ levels within the cellular organelles
also vary dramatically. The ER/SR is the major intracellular Ca2+ store and is critical for protein
synthesis and muscle contraction.
The intricate intracellular regulation of Ca2+ levels involves Ca2+ trigger proteins such as
calmodulin (CaM), channels such as inositol (1,4,5)-trisphosphate receptor (IP3R) and the
ryanodine receptor (RyR), and pumps such as sarco/endoplasmic reticulum calcium-ATPase
(SERCA).

It also involves various buffer proteins such as calbindin in the cytosol and

calsequestrin in the ER. Specific organelle Ca2+ concentrations also fluctuate, with the highest
concentrations of Ca2+ being in the ER/SR, often referred to as the Ca2+ storage of the cell.
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Figure 1.2 – Calcium signaling inside the cell.
Ca2+ signaling dynamics in the cell to communicate the Ca2+ homeostasis between the
high [Ca2+] extracellularly in the mM range and the low [Ca2+] intracellularly in the
µM range is regulated by a multitude of proteins as well as by the internal organelle
Ca2+ storage in the ER/SR in the mM range. These proteins operate in a variety of
differing rates of Ca2+ transport from the millisecond (ms) to seconds (s) range. On
the plasma membrane are channels that either remove Ca2+ from the cytosol to
maintain the µM [Ca2+]i or that bring Ca2+ back into the cytosol from the [Ca2+]o. The
plasma membrane Ca2+ ATPase (PMCA), the sodium-calcium exchanger (NCX), and
the potassium-dependent sodium-calcium exchanger (NCKX) are just a few proteins
which pump Ca2+ out of the cell in exchange for energy (ATP) or gradient transfer
(Na+/K+). On the other hand, proteins such as store-operated channels (SOCs),
transient receptor potential (TRP) channels, and voltage-gated calcium channels
(VGCCs) deliver Ca2+ from the extracellular into the cytosol. [Ca2+]i concentration is
also further regulated by ER proteins such as the IP3R, RyR, and SERCA pump with
either release Ca2+ from the ER/SR into the cytosol or pump Ca2+ back into the
ER/SR, respectively. Additionally, GPCRs such as CaSR can sense [Ca2+]o and lead
to a production of IP3, which then binds the IP3R and release ER/SR [Ca2+] into the
cytosol. The [Ca2+]i is also regulated by the mitochondria by the mitochondrial
calcium uniporter (MCU) and the NCX/hydrogen-calcium exchanger (HCX) whereas
the Golgi is regulated by IP3R, RyR and secretory pathway Ca2+-ATPase (SPCA).

Ca2+ oscillations and transients also regulate cellular function through their frequency and
amplitude, where the rate of frequency or the time frame of Ca2+ signaling can indicate to the cell
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the appropriate response. A quick and rapid frequency, of a few seconds or milliseconds, can
initiate muscle contraction in muscle cells while a slower and measured frequency, of 10-20 hours,
can lead to cell division response[1]. Ca2+ can regulate the cell through transients or oscillations,
Ca2+ sparks or whole cell Ca2+ waves, which can also pass intracellularly between cells for such
processes as wound healing or insulin secretion[1].
The amplitude and release kinetics of Ca2+ from the ER/SR via protein channels such as the RyR
and IP3R can indicate a vast variety of functional roles, such as excitation-contraction (E-C)
coupling during muscle contraction[4] (Figure 1.2). The mitochondria, as the energy production
center of the cell, keeps a Ca2+ store in the low micromolar range. This Ca2+ store in the
mitochondria to communicate with the plasma membrane and ER/SR by controlling its release
kinetics of Ca2+ stores[5]. The ER/SR and mitochondria have a role in regulating Ca2+ homeostasis
by directly communicating with each other through electrostatic connections in a microdomain.
This homeostatic regulation is done by regulation of Ca2+ increases in the mitochondrial matrix,
which in turn activated several enzymes necessary for energy production. This leads to increased
ATP production in the mitochondria, further showing how the mitochondria are the powerhouse
of the cell. In contrast, having prolonged increased Ca2+ concentration can lead to cell death via
apoptosis[6]. Such temporal and spatial regulation of [Ca2+] and signaling is partially regulated by
CaBPs, which can vary by having different Ca2+ binding affinities depending on their cellular
environments. For instance, calmodulin, an indispensable cytosolic CaBP with four helix-loophelix Ca2+ binding motifs (EF-hand), can respond to [Ca2+]i with a large Ca2+ induced
conformational change, this change then can regulate many target proteins through binding[7]. Ca2+
signaling is monitored by extracellular and internal Ca2+ stores. The calcium sensing receptor
(CaSR) is a transmembrane protein which binds extracellular Ca2+ and signals ER [Ca2+] release
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into the [Ca2+]i or inhibition to regulate overall Ca2+ homeostasis. Therefore, understanding CaSR
mediated disease through the structure, Ca2+ binding, and functional signaling can help to
understand the Ca2+ mediated molecular basis for disease regulated by CaSR Ca2+ dynamics.
Extracellular Ca2+ enters the cell through receptor-operated channels (ROCs), store-operated
channels (SOCs), and voltage-operated channels (VOCs). The majority of Ca2+ signaling is
generated by internal Ca2+ stores, such as the ER/SR through release channels RyR and IP3R[8]. A
collapse in the communication of Ca2+ signaling, channel function modification by mutations, or
hyperactivity of the system has been linked to various diseases and conditions, such as heart
failure[9],[10]. Additionally, the divergent nature of the ER/SR with variable expression of the
smooth ER, rough ER, and the SR depending on the cell types leads to the conclusion that the
ER/SR does not uniformly store or signal Ca2+. Thus, there is an unmet need for a methodology
and targeted Ca2+ sensors to study the ER/SR Ca2+ dynamics of these subcellular microdomains to
confirm their existence in cells, skeletal muscles, and neurons and be able to investigate the effects
these microdomains have on the cellular system in normal and disease states.

1.3

Ca2+ Binding Proteins

Ca2+ has an ionic radius of 0.99 Å. The binding geometry of Ca2+ can vary from 3 to 8, but most
predominately prefers a 7-coordination geometry of pentagonal bipyramidal[2, 11]. Ca2+ binding
proteins read subtle Ca2+ changes and communicate these variations to other proteins, organelles,
and cells.

Ca2+ sensor proteins include calmodulin, CaSR, synaptotagmin, S-100, troponin C,

annexins, STIM, etc. Ca2+ buffering proteins includes calreticulin, calsequestrin, parvalbumin,
etc.[2].
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The most common calcium binding proteins bind calcium with a helix-loop-helix calcium binding
motif called the EF-hand motif[12]. There are more than 50 EF-hand subfamilies including CTER
(Calmodulin, Troponin C, and Essential Regulatory light chain proteins), CPR (Calcineurin B,
p22, Recoverin proteins), the S100 subfamily, and other common proteins such as parvalbumin
and aequorin[13]. EF-hand proteins can be composed of multiple EF-hand motifs, Calmodulin
(CaM) is made up of four EF-hands in order to bind up to four Ca2+. While most EF-hand binding
proteins consist of EF-hand pairs, there are instances where there is an odd number of EF-hands,
but it is much less occurrence. Troponin C (TnC) is very similar to CaM since they are in the same
EF-hand family CTER which both have 4 EF-hand motifs. Although their structures are incredibly
similar, these two CaBPs have very different functions. Where CaM modulates a variety of
functions, the only purpose for TnC is to bring together troponin I and T for excitation-contraction
(E-C) coupling in muscles for muscle contraction. The calcium binding ability and cooperativity
of the Ca2+ binding EF-hand motifs in a multitude of CaBPs are essential for their differential
cellular functions[14].
CaBPs also contains calcium binding sites formed by discontinuous calcium ligand residues for a
variety of regulatory and functional purposes. Ca2+ ATPases bind Ca2+ in exchange for ATP
dephosphorylation in order to pump Ca2+ against the Ca2+ gradient. Ca2+ ATPases pump Ca2+
either outside of the cell through the plasma membrane or into the ER/SR. The most prevalent
Ca2+ ATPases are the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump and plasma
membrane Ca2+ ATPase (PMCA). Maintaining the Ca2+ homeostasis and gradients is important
to be able to utilize cellular signaling with Ca2+. Annexins are another large CaBP type which
does not utilize the EF-hand domain and has 16 subfamilies A1-A16[15]. Annexins interact with
proteins on the cytosolic plasma membrane as well as inside of the cytosol, even including CaBPs
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such as S100[3]. C2 domains, e.g., synaptotagmin and copines, are another type of CaBP with over
100 sequences. These proteins interact with membranes and proteins and are commonly found
binding to enzymatic domains[3].
There are also CaBPs specific for the endoplasmic and sarcoplasmic reticulum (ER/SR) such as
the Ca2+ buffering protein calsequestrin (CaSQ) found in the SR as well as the chaperone proteins
calnexin and calreticulin in the ER to specify proteins for retention or degradation. Together
calnexin and calreticulin help to regulate the correct protein folding as well as glycoprotein quality
control. The SR can hold up to 50 mM Ca2+ for the necessary rapid Ca2+ release and refilling
required for muscle contraction and release in skeletal and cardiac muscle, but a majority of this
Ca2+ is bound to CaSQ[3]. In order to regulate such a high concentration of Ca2+ in the ER/SR, the
calreticulin and CaSQ CaBPs are present to bind Ca2+ and hold it until ready for release through
the RyR. CaSQ Ca2+ buffering keeps the SR free Ca2+ concentration closer to 1 mM similar to ER
but with the extra Ca2+ bound to CaSQ, whereas the ER has Ca2+ bound to calreticulin[3].
Additionally, in order to keep the low cytosolic Ca2+ levels, the internal cell organelles have
personal Ca2+ stores. Organelles such as the ER/SR have one of the largest stores at 0.1-1 mM
range, while the mitochondria also have its own store for energy production at nM to μM range.
Cellular signaling can be highly dependent on CaBPs, and Ca2+ gradients and fluctuations in these
gradients, as well as CaBPs functionality disruption, can cause relevant physiological diseases.

1.4

Family C G-protein Coupled Receptors (GPCRs)

G-protein coupled receptors (GPCRs) are the largest family of membrane bound proteins. These
proteins are known for their seven transmembrane helices (7TM) which all sub-families of the
GPCR superfamily contain this signature trait. Additionally, all GPCRs have an N-terminal
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extracellular domain (ECD), a C-terminal intracellular domain (ICD), as well as three extracellular
loops (ECL1-3) and three intracellular loops (ICL1-3) which connect the 7TM helices. Currently,
over 800 GPCRs have been discovered, but the exact size of the GPCR superfamily is still not
known[16, 17]. Half of these known GPCRs have been found to regulate sensory functions such as
olfactory, pheromones, taste, and light perception while the other half of the GPCRs have been
shown to mediate cellular signaling through activation of ligands varying from small ions to small
compounds, peptides, and even other proteins[16, 17]. In humans, there are three major classes of
GPCRs, family A the Rhodopsin-like class, family B the Secretin receptor class, and family C the
glutamate class. Family A GPCRs (aGPCR) is the largest group and the most thoroughly studied
classified by its 7TM domain and shorter ECD and ICD regions. aGPCRs have 19 sub-families
which include such proteins as chemokine receptors, angiotensin receptors, opioid receptors,
melatonin receptors, P2 purinergic receptors (P2YR), cannabinoid receptors, rhodopsin receptors,
dopamine receptors, and histamine receptors (H1R) to name a few[18]. Family B GPCRs (bGPCR)
have a moderated ECD domain and three sub-families with such proteins as the calcitonin receptor,
the parathyroid hormone receptor, secretin receptor, GPR56 orphan receptor, and diuretic hormone
receptor[19]. Family C GPCRs (cGPCR) include metabotropic glutamate receptors (mGluRs), the
calcium-sensing receptor (CaSR), the gamma-amino-butyric acid type B (GABAB) receptors, as
well as three taste type 1 receptors[20]. The cGPCRs are classified by their large ECD where ligand
binding occurs.

1.5

The Calcium Sensing Receptor

The calcium-sensing receptor (CaSR/CaR) belongs to the superfamily class C from the G-coupled
protein receptor family, cGPCR[21]. Before the discovery of CaSR, Ca2+ was mainly considered
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as a crucial second messenger thought to only regulate function through rapid, yet efficient,
alterations in the intracellular calcium. After the discovery of CaSR in 1993 by Dr. Edward M.
Brown who had cloned the receptor that is primarily responsible for this type of regulation from
bovine parathyroid gland[22], it was realized that Ca2+ could also act as a first messenger. When
Ca2+ plays a role as the first messenger for the CaSR, it integrates calcium signaling from changes
in the extracellular Ca2+ concentration ([Ca2+]o) to intracellular signaling networks that are
critically important for many physiological processes by cooperatively responding to small
changes in [Ca2+]o to activate multiple signaling pathways. The CaSR has a topology of a
dominantly large extracellular N-terminus domain (ECD), seven transmembrane helices, and an
intracellular C-terminus. The CaSR regulates the narrow fluctuations allowable in calcium balance
through the parathyroid glands and the production of the parathyroid hormone (PTH). This protein
is a potential target for such diseases as hyperparathyroidism, hypoparathyroidism, bone diseases,
tetany, osteoporosis, kidney stones, kidney failure, etc. The CaSR binds calcium, in addition to
other drug targets, other metals, and amino acids[23, 24]. The GPCR class C family of proteins has
been shown to function similarly while the specific end goals may differ. Ca2+ homeostasis
between the intracellular and extracellular, as well as through the whole body, is mainly regulated
by the CaSR. CaSR is a family C G-protein coupled receptor (cGPCR) which binds Ca2+
extracellularly and then initiates its coupled G-protein to cause a downstream production of
inositol trisphosphate (IP3) which binds the IP3 receptor (IP3R) releasing Ca2+ from the ER in
oscillations. The activation of CaSR leads to a release of Ca2+ from the ER which then induces
the inhibition the parathyroid hormone (PTH), while inhibition of CaSR leads to a decrease in
serum Ca2+ levels and this induces PTH production. PTH production activate the kidneys to
reabsorb more Ca2+ and producing active vitamin-D which prompts the intestines to uptake more
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Ca2+, in severe cases Ca2+ will also be absorbed from the bone engendering osteoporosis, all of
this raises Ca2+ blood serum levels prompting the activation of CaSR and inhibition of PTH
stopping these reactions until the blood Ca2+ levels drop again.

1.5.1

The CaSR induced intracellular calcium oscillation and signaling

The GPCR class C family of proteins has been shown to function similarly while the specific
downstream signaling responses differ (Figure 1.3). The CaSR is activated on the extracellular Nterminus end of the heptahelical transmembrane protein by binding of activators such as calcium,
magnesium, glutamate, amino acids, drugs, etc. This activated protein then associates with the
alpha, beta, gamma complex to break off the G protein Gq, alpha-q in Figure 1.3, to activate
phospholipase C (PLCβ). PLCβ then converts phosphatidylinositol bisphosphate (PIP2) into
diacylglycerol (DAG) and inositol trisphosphate (IP3). DAG activates protein kinase C (PKC) and
downstream effectors while IP3 activates the release of Ca2+ from the ER by binding to the IP3R.
The IP3R releases Ca2+ from the ER in an oscillation pattern, where the frequency of oscillation
can affect the function of the cell for fast processes such as insulin secretion in the seconds range
or slow processes such as fertilization in the minute range[25-28]. In addition to the Gq pathway
GPCRs and CaSR can be activated through the Gi pathway for cAMP inhibition and the Gs
pathway for increased cAMP production, although the G-protein pathway utilized by CaSR can
depend on ECD binding partners or cell type for G-proteins present[29].
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Figure 1.3 – A diagram of the CaSR signaling pathway.
The CaSR is shown in the VFT domain in dimer form bound to calcium in the hinge
region and with other agonists/antagonists. This shows the general pathway for
GPCR superfamily C proteins. After binding to an agonist, this activated protein then
associates with the alpha, beta, gamma complex to break off the G protein Gq, alphaq in the image below, to activate phospholipase C, PLCβ. PLCβ then converts
phosphatidylinositol bisphosphate, PIP2, into diacylglycerol, DAG, and IP3. DAG
activates PKC and downstream effectors while IP3 activates the release of Ca2+ from
the ER.

1.5.2

Diseases of CaSR and mutation

Unlike other families of GPCRs, the majority of cGPCRs size and functionality resides in the large
ECD. Over 390 mutations on CaSR that have been found in disease states such as familial
hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT) which
reduce CaSR’s sensitivity to [Ca2+]o, whereas activating mutations of autosomal dominant
hypocalcemia (ADH) as well as carcinomas. Of the 390 mutations over 225 mutations are in the
ECD alone, accounting for over 57% of the disease-causing mutations for CaSR. Since the Ca2+
binding to CaSR has long been shown through binding assays and mutation studies to bind in the
ECD, it comes as no surprise that many disease mutations occur in this critical domain of the
receptor. Additionally, if looking at the diseases associated directly with dysfunction in the Ca2+
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homeostasis from CaSR mutations (FHH, ADH, and NSHPT) there are 216 mutations for CaSR
and 134 mutations in the ECD alone, accounting for 62% of the mutations. Due to the lack of a
determined CaSR crystal structure, the location of drug binding is still unknown. Thus, although
there are several drugs which target CaSR and one which is FDA approved, cinacalcet, no studies
have been able to show where these compounds definitively bind and can only be done with
mutational studies on the proposed binding regions based on computational binding studies.

1.5.3

Challenges in studying the CaSR

The challenges in studying the CaSR are diverse and in multitudes. First, the CaSR is a membrane
protein, so the challenges associated with membrane proteins may also occur to the CaSR.
Membrane proteins are difficult to separate from the cells due to their hydrophobic transmembrane
domain. Also, heating may cause aggregation and thus reduce the solubility of the protein.
Secondly, X-ray crystallography has been used as one of the major tools to study the structure of
proteins, but in a glycosylated protein, such as the CaSR, it is difficult at best. Like other
glycosylated proteins, the complex form of the glycans on the CaSR can prevent the crystallization
of this protein because they usually inhibit crystallization. Moreover, the selectivity of the CaSR
for different amino acids is not apparent and the interaction between amino acids and the CaSR
are relatively weak, in the mM range.
Currently, methods for direct measurement of Ca2+ and amino acid binding to the CaSR have not
yet been well established, nor are there methods for directly monitoring ligand-induced
conformational changes of the proteins. Approaches for addressing these questions rely on indirect
measurements of calcium-induced intracellular signaling changes in living cells or utilizing the
Fluorescence Resonance Energy Transfer (FRET) assay for monitoring ligand generated
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fluorescence changes in isolated proteins. Last, but not least, the large size of the protein,
extracellular domain 612 amino acids; whole protein 1078 amino acids, and the fact that the CaSR
functions as a dimer, contribute to the difficulties in studying the protein.

1.6

Calcium Related Disorders

The disruption in Ca2+ homeostasis can lead to a host of issues since Ca2+ is necessary for such
functions as muscle contraction, cardiac function, and bone formation. Here, Ca2+ disease states
regulated by the major Ca2+ storage organelle the ER/SR and neurodegenerative diseases will be
discussed. Dysregulation of Ca2+ leads to many disease states, homeostasis disease states by the
Ca2+ homeostasis regulator CaSR is outlined more specifically in Chapter 2 and 3.

1.6.4

Differential expression of key CaBPs and ER/SR related disorders

There are three major membrane proteins on the surface of the ER/SR which regulate the Ca2+
homeostasis of the ER Ca2+ store. These three proteins are the ryanodine receptor (RyR), the
inositol triphosphate receptor (IP3R), and the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA)
pump. The RyR and IP3R both release Ca2+ from the ER/SR into the cytosol while the SERCA
pump brings Ca2+ back into the ER/SR. Each of these ER/SR membrane proteins have different
isoforms for differential expression in varying tissue types for Ca2+ regulation (Table 1.1).
RyR1 is expressed in skeletal muscle, brain cerebellum, and hippocampus[30]. RyR2 is expressed
in the heart muscle, brain cerebellum, and hippocampus, as well as in the placenta[9, 30, 31]. RyR3
is expressed more broadly than RyR1 and RyR2, having been found in such regions as liver,
kidney, brain, placenta, and skeletal muscle. RyR3 in the brain is found to be most highly
expressed in regions such as the hippocampus, cerebellum, caudate nucleus, amygdala, and lower
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expression in the thalamus, corpus callosum, and substantia nigra[30, 32]. The IP3R also has three
isoforms called IP3R type 1-3. Further, SERCA pumps also present with three primary genes
encoding SERCA type 1-3. Table 5.1 outlines the differential cellular expression of the RyR,
IP3R, and SERCA pump isoforms. SERCA1 has two characterized additional isoforms from
alternative splicing referred to as SERCA1a and SERCA1b. SERCA1 is mainly expressed in
skeletal muscle and fast-twitch muscle fibers[33]. For the isoforms SERCA1a is the dominant form
found in adult skeletal muscle while SERCA1b is found in fetal skeletal muscles[34, 35]. SERCA2
is expressed in all tissue types with its isoforms being distributed in differing tissue types.
SERCA2a isoform is found mainly in slow-twitch skeletal muscle, cardiac muscle, and slightly in
smooth muscle[36-40]. The SERCA2b isoform is found at low levels throughout all tissue types
including smooth muscle and non-muscle tissues such as the liver, pancreas, brain, and kidneys[3638, 41-43]

. The isoform SERCA2c is also found in cardiac and cardiomyocytes, hematopoietic,

kidney, liver, lung, and epithelial cells[36-38]. SERCA3 is found mainly in non-muscle cells with
minor expression in muscle cells[44-47].

There are seven known SERCA3 isoforms named

SERCA3a to SERCA3g, with SERCA3a, SERCA3b, and SERCA3c being the most thoroughly
studied of the known isoforms[46-50]. Based on the discovery of differential expression of isoforms
at different locations, it has been hypothesized that calcium dynamics at microdomains close to
the essential proteins could be very different. Alteration of the differential expression of their
isoforms by mutations leads to a multitude of disease states (Table 1.1). However, such calcium
subcellular microdomain dynamics have yet to be reported before.
Table 1.1 – ER/SR protein diseases related to calcium signaling.
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Malignant hyperthermia (MH) is associated with RyR1 since MH is an autosomal dominant
disease associated with skeletal muscle where the RyR1 is highly expressed. 100 naturally
occurring RyR1 mutations have been found in relation to MH[51-94]. MH is a severe reaction to
anesthetic drugs resulting in muscle rigidity, fever, acidosis, and if not treated immediately, death.
Central core disease of muscle (CCD) is another disease mainly affected by the 48 point mutations
and one deletion associated with the RyR1

[51, 59, 69, 72, 89, 92, 93, 95-113]

. CCD is marked by skeletal

muscle weakness that can be mild to severe since this disease is related to the RyR dysfunction
many also simultaneously have MH. CCD can cause delayed development of motor skills and
cause scoliosis. Multiminicore disease with external ophthalmoplegia (MMDO) is attributed by
five mutations on RyR1[114-116]. MMDO is a heterogeneous neuromuscular disease that affects
muscle fibers, specifically skeletal muscles like CCD, and many also present with MH too.
MMDO can also cause issues with respiratory failure when the muscles required for breathing are
affected.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a disease caused by mutations
in RyR2 or CaSQ. There are 40 mutations to RyR2 known to cause CPVT[117-130]. CPVT affects
the muscles in the heart where activity or stress can trigger arrhythmia, and in untreated or severe
cases lead to cardiac arrest.

Additionally, one RyR2 mutation has been shown to cause

arrhythmogenic right ventricular dysplasia (ARVD)[131]. ARVD leads to a steady break own of
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the heart wall muscle called the myocardium, this weakening can lead to arrhythmias and cardiac
arrest. Disease-related mutations in RyR3 has been less studied than the RyR1 and RyR2 isoforms,
and as such has not currently reported disease-related mutations.
Similarly, to RyRs, differing mutations of IP3Rs leads to a variance of disease states. The IP3R1
has three associated disease with mutations occurring on IP3R1. One mutation on IP3R1 causes
spinocerebellar ataxia 15 (SCA15) and two more mutations cause spinocerebellar ataxia 29
(SCA29), SCA is a disease of cerebellum leading to slow degradation of motor functions [132-135].
Additionally, four more IP3R mutations lead to another neurological disorder Gillespie
syndrome[136, 137]. Gillespie syndrome causes underdevelopment of the cerebellum leading to
slight intelligence deficiency, aniridia, balance issues, and speech delay from mouth muscle
dysfunction.
Only one mutation has been found so far on IP3R2 relating to a disease state, this mutation is a loss
of function mutation leading to anhidrosis, isolated, with normal sweat glands (ANHD) which is
also known by Dann-Epstein-Sohar syndrome which disrupts the body’s ability to sweat
normally[138]. So far, there are no IP3R3 related disease mutations found.
SERCA1 has only one disease mutation related to Brody myopathy (BRM), a disease which affects
the skeletal muscles and causes muscles stiffness and cramping especially after exercising and in
cold weather, this disorder also causes an overproduction of myoglobin from the muscle tissue
damage[139]. SERCA2 has two associated diseases, acrokeratosis verruciformis (AKV) and Darier
disease (DD). AKV is associated with one point mutation of P602L while DD has 44 point
mutation and three segment deletions leading to the disease state[38, 140-145]. AKV and DD are both
disorders affecting the skin and causing lesions to appear, which can be crusty or pus filled. These

18

lesions can be aggravated by stress, clothing, or the environment. SERCA3 currently has no
known disease mutations.
Primarily due to limitations of imaging techniques and lack of calcium sensors that are able to
report the local calcium responses with required kinetics and calcium binding affinity, this work
is mostly unexplored. Chapter 5 will report our effort in visualizations of calcium dynamics at
microdomains using our designed calcium sensors.
1.6.5

Neurological calcium diseases

There are two types of neurotransmitters which are classified by their signaling functions as either
excitatory or inhibitory neurotransmitters. Ca2+ functions in neuron physiology by overseeing the
secretion as well as the synthesis of neurotransmitters. Release of neurotransmitters is regulated
by the [Ca2+]i and also affects the postsynaptic action potential capabilities. Ca2+ signaling has
been shown to affect a multitude of processes throughout the body and also in learning, memory,
neuron excitability, dendrite development, and synaptic transmissions. Ca2+ dysfunction through
mGluRs, RyR, IP3R, and the SERCA pump have been linked to many neurodegenerative disorders
including Alzheimer’s disease (AD), bipolar disorder (BPD), amyotrophic lateral sclerosis (ALS),
Huntington’s disease (HD), schizophrenia, spinocerebellar ataxias, Parkinson’s disease (PD),
epilepsy, and fragile X syndrome (FXS) (Table 1.1)[146-172]. The damage of Ca2+ activity-dependent
proteins is associated with the development and evolution of several neurodegenerative diseases.

1.7

Unmet Need to Design Calcium Sensors

There is a lack of Ca2+ sensors for targeting to the ER/SR accurately, at the high Ca2+ environment
of 1 mM, and with appropriate rapid kinetics to monitor quick responses. Currently, Ca2+ ER dyes
cannot be targeted accurately to specific organelles especially for subcellular environments and
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other protein-based Ca2+ ER sensors have slow kinetics related to their multiple Ca2+ binding sites
and the Ca2+ induced large conformational change to induce fluorescence changes. There is a need
for a sensor that can avoid common imaging pitfalls such as photobleaching and methodologies to
combat the cell movement/shape change in response to reagents. Fast dynamic measurements in
the ER/SR using current protein-based fluorophores on the market is not adequate since either their
kinetics are either too slow or their Kd is too low for the high ER [Ca2+]. Also, there is a lack of
having an imaging methodology capable of imaging fast kinetics and in subcellular location
differences with high resolution of the ER network. Using an improved targeted designed sensor,
we could more accurately investigate the heterogeneous distribution of ER/SR pumps and
channels.

1.8

Fluorescent Proteins

The discovery of fluorescent proteins (FPs) in 1962 allowed for the field of genetically encoded
calcium indicators to flourish by utilizing these FPs. The first discovered FP was green FP (GFP)
by Shimomura et al. from the jellyfish Aequorea victoria as a side product of purifying aequorin
protein[173]. With the first cloning and expression of GFP in the early 1990s, the protein was
demonstrated to be able to retain its fluorescence in other systems of expression besides the species
it was extracted from[174-176]. Upon solving the GFP crystal structure in 1996, the studies of altering
GFP for the creation of genetically encoded indicators took off[177, 178]. GFP structure is marked by
a β-barrel motif with the fluorescence from the central chromophore within the β-barrel center.
This chromophore is a three amino acid aromatic sequence from the transcription of GFP itself,
comprised of Ser65, Tyr66, and Gly67. The first significant improvement of GFP to utilize the
protein for further development as a fluorescent probe was the mutation of WT GFP into enhanced
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GFP (EGFP) which showed brighter fluorescence at 488 nm and enhanced expression at 37°C[179].
In order to broaden the fluorescence color spectrum, mutations were made directly or indirectly to
the chromophore of GFP to make blue FP (BFP) with the best mutation being Tyr66 in the
chromophore into a His changing the excitation/emission wavelength from 488/510 nm for GFP
to 382/448 nm for BFP, respectively[180]. Additionally, when the Y66 chromophore amino acid
was mutated to tryptophan, instead of histidine, a cyan FP (CFP) was formed instead with an
excitation/emission of 436/485 nm, respectively. Via further mutating the GFP to Y66H and
Y145F double mutation led to an even better BFP with fluorescence intensity and production
comparable to the WT GFP[181] and adding the third mutation F64L led to an enhanced BFP
(EBFP)[182-184]. Further mutagenesis of CFP led to a group of mutations called W7 (Y66W, N146I,
M153T, V163A, and N212K) which shifted the excitation/emission to 434/476 nm, respectively,
making an enhanced CFP (ECFP)[181-183]. Another variant of GFP was made by mutations T203Y,
S65G, V68L, and S72A that shifted GFP to yellow FP (YFP)[177, 185]. Furthermore, an enhanced
version EYFP was also developed with increased pH sensitivity compared to EGFP, increasing
the pKa from 6.15 to 7.1[186]. These early YFP variants had issues relating to photobleaching and
chloride sensitivity, thus after several rounds of more mutations improved YFPs were developed
called Citrine, from V68L and Q69M, and Venus, from F46L, F64L, M153T, V163A, and S175G.
These new variants Citrine and Venus had not only removed their chloride sensitivity but also
improved the pH sensitivity and reduced the photobleaching effects[187, 188].
There was a pressing need to design FPs with other wavelengths within the full light spectrum, but
mutation studies upon GFP were on ever able to extend past 529 nm thus precluding red fluorescent
proteins from being designed[182]. Therefore, focus turned to find naturally occurring other color
variants of FPs similarly to how GFP was discovered in the jellyfish Aequorea victoria. Matz et
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al. were able to identify and clone six FPs from fluorescent coral species, with the most hopeful
being the one derived from Discosoma sp. “red” mushroom anemone, drFP583 or DsRed as it is
now referred to[189]. Unfortunately, DsRed itself was not ideal for studies since it oligomerized,
leading to aggregation, toxicity, and activating other proteins which are affected by
oligomerization. While DsRed did present with these caveats, there were benefits of being
insensitive to pH, having little photobleaching, and being able to be mutated to even longer
wavelengths, thus still making DsRed a good starting point for further optimization studies [190].
Just three years later in 2002 was discovered the first monomeric version of DsRed termed mRFP1
(monomeric red fluorescent protein)[191]. It took 33 mutations on DsRed to created mRFP1 and
with these mutations come faster maturation time and a shift in fluorescence of 25 nm to 584 and
607 nm. Unfortunately, the mRFP1 does have more sensitivity to photobleaching as well as a
decreased quantum yield and extinction coefficient[191]. This first step in producing a stable RFP
allowed for further mutation studies to be performed which was able to produce a wider variety of
FPs from excitation of 487 to 587 and with emission from 537 to 610, respectively. These newly
designed monomeric (m) and dimeric (d/td) FPs are mHoneydew (Ex 487/504, Em 537/562 nm),
mBanana (Ex 540/Em 553 nm), mOrange (Ex 548/Em 562 nm), dTomato (Ex 554/Em 581 nm),
tdTomato (Ex 554/Em 581 nm), mTangerine (Ex 568/Em 585 nm), mApple (Ex 568/Em 592 nm),
mStrawberry (Ex 574/Em 596 nm), and mCherry (Ex 587/Em 610 nm)[192, 193].

1.9

Fluorescent Ca2+ Dyes

Ca2+ is a critical intracellular messenger and imaging these cytosolic Ca2+ changes were necessary
not only to understand Ca2+ signaling and dynamics but also to see the effects diseases or drugs
have upon these Ca2+ signaling cascades. Many previous Ca2+ probes initially were not cell-
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permeable, and thus the cell had to be permeabilized to allow the indicator to enter the cell, which
changes the signaling responses as well as allows for the probes to potentially be washed away.
Thus, designing Ca2+ indicators which were cell-permeable became the goal for many. In 1980
Ca2+ indicators were designed based on Ca2+ chelator BAPTA, which is derived from EGTA, to
create several indicators, with the ideal being Quin-2[194]. There was still the issue of the probe not
being cell-permeable, which was brilliantly circumvented in 1981 by adding acetoxymethyl groups
onto each oxygen group (COO-) creating a hydrophobic indicator which was able to pass through
the plasma membrane and then be de-esterified by naturally occurring esterase within the cell
cytosol and therefore cleaved into the active Quin-2 Ca2+ indicator[195]. Quin-2 continued to be
improved upon by making other BAPTA derivatives, and six new Ca2+ indicators were designed
in 1985, stil-1, stil-2, indo-1, fura-1, fura-2, and fura-3[196]. Fura-2 and Indo-1 immediately became
famous for their new properties of being ratiometric. Fura-2 has dual excitation peaks (340/380
nm) which are ratiometrically Ca2+ dependent and a single emission peak (510 nm). Indo-1, on
the other hand, has dual emission peaks (400/475 nm) and a single excitation peak (350 nm)[196].
Currently, there are over 30 Ca2+ indicators on the market for Ca2+ imaging with single or
ratiometric fluorescence properties, excitation wavelengths from 340-615 nm, and Kd values for
Ca2+ between 60 nM and 320 µM.
Table 1.2 – Current calcium indicators on the market.
Kd for Ca2+
Excitation
Indicator
(µM)
(nm)

Emission
References
(nm)

Calcium Green-1

0.19

490

530

[197, 198]

Calcium Orange

0.19

550

575

[197]

Calcium Crimson

0.19

590

615

[197]
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Fluo-3

0.33

505

525

[199, 200]

Fluo-4

0.35

494

520

[201-203]

Fluo-4FF

9.7

494

520

[204, 205]

Fluo-5F

2.3

494

520

[206, 207]

Fluo-5N

90

494

520

[208, 209]

Fura-2

0.15

340/380

510

[196, 197, 210-213]

Fura-4F

0.77

340/380

510

[214]

Fura-6F

5.3

340/380

510

[214, 215]

Fura-FF

5.5

340/380

510

[214, 216, 217]

Fura Red

0.14

420/480

650

[218, 219]

Indo-1

0.23

488

405/485

[196]

Mag-fluo-4

22

490

520

[220]

Mag-fura-2

25

340/380

510

[221-223]

Mag-indo-1

35

350

405/485

[224]

Magnesium Green

6

530

[225]

Oregon Green 488 BAPTA-1

0.17

488

520

[226]

Oregon Green 488 BAPTA-5N

20

494

520

[215]

Oregon Green 488 BAPTA-6F

3

494

520

[227, 228]

Quin-2

0.06

350

495

[194]

Rhod-2

0.57

552

580

[229, 230]

Rhod-FF

19

522

580

[231, 232]

X-rhod-1

0.7

580

600

[233, 234]

X-rhod-5F

1.6

580

600

[233, 235]
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While Ca2+ sensing dyes have proliferated the market, they do have certain advantages and
limitations. Calcium dyes are highly conjugated species found as salts, dextran conjugates, or
acetoxymethyl esters. The commonly used synthetic dyes are suitable due to the wide variety of
binding affinities available as well as the quick introduction to the cell. Ca2+ dyes are mainly
targeted to the cytosol and are incubated with the cells to allow permeabilization of the dye into
the cytosol, this incubation is easier on the cells than protein transfection and expression.
Additionally, chemical Ca2+ indicators come in a broad range of Ca2+ affinities for a multitude of
uses cellularly. Unfortunately, while Ca2+ dyes have been targeted to other cellular organelles,
their small compound chemistry prevents accurate organelle targeting and instead is a pseudotargeting by a recombinant targeting of the esterase that cleaves the AM form of the Ca2+ dyes and
thus cleaves them into the organelle the esterase is targeted to[236, 237]. This targeting method,
targeted-esterase-induced dye loading (TED), is shown to have residual Ca2+ dye in the cytosol
and other regions, but by using a low affinity dye such as Fluo-5N mitigates this incomplete
targeting by having the ER signal be larger than the cytosolic signal, while this method does work
it is not entirely accurate since there is dye in the cytosol as well as the organelle and removes the
advantage of having a wide array of affinity dyes to choose from[236, 237]. Additionally, extended
experiments can have an issue in that the chemical Ca2+ dyes are eventually compartmentalized
and removed from the cells[238]. The setbacks are that these dyes cannot easily be targeted to
specific organelles and often are compartmentalized and thus diffuse out of the cell after a
prolonged time, commonly seen in longer experimental procedures. Attempts to remedy this
compartmentalization have proven successful with large dextran tags, but this method also made
the dyes too large for the easy loading. Thus, a protein Ca2+ sensor with appropriate protein
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retention sequences would be ideal for sensor targeting to organelles and having a stable Ca2+
sensor for different experiment conditions throughout the cell.

1.10 Fluorescent Ca2+ Sensor Proteins
Ca2+ has an essential role in biological functions and influences a multitude of diseases such as
osteoporosis, cancers, heart disease, and Alzheimer’s. This regulation of diseases creates a dire
need for intracellular Ca2+ probes to measure the dynamics of Ca2+ in vivo. When FPs were first
discovered, they were always planned to be used for fluorescence usage whether they would be
tagged to organelles/proteins for investigation or to be used as direct binding sensors. The first
genetically encoded calcium indicators (GECIs), designed from fluorescent proteins (FPs), were
the cameleon (CaMeleon) series in 1997, getting its name from their CaBP being CaM and their
Förster resonance energy transfer (FRET) color change giving the idea to name their series after
the color-changing animal the chameleon[239]. This discovery was made possible by earlier work
investigating CaM and M13 a synthetic peptide derived from the CaM binding domain on the light
chain of the myosin motor protein[240]. Porumb et al. found if they connected CaM and the M13
peptide by a glycylglycine linker that after CaM binds Ca2+ then it can further bind the attached
M13 domain, this Ca2+ dependent binding through a linker opened up the possibility of fluorescent
proteins having FRET interactions when brought together attached to this CaM/M13
interaction[239, 240]. The cameleon series was made with initially seven FRET sensors with different
combinations of FPs as well as retention sequences for organelle targeting. These first seven were
cameleon-2 (EBFP/EGFP), cameleon-2nu (nucleus EBFP/EGFP), cameleon-3er (ER EBFP/EGFP
and E104Q), yellow cameleon-2 (ECFP/EYFP), yellow cameleon-3er (ER ECFP/EYFP and
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E104Q), yellow cameleon-4er (ER ECFP/EYFP and E31Q), and ECFP-CaM and M13-EYFP
separated domains[239].
Just two years later a new class of GECIs were introduced using a technique of circular permutation
of a single FP leading to a removal of the necessity of FRET between two FPs and allowing the
direct CaBP being attached to the single FP[241]. This new class of GECIs was named camgaroos
since they had a direct CaM CaBP inserted between residues 145/146 leading to the idea that the
CaM was being carried by the GFP/YFP in a pouch position similar to kangaroos[241]. When Ca2+
binds to the CaM in camgaroos the FP is able to become fluorescent through conformational
change[241]. In 2001 pericams and GCaMPs were simultaneously developed by combining the split
FP concept from camgaroos with the CaM/M13 binding partners from the cameleon sensors[242,
243]

. The pericams have CaM on one half of the EYFP and M13 on the other half, so when Ca2+

binds to CaM then the bound form of CaM can bind M13 and either bring the FP halves together
or separate them through conformational change and resulting in a fluorescence signal gain or loss,
respectively. Pericams come in different forms and organelle targeting such as pericam, flash
pericam,

inverse

pericam,

ratiometric-pericam,

ratiometric-pericam-mt

(mitochondria),

ratiometric-pericam-nu (nucleus), and split-pericam[242]. GCaMPs were developed from the EGFP
instead of EYFP and did not have any inverse forms, so they only gain fluorescence upon
Ca2+/CaM/M13 binding[243]. GCaMP was the initially engineered EGFP variant but was later used
as a steppingstone for production of a plethora of further CaMP variants with different colors as
well as targeting, which are still being further improved to date.
Improvements were then made on the original cameleon series of sensors in 2006 designing a
series of sensors based on the newly engineered YFP Venus in circularly permuted (cpV) form
and CFP[244]. Additionally, they made three different computationally directed mutations on the
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M13 peptide in order to reduce perturbation of the sensors by naturally occurring CaM in the
cell[244]. The change of the FP to cpV led to a 3-5-fold increase in the dynamic range, and the
modified M13 led to higher Ca2+ sensitivity of the sensors. Three different M13 modifications
were made leading to three sensors D2cpv (A13I), D3cpv (I14F), and D4cpv (V11W)

[244]

.

Furthermore, targeted versions were made to target the plasma membrane and the
mitochondria[244].
GCaMPs were being further modified for improvements and in 2006 GCaMP2 was designed,
which was able to do cell imaging since it was more stable at body temperatures[245]. Subsequently,
GCaMP3 was designed in 2009 from GCaMP2 with a 3-fold increase dynamic range and 1.3-fold
increased Ca2+ sensitivity. Zhao et al. then began working in 2011 on large scale random mutations
of GCaMP3 in order to elucidate improved and variant GCaMPs across the FP color spectrum[246].
These new indicators were termed genetically encoded Ca2+ indicators for optical imaging
(GECOs)[246]. This led to the development of G-GECO series (GFP), R-GECO series (RFP
mApple), B-GECO series (BFP), GEM-GECO series (blue-green FP), and GEX-GECO series
(ratiometric GFP)[246].

1.11 Research Objectives and Questions to be Addressed
The overall goal of our research is to understand the Ca2+-mediated molecular basis for disease in
high Ca2+ environments of extracellular and ER/SR. We committed to investigating this quandary
by looking at the calcium sensing receptor (CaSR) for the sensing of high extracellular Ca2+ to
signal intracellular Ca2+ function through the ER oscillatory Ca2+ release through the IP3R. In
order to understand the ER high Ca2+ dynamics relationship, we designed an ER Ca2+ sensor
capable of fast kinetics and able to investigate subcellular microdomain changes. The overall
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question of what is the Ca2+-mediated molecular basis for disease in high Ca2+ environments of
extracellular and ER/SR is addressed in our research. We address this wide-ranging question by
delving into the CaSR and ER/SR targeted Ca2+ sensors projects.
Chapter I provides an overview of the background related to calcium regulation by calcium binding
proteins, especially calcium sensing receptor and related diseases. Calcium dynamics and the need
for design calcium sensor in subcellular calcium. Objectives and questions will be addressed in
this dissertation are provided.
In Chapter 2, we accomplished this goal by elucidating the first CaSR crystal structure of the ECD
domain using purified protein from a mammalian expression system. After determining the first
crystal structure of CaSR ECD, we investigated the effect and functionality of cations and/or CaSR
binding ligands on WT CaSR and disease-related mutations in order to understand the mechanisms
of how CaSR integrates the Ca2+-mediated signaling and to probe the molecular basis for diseases
resulting from alterations in Ca2+ homeostasis.
In Chapter 3 we were then interested in if we could correlate the changes between the WT CaSR
and disease-related mutations using bacterially expressed CaSR for structural information in
comparison to functional and signaling information gained from cellular CaSR studies in order to
expand our understanding in disease-mediated function differences.
In Chapter 4, we also used TNCA as a potential lead compound for therapeutic CaSR drug
screening and structure-based drug design in order to discover a new and improved therapeutic for
CaSR either as a calcimimetic or calcilytic.
In Chapter 5, we then turned to look at the relation of ER/SR Ca2+ dynamics in global and localized
microdomain regions for the understanding of the regulation of cellular Ca2+ dynamics. First, we
designed an ER/SR sensor with the capability to detect high ER [Ca2+] with fast kinetics for
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variable Ca2+ dynamics called CatchER+. We were then interested in if CatchER+ able to function
in the ER/SR under live-cell imaging and monitor the global and the local ER/SR subcellular
changes of Ca2+ dynamics through activation of RyR, IP3R, and SERCA pumps and were able to
use new imaging modalities of HILO and STORM imaging. In order to further investigate these
microdomain localized to these subcellular locations of the ER/SR, we designed a targeted sensor
to the skeletal muscle RyR co-localizing junctional protein 45 (JP45) at a local microdomain called
CatchER+-JP45 in order to observe local versus global Ca2+ dynamics.
In Chapter 6 we were also interested in the microdomains through the variable ER expression of
neuronal systems, so we applied CatchER+ in hippocampal neurons to see the differential
subcellular signaling in response to DHPG activation of mGluR1/5 to potentiate LTD.
In Chapter 7, we review the significance of our work as well as encompassing the major findings
from this research. We also go into future routes of research to continue progressing these
significant findings.
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2
2.1

Structural Determination of CaSR ECD

Introduction

CaSR is a part of the family C of GPCR superfamily with a large ECD, a cys rich domain (CRD),
a 7TM domain, and an ICD[21]. The CaSR primary function is to regulate Ca2+ homeostasis and is
predominantly expressed in the parathyroid, thyroid, and kidney cells for the modulation of
parathyroid hormone (PTH) secretion and reabsorption in the renal system.[22, 247, 248]. CaSR plays
critical functional roles in biological and pathological regulation and is extensively expressed
throughout the body in the skin, gastrointestinal, the central nervous system (CNS), cardiovascular,
in bone, kidney, breast, and the parathyroid tissues[249-252]. The main agonist for CaSR is Ca2+ in
regulation of Ca2+ homeostasis but has been shown to respond to various other cations such as
Mg2+, Gd3+, and Tb3+, while Mg2+ is found natively in the body at higher concentrations than Ca2+
it has not been shown to induce the same oscillatory effect as seen with Ca2+ activation of CaSR[22,
253, 254]

. In addition to cations, L-amino acids such as L-Phe as well as polypeptides and polyamines

have been shown to be CaSR binders. L-Phe has been shown to enhance the CaSR activity with
Ca2+ as a co-agonist and improving activation on WT and loss of function mutations [23,

24]

.

Additionally, several drugs have been designed which affect CaSR function with cinacalcet and
AMG-416 as examples of agonist calcimimetics and NPS-2143 as an antagonist calcilytic, where
only cinacalcet has been FDA approved[255-258]. Determination of the CaSR crystal structure of
the ECD domain using purified protein from a mammalian expression system in order to garner
more critical structural and functional information for drug and signaling studies. We are also
curious on the actual ion binding sites to investigate the effect and functionality of cations and/or
CaSR binding ligands on WT CaSR and disease-related mutations in order to understand the
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mechanisms of how CaSR integrates the Ca2+-mediated signaling and to probe the molecular basis
for diseases resulting from alterations in Ca2+ homeostasis.

Figure 2.1 – CaSR proposed Ca2+ binding sites.
A – The overall dimer binding of two CaSR proteins. B – Based off of electronegativity
the proposed calcium binding sites. C – The resides shown of the proposed calcium
binding sites from B[259].

With the challenges surrounding GPCR purification, our lab looked at other methods of analyzing
CaSR structure and function while simultaneously optimizing CaSR ECD expression and
purification. The amino acid sequence of CaSR was known and using that information we did
sequence alignment with ClustalW program and other cGPCRs to find that mGluR1 had the
highest sequence homology[260]. Since mGluR1 had two structures determined, 1EWT and 1ISR,
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we were able to utilize these structures and WISS-MODEL and MODELLER[261-263] software to
create a preliminary CaSR model structure in 2007 with which to investigate potential Ca2+ binding
sites using the program MetalFinder[264] which was an initial version of our developed prediction
algorithm MUG (MUltiple Geometries)[265-268]. Using this methodology, we were able to initially
determine three Ca2+ binding sites on CaSR ECD which were the hinge binding site, the dimer
binding site, and another near the top of the ECD as outlined in Figure 2.1. We were then able to
do grafting of these binding sites onto a non-CaBP CD2 to see if Ca2+ was able to bind to these
proposed residues and confirmed they were able to produce Ca2+ binding sites and that mutation
of these grafted residues led to a decrease or loss of binding activity[259].
We further were able to create an even better CaSR modeled structure using three mGluR1
determined structures (1EWK, 1EWT, 1ISR). We choose mGluR1 as the template for CaSR
structure modeling since mGluR1 and CaSR are in the same family C of GPCRs and share the
most sequence similarity to each other as compared to other family C GPCRs. In order to conserve
time and resources, we were only able to computationally model the CaSR structure of the ECD
in monomer form, not dimer form, since the ECD is where Ca2+ binding is hypothesized to occur.
After computation modeling was performed, we were able to obtain a hypothetical CaSR structure
model (Figure 2.2). Using this structure model, we were able to apply our calcium binding site
program MUG in order to identify possible Ca2+ binding sites in the ECD of the CaSR[265-268].
MUG was able to identify five potential binding sites (BS). Binding site 1 (BS1), previously
named binding site 3, was in the hinge region of the ECD with residues S147, S170, D190, Y218,
and E297 (Figure 2.1). This binding site correlates most closely with the primary binding site in
the hinge region of the ECD of mGluR1 for glutamate. BS2 was identified as residues D215,
L242, S244, D248, and E253. BS3, previously called binding site 1, was identified as residues
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E224, E228, E229, E231, and E232 and was near the back of the CaSR model and most likely for
dimerization stability (Figure 2.1). BS4 was identified as residues E350, E353, E354, N386, and
S38.

Figure 2.2 – CaSR modeled structure.
Based off of mGluR1 structures (1EWK, 1EWT, 1ISR). Potential Ca2+ brick red
spheres. 1EWK bound with Glu and Mg2+, 1EWT Apo form, 1ISR bound with Glu
and Gd3+.
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Lastly, BS5, previously called binding site 2, was identified as residues T396, D398, E399, E378,
and E379 (Figure 2.1).

With these new binding sites identified, as well as confirmation of

previously found binding sites and in conjunction with our improving CaSR expression, we were
able to express subdomains of the CaSR ECD in order to look at Ca2+ binding in each purified
subdomain and examine the cooperative binding of the Ca2+ binding sites[269]. These three
subdomains were subdomain 1 with amino acids (AA) 132–300 containing BS1-3, subdomain 2
with AA 185 to 324 containing BS 2-3, and subdomain 3 with AA 340–445 containing BS 4-5[269].
Using mutations of these binding sites, and these three different subdomains being investigated,
we found that the hinge site BS1 and the dimer site BS3 are critical for binding and
cooperativity[269]. We next optimized the purification of full CaSR ECD from bacteria and
mammalian expression systems and were able to look at full CaSR ECD binding, cooperativity,
and reaction to amino acids as well as Ca2+ binding and found that L-Phe acts as a co-activator of
CaSR with Ca2+ and using modeling and mutation studies is thought to bind with Ca2+ in the hinge
region BS1[23, 24].

2.2

Results
2.2.1

Mammalian Expressed CaSR Optimization

In addition to expression CaSR in a bacterial system, we also expressed CaSR ECD in a
mammalian host system for X-Ray Crystallization and binding studies. Bacterial and mammalian
vectors expressing human CaSR, bCaSR and mCaSR, respectively, are done utilizing the CaSR
ECD. We use mammalian expression for the correct folding of the protein and post-translation
modifications. We have improved upon previous expression and purification techniques by using
Dr. Moremen’s Lec1 cells to express CaSR, which prevents complex glycosylation from forming
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on the nine potential N-linked glycosylation sites on the CaSR ECD. This is beneficial because
then only high mannose glycans can bind which are readily cleaved by Endo F1, whereas complex
glycans are not as wholly cleaved. For binding studies using mCaSR the glycans are not cleaved
and high mannose glycosylation are still present. Deglycosylated mCaSR is not as stable as
glycosylated mCaSR and tends to aggregate before binding studies can be performed (Figure 2.3).

Figure 2.3 – History of mCaSR expression optimization.
Initial expression was done in WT HEK293 cells but showed high degradation.

The expression procedure for Lec1 cells with CaSR-ECD transfected has already been optimized
by Dr. Moremen’s lab. After suspension cell growth to optimal confluency the cells are transfected
with CaSR-ECD DNA previously amplified by our lab. 24 hr post-transfection, day 1, the culture
is diluted 2-fold with fresh media and the culture is continued for five additional days of batchmode protein production. This method has been successful for expression of mCaSR but was
further modified for successful crystallization of the samples.
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We saw high aggregates in previous expression batches though, so in order to optimize protein
expression we attempted a new procedure. Same as the old method up to 24 hr post-transfection,
day 1, but at this point the culture was centrifuged and resuspended in fresh media for the
production phase. The media change removed excess DNA and PEI and result in protein
production into clean media. Protein expression generally remains high on days 2-6 and the
benefit, in this case, is that the potential for the DNA or PEI in contributing to aggregation in the
final protein preparation will potentially be eliminated by the media change (Figure 2.4).
Additionally, we removed the CRD and flag tag from the mCaSR ECD in order to potentially get
a protein expression that could form better crystals for X-ray diffraction and not form aggregates.

Figure 2.4 – Three separate mCaSR expression batches under GF purification.
(Left) Small third left peak is aggregation and large fourth peak in mCaSR. (Middle)
All aggregated. (Right) Aggregation peak and mCaSR peak are too close together and
are overlapping. (ADD ABC)
2.2.2

CaSR Determined Structures

We were able to crystallize the CaSR ECD at 2.1 Å and showed many loops not previously seen
in any other cGPCR and a unique one to CaSR. Additionally, we did a Gd3+ soaking of another
crystal from the same expression batch to visualize the Gd3+ binding site, this crystal was 2.7 Å
and the partial dimerization loop was not visible in this less resolved crystal (Figure 2.5). The
Venus flytrap domain of human CaSR-ECD (hCaSR-ECD; residues 20 to 541) expressed in human
embryonic kidney HEK293S (GnTI-) Lec1 cells was crystallized in the presence of 200 mM Mg2+
and 10 mM Ca2+. The structure was solved by molecular replacement using the structure of

37

mGluR2 [Protein Data Bank (PDB) ID: 4XAQ] as the search template. hCaSR-ECD contains two
globular lobes with an overall structure similar to other cGPCR family members, despite a low
sequence similarity between these cGPCR family members of 20 to 30%[270]. Both the large lobe
(subdomain 1) and the small lobe (subdomain 2) are typical α/β folds where the central parallel b
strands are sandwiched by α helices. hCaSR-ECD forms a homodimer in solution and the crystal
structure, with both protomers in a closed conformation similar to the equivalent closed
conformation of mGluR1 bound with glutamate. Besides, the direct and extensive homodimeric
subdomain 2 interactions in hCaSR-ECD are analogous to those observed in the mGluR2 dimer
with a bound agonist (PDB ID: 4XAQ), strongly suggesting that hCaSR-ECD crystal structure
represents an active conformation[271]. In the crystal structure, two Mg2+ binding sites were
identified at positions designated as the new top site 3 and the dimerization site 2, and an
unpublished hinge binding site 1 (Figure 2.7).
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Figure 2.5 – Science Advances CaSR structures
PDB 5FBK is a holo 2.1 Å form (green) with Mg2+ yellow spheres and TNCA blue
sticks by element. PDB 5FBH is also a holo 2.7 Å (blue) structure with Mg2+ yellow
spheres, TNCA green sticks by element, Gd3+ green spheres, and the same conditions
as 5FBK plus 0.5 mM GdCl3. These structures are of hCaSR (20-621) in pXLG vector
expressed in Lec1 cells with high mannose only and cleaved with Endo F1. Under the
conditions of 10% polyethylene glycol 8000, 200 mM MgCl2, 10 mM CaCl2, and 100
mM Tris-HCl, pH 7.0.
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Site 2 is located at the dimerization interface of subdomain 2 and the bound Mg2+ coordinates with
S240 and four water molecules with an ideal geometry for a Mg2+ ion. Notably, site 2 is
surrounded by highly conserved residues (E228, E231, and E241*) (* means from the other
protomer) within 5 Å from an “acidic patch” composed of negatively charged residues on
subdomain 2 (Figure 2.6). Site 3 is found on the periphery of subdomain 1, coordinated by S84
and backbone interactions with I81, L87, and L88, as well as two water molecules. An equivalent
cation binding site has been observed in mGluR[270] and likely plays a structural role.

Figure 2.6 – Metal binding at the acidic patch.
The electrostatic potential map of hCaSR-ECD is colored in accordance with
electrostatic potential; red indicates negative potential and blue indicates positive
potential. Mg2+ is represented by hot pink spheres, while Gd3+ is shown as blue
spheres. The large surface with negative potential at the dimerization interface of
subdomain 2 is referred to the “acidic patch”, where both Mg2+ and Gd3+ bind.
To locate additional high off-rate metal binding sites, we generated Gd3+-derived crystals and
identified another metal binding site on the acidic patch in proximity to the subdomain 2
dimerization interface and adjacent to Mg2+ binding site 2 (Figure 2.6). The Gd3+ binding site
largely overlaps with a previously predicted Ca2+ binding site in the dimerization region[269]. These
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sites are more clearly outlined by their residues of binding and areas in the CaSR ECD in Figure
2.7.

Figure 2.7 – Binding sites of Mg2+/Ca2+/TNCA/Bicarbonate in CaSR ECD
Binding sites on the CaSR ECD with a dimer Mg2+/Ca2+ binding site 2 (E228, E231,
S240, and E241), a hinge region TNCA/Mg2+/Ca2+ binding site 1 (S147, A168, S170,
A214, D216, Y218, S272, D275, and E297), a new top Mg2+/Ca2+ binding site 3 (I81,
S84, L87, L88, L91), and a bicarbonate binding site (R66, R69, W70, R415, I416, and
S417).

Unexpectedly, an elongated planar electron density was observed in the hinge region between the
two subdomains where orthosteric ligand binding is thought to occur. High-resolution liquid
chromatography–electrospray ionization–mass spectrometry (LC-ESI-MS) of the purified protein
preparation identified a species that was eluted at ~4.65min with a mass/charge ratio (m/z) of
215.0824 in negative-ion mode. The predicted elemental formula based on the observed mass
corresponds to C12H11N2O2 (calculated mass, 215.0821; mass accuracy, 1.4 ppm). A search of
PubChem identified a tryptophan derivative, L- 1,2,3,4-tetrahydronorharman-3-carboxylic acid
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(TNCA) with the predicted molecular weight (MW) and shape of the observed density. When
compared to tryptophan, TNCA contains one extra carbon atom linking the amine nitrogen atom
and the C2 atom of the indole ring. TNCA can be detected in various food and biological systems
and is likely produced by tryptophan reacting with formaldehyde or ketones in humans[272], and is
perhaps generated during production of the recombinant protein in Lec1 cells. CaSR strongly
prefers aromatic amino acid ligands, such as Phe and Trp, over negatively charged Glu, which is
the ligand for mGluRs. Structural comparison of the ligand binding pocket in the hinge region
between subdomains 1 and 2 of hCaSR-ECD with that of mGluR1 reveals the structural basis of
ligand selectivity. Although the amino acid backbone of TNCA adopts a similar conformation as
Glu in mGluR1 through extensive interactions with S147, A168, S170, and Y218 (S156, S186,
T188, and Y236 in mGluR1)[270], hCaSR and mGluR1 recognize the side chains of their preferred
ligands differently. Two positively charged residues in mGluR1 (R78 and K409) that associate
with the carboxylate group of the Glu ligand are replaced in hCaSR by W70 and I416, which
interact with the indole ring of TNCA. Bulky residues (Y74, W110, and R323) that limit the
mobility of the Glu side chain are replaced by smaller residues in hCaSR (G67, N102, and S302).
As a result, the size of the ligand binding pocket of hCaSR is significantly larger than that of
mGluR1, consistent with the preference of CaSR for larger ligands. Unlike Trp, TNCA is in a
fixed and presumably preferred conformation, accounting for the higher binding affinity compared
to Trp. Mapping of disease-associated mutations on the structure of hCaSR-ECD shows that the
mutations are clustered in two regions: the hinge region between subdomains 1 and 2 and the
dimerization interface[273,

274]

. Indeed, our structural and functional data strongly support the

pivotal roles of these two regions in CaSR function.

42

The hinge region between subdomains 1 and 2 harbors the binding site of TNCA, supporting its
role as a co-agonist of CaSR. A close inspection of the structure reveals that the side chain of
E297, a critical residue predicted for Ca2+ binding in site 1, swings away from the other residues
in site 1 (S170, D190, Q193, and Y218), probably due to the extra carbon atom and the rigid
structure of TNCA, ultimately resulting in its failure to capture the Ca2+ ion in combination with
other site 1 residues. A bicarbonate anion was also identified in the hinge region in proximity with
TNCA, coordinated by the side chains of R66, R69, W70, and S417 and the backbone amide
nitrogen atoms of I416 and S417), potentially contributing to the known pH sensitivity of the
CaSR[275]. Additionally, we found two Mg2+ binding sites on each crystal, as well as a TNCA
compound bound in each of the hinge domains in each monomer.

2.2.3

Structure Analysis

The modeled structure’s proposed Ca2+ binding site 1 shares 4/5 binding residues similar to the
TNCA and Trp binding sites of the determined structures (Figure 2.8). While our dimer site 2 for
Mg2+ overlaps 2 residues with binding site 3 dimer site for Ca2+ in the modeled structure. These
similarities in binding sites show that these residues are most likely conserved and crucial to the
function and structure of CaSR.
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Figure 2.8 – Comparison of our CaSR 5FBK (green) and the modeled CaSR (orange)
5FBK has Mg2+ yellow spheres, TNCA blue sticks by element, and Loop 1 in cyan.
While the modeled CaSR has potential Ca2+ brick red spheres and Loop 1 in yellow.

When comparing our determined structure to our modeled structure, we can see while there are
some differences, mainly in the loops which are hardest to model, but overall they are very similar
(Figure 2.8). This gives us confidence that our predictions and previous work based on this
modeled structure are still viable and accurate. As mentioned, one of the main differences in the
loops. First, loop 1 on the bottom of Figure 2.8 in blue for the determined structure versus yellow
for the modeled one. This loop is important because it is twice as long as a similar loop in mGluRs
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and a unique attribute to CaSR. It is present on both monomers stretching out to the other monomer
in the dimer to form a hug-type structure and further stabilizing them. The modeled loop 1 is
distorted upon itself and does not stretch out as the determined one does. Secondly, loop 2, the
dimerization loop on the top, has a partial helix structure in it whereas the modeled structure shows
only a loop form. This is not surprising since the mGluR structures used to model CaSR did not
have this loop determined.

Figure 2.9 – Key determinants for the molecular basis of disease-associated mutations
and regulation.
(A) Involvement of loop 1 (yellow) and loop 2 (gold) in dimerization. (B) Working
model for activation occurs through a conformational change induced by ligand
binding at the hinge region between subdomains 1 and 2, as well as bridging
interactions provided by metal ion binding at the acidic patch at the interface between
the two subdomain 2 regions of their respective protomers. Mutations at these key
determinants in the ECD of CaSR cause human disorders with abnormal [Ca2+]o and
[Mg2+]o homeostasis.

The loops that mediate subdomain 1 dimerization are functionally important (Figure 2.9). Loop 2,
following a2, is largely disordered in mGluR structures but is known to participate in two
intermolecular disulfide bonds in CaSR through two conserved cysteine residues (C129 and C131)
(Figure 2.9B)[276, 277]. The N-terminal part of loop 2 forms a short a helix extended from a2 with a
kink at N118. The a2a segments from each protomer embrace each other, likely stabilizing
dimerization (Figure 2.9). Because several activating ADH mutations (L125P/F, E127G/A/K,
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C129Y/F/S/R, and N118K) and one inactivating FHH mutation are present on loop 2, subdomain1
dimerization that is facilitated by loop 2 appears to be crucial in regulating the function of CaSR.
Moreover, the highly conserved loop 1, which is significantly longer than the corresponding loop
in mGluRs (Figure 2.9 and Figure 2.10), reaches across the dimerization interface to a hydrophobic
surface on a13*. The hydrophobic interaction, primarily mediated by P55, L51, and W458*,
stabilizes an extended conformation of loop 1, and a conserved positively charged patch also
appears to contribute to dimerization of subdomain 1 (Figure 2.9). Notably, mutation of P55 causes
FHH, indicative of a critical role of loop 1. Figure 2.9B summarizes our present model for receptor
activation. The presumed conformational change induced by ligand/metal binding in the hinge
region between subdomains 1 and 2, with homodimerization of protomer subdomains 1 through
loops 1 and 2, facilitates the approach of subdomain 2 from their respective protomers. By
neutralizing the repulsive effects of the conserved and negatively charged acidic patch, metal
binding would stabilize subdomain 2 interactions (Figure 2.10).

Figure 2.10 – A positively charged pocket for loop 1 association.
Loop 1 for CaSR (A) and the corresponding loop in mGluR1 (B, PDB code 1EWK)
are highlighted in yellow. The electrostatic potential map is colored in accordance to
charge, with red representing negative potential and blue positive potential. Loop 1
in CaSR is significantly longer than the counterpart in mGluR1, reaching across the
dimer interface to nestle into a positively charged pocket which is absent in mGluR1.
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Dimerization of subdomain 2 is also critical for the activation of mGluRs and GABAB (gammaaminobutyric acid B) receptors[278, 279] and therefore appears to be a common activation mechanism
among cGPCRs that presumably leads to conformational changes of the transmembrane domain,
through which the intracellular signal cascades are initiated. Thus, the proposed model, which is
based on structural and associated biochemical and cellular studies on WT and mutant proteins,
reveals the structural basis of agonist/co-agonist binding to CaSR and provides a framework for
further studies on the mechanism of receptor activation.

2.2.4

Trp Compound Analysis and Uncovering TNCA

Unexpectedly, an elongated planar electron density was observed in the hinge region between the
two subdomains where orthosteric ligand binding is thought to occur (Figure 2.11A). No naturally
occurring CaSR ligands (CaSRLs) or reagents that were used in sample preparation and
crystallization or any currently known CaSRLs fit the density well, suggesting a novel CaSRL.
High-resolution liquid chromatography–electrospray ionization–mass spectrometry (LC-ESI-MS)
of the purified protein preparation (Figure 2.11B) identified a species that was eluted at ~4.65min
with a mass/charge ratio (m/z) of 215.0824 in negative-ion mode. The predicted elemental formula
based on the observed mass corresponds to C12H11N2O2 (calculated mass, 215.0821; mass
accuracy, 1.4 ppm) (Figure 2.11B). A search of PubChem identified a tryptophan derivative, L1,2,3,4-tetrahydronorharman-3-carboxylic acid (TNCA) with the predicted molecular weight and
shape of the observed density. When compared to tryptophan, TNCA contains one extra carbon
atom linking the amine nitrogen atom and the C2 atom of the indole ring. TNCA can be detected
in various food and biological systems and is likely produced by tryptophan reacting with
formaldehyde in humans[272], and is perhaps generated during production of the recombinant
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protein in HEK cells. Elution time, molecular weight, and MS fragmentation of synthetic TNCA
matched those of the CaSRL, confirming the identity of the compound as TNCA (Figure 2.11B).
The ligand will be referred to hereafter as TNCA.

Figure 2.11 – Identification and characterization of a tryptophan derivative bound to
hCaSR-ECD as a novel high-affinity co-agonist of CaSR.
(A) Fo-Fc omit map (Fo and Fc are the observed and the calculated structure factor
amplitudes, respectively) of TNCA at s = 4.5. The protein is shown in ribbon mode,
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and the ligand is shown in stick mode. The residues around TNCA are labeled in the
zoomed-in figure. (B) LC-ESI-MS of protein sample (top), buffer (middle), and the
standard compound (bottom) in negative-ion mode. The high-resolution isotopic MS
spectra of the indicated peaks are shown in the inserted figures.

The discovery of an unexpected tryptophan derivative ligand (TNCA) with unusually high affinity,
which potentiates the activation of CaSR by [Ca2+]o and [Mg2+]o, also opens new avenues for the
development of agonists and antagonists as therapeutics for CaSR related diseases[280].

2.2.5

Molecular Regulation of CaSR by Co-activators Mg2+, Ca2+, and TNCA

While being able to successfully crystalize the structure of the CaSR ECD is groundbreaking in
our research to better understand the way CaSR functions and therefore can be targeted for disease
treatment, the structure is still only of the ECD and not the full 1078 amino acid CaSR. Thus, we
can turn to hCaSR studies, which refers to the full-length human CaSR transfected into HEK293
cells, so that we can test the effects on the structure of CaSR ECD has on the signaling inside the
cell with WT hCaSR and mutations of the ion/drug binding sites as well as disease mutations to
see the response differences with Ca2+ and possible drug targets.
Our data indicate that Mg2+ binds to hCaSR-ECD and elicits CaSR-mediated [Ca2+]i signaling and
ERK1/2 phosphorylation in CaSR expressing cells with a lower potency than Ca2+ (Figure
2.12)[254]. Similar to [Ca2+]o activation, [Mg2+]o activation is further potentiated by the known
CaSR co-agonist, L-Phe (Figure 2.13A)[23, 281]. [Ca2+]o potentiates [Mg2+]o-stimulated intracellular
response mediated by CaSR because an increase of [Ca2+]o from 0.5 to 1.5 mM results in a
reduction of the median effective concentration at 50% (EC50) of [Mg2+]o from 7.2 ± 0.4 to 4.5 ±
0.3 mM for stimulation of [Ca2+]i signaling. These results suggest that there is an additive effect
of both Ca2+ and Mg2+ and that they share a similar activation mechanisms (Table 2.1)[254, 282]. The

49

binding of Mg2+ can be visualized by the reduction of intrinsic Trp fluorescence upon addition of
Mg2+ to the purified ECD and the reduction of Tb3+-sensitized energy transfer by Mg2+
competition. In the crystal structure, two Mg2+ binding sites were identified at positions designated
as site 1-3. Mutation of site 2 coordinating residues (E228I or an E228I/E229I double mutant)
reduced Ca2+/Mg2+ sensing as well as Mg2+-evoked intracellular Ca2+ mobilization. These results
suggest the critical role of these metal binding sites on the acidic patch in both metal sensing[269]
and regulation of CaSR function (Figure 2.6, Figure 2.16, and Table 2.2).
TNCA is a strong co-agonist with [Mg2+]o in activating [Ca2+]i oscillations and ERK1/2
phosphorylation (Figure 2.12, Figure 2.13 and Figure 2.16). Similar to Trp and other amino acids,
the addition of exogenous TNCA alone cannot activate the receptor. However, TNCA is ~1000fold more potent than Phe in reducing the EC50 for [Mg2+]o or [Ca2+]o activation of [Ca2+]i signaling
in both WT and mutant CaSRs (Figure 2.13), with an apparent EC50 of ≤ 2 mM (Figure 2.13). The
apparent EC50 of TNCA was indirectly determined through the EC50 change of [Mg2+]o when
incubated with different concentrations of TNCA (Figure 2.13). Because the bound TNCA can be
partially replaced by incubation with 150 mM Phe as assessed by MS, TNCA and Phe likely share
the similar binding site in CaSR-ECD. Together, TNCA is a novel, high-affinity co-agonist of
CaSR in the activation of both [Ca2+]i signaling and ERK activity. CaSR strongly prefers aromatic
amino acid ligands, such as Phe and Trp, over negatively charged Glu, which is the ligand for
mGluRs.
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Figure 2.12 – Cell imaging using the novel hCaSR agonist TNCA.
(A and B) A representative oscillation pattern from a single HEK293 cell stimulated
with various concentrations of extracellular Ca2+ orMg2+ in the absence (A) and
presence (B) of 0.25 mM TNCA. (C) Frequency distribution of the [Ca2+]i oscillation
frequency (peak/min) in HEK293 cells transfected with WT CaSR stimulated with
metals in the presence (red bar) and absence (black bar) of TNCA. The frequency
was recorded at the point when more than 50% of single cells started to oscillate.
Around 40 cells were analyzed and further plotted as a bar chart.

Structural comparison of the ligand binding pocket in the hinge region between subdomains 1 and
2 of hCaSR-ECD with that of mGluR1 reveals the structural basis of ligand selectivity. Although
the amino acid backbone of TNCA adopts a similar conformation as Glu in mGluR1 through
extensive interactions with S147, A168, S170, and Y218 (S156, S186, T188, and Y236 in
mGluR1)[270], hCaSR and mGluR1 recognize the side chains of their preferred ligands differently.

Figure 2.13 – Cell population using the novel hCaSR agonist TNCA.
(A and B) TNCA potentiates [Mg2+]o- or [Ca2+]o-evoked [Ca2+]i responses in a
population assay in HEK5001 cells measured by Fura-2 acetoxymethyl (AM) in the
absence (black square) or presence of Phe (blue triangular) or TNCA (red closed
circle). (C) A maximally active concentration of 0.1 to 0.5 mM TNCA markedly
reduces the EC50 for activation of [Ca2+]i signaling by [Mg2+]o in the presence of 0.5
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mM [Ca2+]o. Inset: The EC50 changes of [Mg2+]o is shown over a narrow concentration
range of TNCA.

Two positively charged residues in mGluR1 (R78 and K409) that associate with the carboxylate
group of the Glu ligand are replaced in hCaSR by W70 and I416, which interact with the indole
ring of TNCA. Bulky residues (Y74, W110, and R323) that limit the mobility of the Glu side
chain are replaced by smaller residues in hCaSR (G67, N102, and S302). As a result, the size of
the ligand binding pocket of hCaSR is significantly larger than that of mGluR1, consistent with
the preference of CaSR for larger ligands. Unlike Trp, TNCA is in a fixed and presumably
preferred conformation, accounting for the higher binding affinity compared to Trp.

Table 2.1 – EC50 of [Mg2+]o for stimulation of [Ca2+]i signaling in the presence of different
co-activators and TNCA.
Population Assay
Single Cell assay
Co-activator (mM)
EC50
Hill Number
EC50
Hill Number
0.0 Ca2+

ND

ND

12.9 ± 0.3

2.9 ± 0.2

0.5 Ca2+

7.2 ± 0.4

5.5 ± 0.5

7.5 ± 0.3

4.7 ± 0.8

1.5 Ca2+

4.5 ± 0.3

2.9 ± 0.6

5.9 ± 0.4

4.1 ± 0.8

0.5 Ca2+ + 0.5 TNCA

3.3 ± 0.7

3.5 ± 1.0

ND

ND

0.0 Ca2+ + 0.25 TNCA

ND

ND

5.6 ± 0.3

5.2 ± 1.3

0.5 Ca2+ + 0.25 TNCA

ND

ND

4.8 ± 0.2

4.7 ± 0.6

1.5 Ca2+ + 0.25 TNCA

ND

ND

4.4 ± 0.1

3.5 ± 0.2

0.5 Ca2+ + 10.0 Phe

6.0 ± 0.7

4.9 ± 2.3

ND

ND

ND = not determined
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Mapping of disease-associated mutations on the structure of hCaSR-ECD shows that the mutations
are clustered in two regions: the hinge region between subdomains 1 and 2 and the dimerization
interface (Figure 2.14)[273, 274]. Indeed, our structural and functional data strongly support the
pivotal roles of these two regions in CaSR function.

Figure 2.14 – Disease-related mutations on CaSR ECD.
Blue: Loss-of-function mutations associated with familial hypocalciuric
hypercalcemia (FHH), Red: Gain-of-function mutations associated with autosomal
dominant hypocalcemia (ADH).

The hinge region between subdomains 1 and 2 harbors the binding site of TNCA, supporting its
role as a co-agonist of CaSR. Two other co-agonists of CaSR, Phe and Trp, likely bind in the same
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position. We did not observe metal binding at the previously proposed site 1 for Ca2+ [259, 269, 283].
A close inspection of the structure reveals that the side chain of E297, a critical residue predicted
for Ca2+ binding in this proposed site 1, swings away from the other residues in site 1 (S170, D190,
Q193, and Y218), probably due to the extra carbon atom and the rigid structure of TNCA,
ultimately resulting in its failure to capture the Ca2+ ion in combination with other site 1 residues.
We were able to make several mutations on the ECD of hCaSR in order to test the functionality of
these binding sites for TNCA and Mg2+. These mutations were E297I, Y218K, S272I, D275I, and
E228I.
Mutations of E297I, Y218K, S272I, and D275I saw a complete loss of cell response to Ca2+ (Figure
2.15). Upon testing the cell surface expression of these CaSR mutants using confocal staining of
non-permeabilized cells we saw that they were expressed on the cell (Figure 2.15). The fact that
these mutations are expressed on the cell but have no cellular response tells us that the mutations
are critical for function and/or correct structural conformation of CaSR.

Figure 2.15 – Complete loss of function hinge CaSR mutations.
Representative plots for WT hCaSR (black), E297I (red), Y218K (green), S272I
(blue), and D275I (purple) CaSR mutants of the loss of oscillation function in response
to increasing [Ca2+]o. CaSR structure (right) with zoom in on hinge binding site with
mutations in red. Representative membrane expression (right lower) of CaSR on the
cell surface of WT and the E297I, Y218K, S272I, and D275I CaSR mutants as shown
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here with Y218K and D275I as examples. NC = no CaSR transfected, blue center =
DAPI, and green outline = CaSR expression.

As for the E228I CaSR mutation was not only successfully expressed on the cell membrane but
also had functionality in response to [Ca2+]o and [Mg2+]o (Figure 2.16). Although the E228I
mutation does have cell expression and functionality the EC50 for [Mg2+]o activation is partially
lost from 12.9 mM for WT CaSR to 15.6 mM for E228I mutation as well as a loss in functional
cooperativity (Figure 2.16).

Figure 2.16 – Determining TNCA binding capability to hCaSR-ECD.
(A) TNCA potentiates [Mg2+]o-evoked [Ca2+]i responses in CaSR mutant E228I and
the double mutant E228I/E229I analyzed using fluorimetry in cell population assay
in 0.5 mM basal [Ca2+]o. (B) Calcium and (or) TNCA potentiate the [Mg2+]ostimulated intracellular calcium responses in the single-cell imaging assay. Black
squares are without [Ca2+]o or TNCA, green triangles are with 0.25 mM TNCA, red
circles are with 0.5 mM [Ca2+]o and 0.25 mM TNCA, and blue diamonds are with 1.5
mM [Ca2+]o and 0.25 mM TNCA. Single-cell intracellular calcium responses were
recorded using a fluorescence microscope and normalized [Ca2+]i was plotted against
[Mg2+]o then further fitted using the Hill equation. (C) TNCA potentiates [Ca2+]i
responses of both WT CaSR or mutant E228I to [Mg2+]o stimulation in the single-cell
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imaging assay in the absence of basal [Ca2+]o. Black squares are the WT without
TNCA, black triangles are the WT with 0.25 mM TNCA, red circles are the E228I
mutant without TNCA, and red diamonds are the E228I mutant with 0.25 mM
TNCA. (D) Membrane expression of CaSR, mutant E228I and double mutant
E228I/E229I. Blue: DAPI staining cell nuclei. Green: hCaSR immunoreactivity.

We then added 0.25 mM of the Trp-derivative TNCA to the mutation which still had function
E228I and found that not only does TNCA recover the loss of function of the E228I from 15.6 mM
in comparison to the WT CaSR of 12.9 mM, but actually recovered the function all the way to 6.3
mM which is similar to the activated WT CaSR with TNCA itself at 5.6 mM as well as recovering
the loss of functional cooperativity (Figure 2.16-Figure 2.17 and Table 2.2). This shows that
TNCA is a strong calcimimetic able to recover disease related mutations affecting molecular
biological functionality.

Figure 2.17 – CaSR mutation E228I representative oscillations.
A&B – Representative plots for E228I CaSR mutant oscillation function in response
to increasing [Mg2+]o. EC50 plots for the respective trials are shown on the far right.
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Nevertheless, the essential role of E297 in Ca2+ sensing has been supported by previous mutational
studies[23, 269] and in the abrogated Mg2+ sensing of the E297I mutant (Table 2.2). A bicarbonate
anion was also identified in the hinge region in proximity with TNCA, coordinated by the side
chains of R66, R69, W70, and S417 and the backbone amide nitrogen atoms of I416 and S417,
potentially contributing to the known pH sensitivity of the CaSR[275].
Table 2.2 – EC50 of [Mg2+]o for stimulation of [Ca2+]i signaling with or without TNCA.
Co-activator (cell population)
0 mM TNCA
0.5 mM TNCA
(0.5 mM Ca2+)

EC50

Hill Number

EC50

Hill Number

WT

7.2 ± 0.4

4.0 ± 1.0

3.3 ± 0.7

3.5 ± 1.0

E228I

10.8 ± 0.3

3.9 ± 0.4

4.9 ± 0.3

6.2 ± 2.6

E228/E229I

10.0 ± 0.5

4.6 ± 0.5

3.5 ± 0.5

4.3 ± 1.7

Y218K

No Response

No Response

S272I

No Response

No Response

D275I

No Response

No Response

E297I

No Response

No Response

Co-activator (single cell imaging)

0 mM TNCA

0.25 mM TNCA

(0.0 mM Ca2+)

EC50

Hill Number

EC50

Hill Number

WT

12.9 ± 0.3

2.9 ± 0.2

5.6 ± 0.3

5.2 ± 1.3

E228I

15.6 ± 0.9

3.5 ± 0.6

6.3 ± 0.2

4.6 ± 0.6

Y218K

No Response

No Response

S272I

No Response

No Response

D275I

No Response

No Response

E297I

No Response

No Response
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No Response mutants were tested for expression and showed cell surface expression but without
CaSR activity

2.3

Discussion

We report here the first crystal structure of the ECD of human CaSR bound with Mg2+ and a
tryptophan derivative ligand at 2.1 Å. The structure reveals important determinants for cooperative
activation of the CaSR by metal ions and aromatic amino acids, including key residues in the ECD
participating in Mg2+ and amino acid binding. We have found two confirmed Mg2+/Ca2+ binding
sites, a drug TNCA binding site, and a bicarbonate binding site.

Figure 2.18 – Working model of CaSR binding and activity.
Unbound inactive CaSR is activated by Ca2+/Mg2+ binding cooperatively upon
multiple binding sites. Then CaSR is further activated and stabilized by TNCA or
amino acids (AA).

The hinge TNCA binding site consists of residues S147, A168, S170, Y218, and E297. Four of
these residues overlap exactly with our predicted Ca2+ binding site. The dimerization binding site
of Mg2+, which is possible to also be Ca2+ since with weak binding Ca2+ did not show on the crystal
structure, are residues E228, E231, S240 and E341 from the other monomer. Two of these residues
overlap a binding site on the modeled structure. Lastly, a new Mg2+ site was found that was not
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predicted using our modeled structure and also found in the Geng et al. paper, these residues are
I81, S84, L87, and L88[284].
Several lines of evidence indicate a critical role of CaSR-ECD dimerization in CaSR function
(Figure 2.5 and Figure 2.9). First, two metal binding sites are identified within the acidic patch at
the dimerization interface of subdomain 2 (Figure 2.6). A double mutant of CaSR (E228I/E229I)
in site 2 showed a significantly decreased responsiveness to [Ca2+]o, and the E228I mutation also
reduced activation of [Ca2+]i oscillations induced by [Mg2+]o as well as reduced Mg2+ binding,
despite a similar level of membrane expression as WT CaSR (Figure 2.16 and Table 2.2)[259]. These
data strongly suggest a role of metal binding at the acidic patch in metal sensing and signal
transduction which supports our working model that Ca2+ and Mg2+ activate CaSR and that TNCA
further activates and stabilizes disease mutations (Figure 2.18).
Table 2.3 – Comparison of the binding sites between CaSR structures.
Potential Binding Sites Modeled
Ca2+ BS 1 BS2

BS3 BS4

BS5

CaSR Determined Structure

Elife CaSR

TNCA Mg2+ BS1 BS2

Trp

Ca2+ BS1 BS2
I81

BS3 BS4

S147

D215 E224 E350 T396

S147

E228

I81

S147

S170

L242 E228 E353 D398

A168 E231

S84

A168 N82

N102 S303 D234

D190

S244 E229 E354 E399

S170

L87

S170

S84

T145

Y218

D248 E231 N386 E378

Y218 S240

L88

Y218 L87

G146

E297

E253 E232 S388 E379

E297

E341*

E297

T100 S302 E231

G567

L91

Several months after our crystal was published another group was able to crystallize the CaSR
ECD with the cys-rich domain as well but lacking the dimerization loop on top. They also observed
several Ca2+ binding sites in the holo form, as well as one in the apo form too. They also observed
Trp bound in the hinge site of each monomer in the holo form, which perfectly corresponds to our
TNCA binding site. The dimer site 2 for Mg2+ overlaps 2 residues with binding site 3 dimer site
for Ca2+ in the modeled structure as well as 1 residue in Ca2+ site 4 in the Geng et al. paper[284].
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Figure 2.19 – Comparison of our CaSR 5FBK and the Geng et al. CaSR 5K5S[284].
CaSR 5FBK (green) and the Geng et al. CaSR 5K5S (Active Form) (gray). 5FBK has
Mg2+ yellow spheres, and TNCA blue sticks by element, while 5K5S has Ca2+ red
spheres, Trp orange sticks by element, and PO4 pink spheres.
Lastly, our Mg2+ binding site 3 overlaps three residues with the Geng et al. Ca2+ binding site 1[284].
These similarities in binding sites show that these residues are most likely conserved and highly
important to the function and structure of CaSR. Since our structure was treated with Mg2+ we
had Mg2+ binding sites resolved while the Geng et al. paper showed Ca2+ binding sites[284]. We
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also compared the TNCA and Trp binding sites as well as the modeled binding sites in table form
(Table 2.3).

Figure 2.20 – Comparison of our CaSR 5FBK and the Geng et al. CaSR 5K5T[284].
CaSR 5FBK (green) and the Geng et al. CaSR 5K5T (apo) (magenta). 5FBK has Mg2+
yellow spheres, and TNCA blue sticks by element, while 5K5T has Ca2+ red spheres,
Trp orange sticks by element, and SO4 yellow-orange spheres with Loop 1 in light
pink.

The structures of our holo form structure versus the Geng et al. holo form are nearly perfectly
identical in their overlap regions (Figure 2.20)[284]. The main differences are that our structure has
the dimer loop 2 and theirs has the cys-rich domain determined. Additionally, the metals binding
is different, as described previously.
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Whereas the holo forms 5FBK and 5K5S perfectly overlap, there are some structural difference
between our holo form 5FBK and the Geng et al. apo form 5K5T (Figure 2.20)[284]. The most
substantial differences are in the space available in the hinge region for binding and loop 1. The
apo form has the hinge region more open and the helixes and sheets around the region moving
away from it, opening the space for binding of metal ions or TNCA. Loop 1 of the apo form also
has moved up, this could be because the structure is less stable when in apo form or because it is
represented only as a monomer.
Besides, extensive interactions between the disulfide linked dimeric ECDs and their respective
subdomains that produce a closed and likely active conformation of the Venus flytrap motifs of
the two ECDs are present. The unexpected tryptophan derivative that was bound in the hinge
region between two ECD subdomains represents a novel high-affinity co-agonist of CaSR that
potentiates activation of the full-length CaSR expressed in HEK293 cells by Ca2+ and Mg2+. We
showed that TNCA is able to alter the [Ca2+]i oscillation frequency when co-activated with [Ca2+]o
showing alteration in cellular signaling function since we know that a change in [Ca2+]i frequency
is related to a change in cellular functions where faster oscillations are necessary for quick
processes such as dendritic growth and insulin production while slower frequency oscillations are
related to slow processes such as fertilization or cell growth[25-28]. Furthermore, TNCA modulates
Mg2+ activity as an agonist shifting the EC50 for Mg2+ down and having stronger Mg2+ functional
activity as well as functional cooperativity which supports our working model that Ca2+ and Mg2+
activate CaSR and that TNCA further activates and stabilizes CaSR (Figure 2.18). In addition,
Mg2+ with TNCA and sub activating Ca2+ concentrations brings the binding efficacy of Mg2+ down
to similar to WT CaSR with Ca2+ alone. Mutations of the primary hinge binding pocket which
binds Ca2+ and TNCA leads to a complete loss of functional activity and functional cooperativity.
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Mutation of residues E297, S272, and D275 to hydrophobic reside Ile led to the annihilation of
CaSR signaling in response to either loss of receptor binding or structural integrity disruption.
Additionally, changing the Y218 residues also in this critical hinge binding pocket to a positively
charged Lys residue also led to a complete loss of CaSR functional activity and functional
cooperativity most likely due to the repulsion of positively charged cations Ca2+ and Mg2+. TNCA
can also act as an agonist and stabilize mutations of E228I and E228/229I which supports our
working model that Ca2+ and Mg2+ activate CaSR and that TNCA further activates and stabilizes
disease mutations (Figure 2.18). These mutations led to a loss of function in CaSR and TNCA
was not only able to stabilize the CaSR structure of the mutants back to WT CaSR function but
further to a gain-of-function activity, which TNCA was able to produce on the WT CaSR itself.
Therefore, TNCA is a potent agonist able to completely remove the effects of loss of function
CaSR mutations.
We would like to further engineer more mutations but rather than binding site disruption we would
like to also investigate known disease mutations of the hinge, dimer, new top, and bicarbonate
binding sites to examine the effects these disease mutations have on CaSR functional activity as
well as cooperativity. Since these disease mutations do not often lead to fetal death, we would
expect a still partially functional CaSR unlike the disruption mutations in the hinge site which led
to a loss of signal. Additionally, expressing and purifying full length CaSR for crystallization
would be the next step so that we could visualize the 7TM domain along with the ECD to see if
drugs added to the protein bind to ECD or 7TM as confirmed by crystal structure since currently
CaSR drug targets have not confirmed the region of binding using a crystal structure.
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2.4

Materials and Methods
2.4.6

Computational prediction

The structure of the extracellular domain of CaSR (residues 25-530) was modeled based on the
crystal structure of the metabotropic glutamate receptor 1 (mGluR1) (1EWT, 1EWK and 1ISR),
and the potential Ca2+-binding sites in the CaSR ECD were predicted using MetalFinder[264] or
MUG (MUltiple Geometries)[265-268].
2.4.7

mCaSR ECD expression

One liter of Life Technologies Freestyle™ 293 Expression Medium was used for HEK293F or
Lec1 mutant HEK293F cell culture. Cells were transfected with pXLG-hCaSR-ECD plasmid
using the polyethyleneimine method when the cell density achieved 8x10^5. The hCaSR-ECD
was secreted into the culture media. When the cell density reached 5 x 106 cell/mL, the media
was collected by centrifugation 3 times at 1500xg for 10 min. The supernatant was diluted with
dilution buffer (Tris NaCl pH=8.0) at a ratio of 1:3 and further filtered through a Millipore 0.45
µm filter. The filtered medium was applied to a 16/10 GE Healthcare HisTag HP column preequilibrated with Buffer A (Tris 50 mM, NaCl, 150 mM, Imidazole 20 mM) and a linear segmented
gradient of 0–100% Buffer B (50 mM Tris, 500 mM NaCl, and 500 mM imidazole, pH 7.4) was
run using FPLC to elute the protein. The hCaSR-ECD concentrations were determined using BioRad protein assay.
2.4.8

mCaSR ECD purification

Purification of hCaSR-ECD secreted from HEK293S GnTI- cells hCaSR-ECD (from residues
Tyr20 to Phe612) was expressed in suspension culture of HEK293S GnTI- cells and purified from
the culture medium by Ni2+–nitrilotriacetic acid chromatography, as previously described[285]. To
deglycosylate the purified protein, hCaSR-ECD was incubated with recombinant endoglycosidase
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F1 (Endo F1) at a 1:100 mass ratio of Endo F1 to hCaSR-ECD[286] overnight at 4°C in 10 mM tris
buffer (pH 7.4). Further separation of hCaSR-ECD from Endo F1 was achieved by size exclusion
chromatography in 10 mM HEPES buffer (pH 7.3)[287].
2.4.9

Crystallization, data collection, and structure determination

The dimeric hCaSR-ECD was concentrated to 10 mg/mL and crystallized in 10% polyethylene
glycol (PEG)–8000, 200 mM MgCl2, 10 mM CaCl2, and 100 mM Tris-HCl (pH 7.0), using the
sitting drop approach at 21°C. No crystals were formed in the absence of Ca2+ or Mg2+. The plateshaped crystals were cryoprotected using 25% glycerol and were flash-frozen in liquid nitrogen.
Dehydration by soaking the crystal in 12% PEG-8000 overnight improved the resolution from 3.5–
4 to 2–3 Å. The diffraction data of the crystals were collected on the beamline of 21-ID-D at LSCAT (Life Sciences Collaborative Access Team) in APS (Argonne Photon Source) and indexed,
integrated, and scaled in HKL2000[288]. The structure was solved at 2.1 Å by molecular
replacement using Auto-MR (automated molecular replacement) in PHENIX[289]. The structure
of chain A of mGluR2 with a bound agonist (PDB ID: 4XAQ) was used as the search template[271].
The electron density map after molecular replacement was clear enough to identify the unique
features of hCaSR-ECD, and iterative model building and refinement were performed using
COOT[290] and Refmac5 in the CCP4[291]

suite, respectively. The restraints of 1,2,3,4-

tetrahydronorharman-3-carboxylic acid (TNCA) were generated by JLigand in COOT.
To generate the Gd3+ derivative, the native crystals were soaked with a solution containing 12%
PEG-8000, 200 mM MgCl2, 10 mM CaCl2, 100 mM Tris-HCl (pH 7.0), and 0.5 mM GdCl3
overnight at 21°C. The anomalous signals of a data set at 2.7 Å collected at the wavelength of
1.6985 Å were used to locate Gd3+ in the structure. The structure was solved by molecular
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replacement using the previously determined structure as the search template. All the figures of
protein structures were generated by PyMOL version 1.3 (Schrodinger LLC).
2.4.10 High-resolution LC-ESI-MS and identification of TNCA
In our crystal structure, there was an unidentified ligand (CaSRL) bound at the putative orthosteric
ligand binding site of CaSR-ECD. The size of the density suggested that the CaSRL contained 14
to 18 heavy atoms (C/N/O/S/P), and the absence of anomalous signal indicated that it did not
contain sulfur or phosphate. To extract CaSRL, 50 mL of purified hCaSR-ECD (10 mg/mL) was
mixed with 120 mL of acetonitrile and was vortexed. After highspeed centrifugation, 10 mL of
the CaSRL extract was injected onto a reverse-phase ACQUITY UPLC BEH C18 column (2.1 ×
100 mm, 1.7-mm particle size; Waters). The column temperature was maintained at 40°C. The
flow rate was 0.3 mL/min with starting conditions at 99% solvent A (water + 0.1% formic acid)
and 1% solvent B (acetonitrile). The 15-min gradient profile for elution was as follows: starting
at 1% solvent B, hold for 1 min, then ramp to 98% B at 10 min, hold at 98% B to 12 min, return
to 99% A/1% B at 12.01 min, and maintain until 15 min. The samples were analyzed using a
Waters Xevo G2-XS QToF LC-MS interfaced to a Waters ACQUITY UPLC system. The MS
settings were as follows: electrospray ionization in negative-ion mode, capillary voltage of 2.00
kV, source temperature of 100°C, desolvation temperature of 350°C, desolvation nitrogen gas flow
rate of 600 L/hour, cone voltage of 35 V, and mass range of m/z 50 to 1500 with spectra
accumulated at 0.1 s per function. Three separate acquisition functions were performed to generate
spectra at different collision energies (5, 25, and 60 eV) providing both non-fragmenting and
fragmenting conditions. Analyses of samples by electrospray ionization in the positive-ion mode
were performed under the same conditions as negative-ion mode except for the collision energies
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(5, 20, and 40 eV).

Fragmentation, formula, and abundances were analyzed with Waters

MassLynx Software.
Using the above approach, we identified a species eluting at ~4.65 min, detected by MS in both
positive-ion mode (m/z of 217.0990) and negative-ion mode (m/z of 215.0824), exclusively
present in protein samples from several different batches but not in the sample buffer. The
predicted elemental compositions based on mass are C12H13N2O2 (calculated mass = 217.0977
Daltons) for positive ion mode and C12H11N2O2 (calculated mass = 215.0824 Daltons) for
negative-ion mode. A thorough search in the PubChem database led to a list of candidates
containing up to 200 compounds with the same MW and formula. By manually fitting the density
map with these compounds, only TNCA fit the density perfectly. Synthetic TNCA dissolved in
the SEC buffer was treated in the same way as the protein samples in the LC-ESI-MS experiment,
and resulted in a peak detected at the same retention time and having the same mass spectrum. In
the LC-ESI-MS experiment, we also noticed a minor species that eluted at ~4.57 min which was
detectable only in the positive-ion mode (m/z of 215.0836) and having a predicted elemental
formula of C12H11N2O2. The 2-dalton smaller MW for this related compound suggested that it was
a derivative of TNCA, likely due to a double bond formation between the backbone N and a
neighboring C. Because it is also likely to be a tryptophan derivative, we cannot exclude the
possibility that it binds hCaSR-ECD with high affinity. This compound may also form during the
extraction of TNCA from the protein sample. Nevertheless, TNCA perfectly fits the electron
density at 2.1 Å, and any extra double bonds in the CaSRL structure would likely be detrimental
to fitting the density.
A phenylalanine replacement experiment was carried out by mixing purified hCaSR-ECD protein
(0.26 mg/mL) with phenylalanine (final concentrations are 0, 50, and 150 mM, respectively). After
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overnight incubation at room temperature, hCaSR-ECD in each sample was re-purified with Ni2+NTA beads. The protein samples were adjusted to the same concentration using SEC buffer and
analyzed by LC-ESI-MS.
2.4.11 Immunohistochemistry antibody staining
Cells transfected with hCaSR-pcDNA3.1(+) were used in the immunostaining experiments, and
this construct contained a FLAG tag between Asp371 and Thr372.

After 48 hours post-

transfection, cells were fixed with 3.7% formaldehyde for 15 min at room temperature, followed
by washing with phosphate-buffered saline (PBS) three times. Mouse anti-FLAG monoclonal
antibody was diluted 500 times and incubated with cells overnight at 4°C to stain the cell-surface
CaSR. The cells were subsequently washed with PBS and stained with goat anti-mouse Alexa
488–conjugated secondary antibody for 1 hour at room temperature. Nuclei were stained with
4′,6-diamidino-2-phenylindole (DAPI). Fluorescence was visualized using a Zeiss LSM780
confocal microscope.
2.4.12 SDS-PAGE gels and western blot
Cells were harvested and then suspended in 200 µL of Western blot lysis RIPA buffer on ice for
15 min. After centrifugation at 15000 × g for 15 min at 4°C, the supernatants were collected. The
proteins were separated on 8.5% SDS-PAGE. After electrophoresis, equal amounts of protein
from each sample were transferred to a nitrocellulose membrane. The membrane was blocked
with 5% nonfat milk in TBS and then incubated with first mouse anti-flag antibody (1:3000)
separately overnight at 4°C. After being washed three times with TBST, the membrane was
incubated at room temperature for 1 hr with goat anti-mouse secondary antibody diluted with
TBST (1:3,000). The detected protein signals were visualized by an enhanced chemiluminescence
reaction system (Bio rad).
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2.4.13 Cell culture and transfection
Monolayer cultures of HEK293 cells were purchased from American Type Culture Collection
(ATCC CRL-1573) and maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and high glucose (4.5 g/L) at 37°C. WT CaSR
or its mutants were transfected into HEK293 cells using Lipofectamine 2000 or 3000 (Life
Technologies) by following the manufacturer’s instructions. Prepare transfection solution: 1
mL/coverslip in dish of 1X Opti-medium, 1 µL of pcDNA The CaSR (1 µg/mL), 2.5 µL of
transfection reagent (Lipofectamine 2000). Incubate transfection solution for 15-20 mins at room
temperature in a dark area. After incubation wash each dish (with coverslip of cells ~70%
confluence) with 1-1.5 mL of HBSS. Add 3 mL of 1X Opti-medium to each dish. Take 1 mL of
transfection solution and add dropwise to coverslip stirring immediately after several drops.
Incubate coverslips within petri dishes for 4-6 hrs. Remove transfection solution and add 2 mL of
fresh, normal medium for cell type. Incubate for 24-48 hr for cell imaging.
2.4.14 Cell imaging
The CaSR WT was transiently transfected into HEK293 cells grown on coverslips and cultured
for 48 hr at 37°C. Fura 2-AM stock solution is diluted from 1 mM to 1 μM (1000-fold) by adding
2 µL Fura 2-AM stock solution into 2 mL of physiological Ringer buffer (10 mM HEPES, 121
mM NaCl, 2.4 mM K2HPO4, 0.4 mM KH2PO4, 1.2 mM MgCl2, 1.2 mM CaCl2 and pH 7.4). The
addition of 2 µL of the non-ionic detergent Pluronic ® F-127 can assist in the dispersion of the
nonpolar AM ester in aqueous media. The cells are incubated in the 2 mL of AM ester solution
for 15–20 minutes at 37°C. After incubation, the cells are washed twice with Ringer buffer,
without calcium. The coverslips are mounted on a bath chamber and placed on the stage of a
fluorescence microscope. The cells were alternately illuminated with 340 or 380 nm light, and the
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fluorescence at an emission wavelength 510 nm was recorded in real-time as the concentration of
extracellular Ca2+ was increased in a stepwise manner. The ratio of emission fluorescence intensity
from both excitation wavelengths was further calculated as a function of [Ca2+]o. All experiments
were performed at room temperature. Oscillations were identified as three successive fluctuations
in the [Ca2+]i after the first main cellular peak.
2.4.15 Measurement of [Ca2+]i changes by [Mg2+]o in single CaSR-transfected cells
Measurement of intracellular free Ca2+ was assessed as described by Huang et al.[259]. Briefly, WT
CaSR or its mutants were transiently transfected into HEK293 cells grown on coverslips and
cultured for 48 hours. The cells were subsequently loaded for 15 min using 2 mM Fura-2 AM in
2 mL of physiological saline buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, and 1.0 mM
MgCl2) (pH 7.4). The coverslips were mounted on a bath chamber on the stage of a Leica DM6000
fluorescence microscope. The cells were alternately illuminated with 340- or 380-nm light and
the fluorescence at an emission wavelength of 510 nm was recorded in real-time as the [Ca2+]o
and/or [Mg2+]o was increased in a stepwise manner in the presence or absence of 0.25 mM TNCA
in buffer (10 mM HEPES, 155 mM NaCl, 5 mM KCl, 2 mM NaH2PO4, and 0.5 mM MgCl2) (pH
7.4). The ratio of the emitted fluorescence intensities resulting[23] from excitation at both
wavelengths was utilized as a surrogate for changes in [Ca2+]i and was further plotted and analyzed
as a function of [Ca2+]o. All experiments were performed at room temperature. The signals from
2 to 100 single cells were recorded for each measurement. Oscillations were identified as three
continuous fluctuations in [Ca2+]i after the initial peak.
2.4.16 Intracellular calcium concentration in cell population by fluorimetry
The [Ca2+]i responses of wild type (WT) CaSR and its mutants were measured as described by
Huang et al.[259]. Briefly, CaSR-transfected HEK293, or stably transfected HEK5001, cells were

70

grown on 13.5 × 20 mm coverslips. After the cells reached 90% or higher confluency, they were
loaded by incubation with 2 μM Fura-2 AM in 20 mM HEPES, containing 125 mM NaCl, 5 mM
KCl, 0 mM CaCl2, 0.5 mM MgCl2, 1 mM NaH2PO4 (pH 7.4) for 15 mins at 37°C and then washed
twice with Ca2+-free Ringer’s buffer. The coverslips with transfected, Fura-2-loaded HEK cells
were placed diagonally in 3-mL quartz cuvettes containing Ca2+-free Ringer’s buffer. The
fluorescence spectra at 510 nm were measured during stepwise increases in [Ca2+]o with alternating
excitation at 340 or 380 nm. The ratio of the intensities of the emitted light at 510 nm, when
excited at 340 or 380 nm, was used to monitor changes in [Ca2+]i. The EC50 and Hill constants
were fitted using the Hill equation, S =

[M ]n
K d + [M ]n
n

, where ΔS is the total signal change in the

equation, Kd is the apparent binding affinity, n is the Hill coefficient, and [M] is the free metal
concentration. Measurements of Fura-2 fluorescence at 510 nm, when excited at 340 or 380 nm,
were performed on a QM1 fluorescence spectrophotometer (Photon Technology International).
The emission ratio of 340/380 was calculated and used to reflect the changes in [Ca2+]i when
different concentrations of [Mg2+]o were applied to the cells. To examine the coactivation of CaSR
by TNCA and [Mg2+]o or [Ca2+]o, different concentrations of TNCA were placed in the
experimental buffer with a fixed concentration of [Ca2+]o and varying concentrations of [Mg2+]o,
or vice versa, as described in the Results section. The effects of other ligands were analyzed by
comparing the changes in [Ca2+]i produced by [Mg2+]o alone or by co-application of Mg2+ with
other ligands. The EC50 of [Mg2+]o obtained during incubation with various concentrations of
TNCA is compared with that observed in the presence of [Mg2+]o alone. The EC50 changes were
plotted as a function of TNCA concentration, and the curve was fit to the Hill equation,
S =

[M ]n
K d + [M ]n
n

, where ΔS is the total signal change in the equation, Kd is the apparent binding
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affinity, n is the Hill coefficient, and [M] is the free metal concentration. The activation of CaSR
by the TNCA, functioning as a co-agonist with [Mg2+]o, was indicated by the increasingly leftshifted EC50 for [Mg2+]o as the concentration of TNCA increases.
2.4.17 BSA standard and protein analysis
Create the samples (total volume of 1 mL) making 2 blanks (800 µL of ddH2O and 200 µL of BioRad) and samples, one for each plate in experiment (800 µL of ddH2O, Usually we use 1 µL of
protein so we would add 800 µL of ddH2O and then remove 1 µL of ddH2O to get 799 µL of
ddH2O, 1 µL of protein, 200 µL of Bio-Rad). Run the samples using UV-Vis quantitative method.
Use the blanks to auto-zero and then run each sample by pressing Start/Run/Record depending on
the instrument. (NOTE: Have the cuvettes all facing the same direction in the machine for each
sample recording). Transfer data into an excel spreadsheet, either one with the already done
standard curve or a new one to make the standard curve and data. After the equation y=mx+b from
the standard curve is known we may use this to solve for each sample’s x-value, the UV-Vis values
being their respective y-values. This will be their protein concentration value.
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3
3.1

Understanding Molecular Basis of CaSR Related Diseases

Introduction

CaSR is a part of the family C of GPCR superfamily with a large ECD, a cys rich domain (CRD),
a 7TM domain, and an ICD[21]. CaSR plays critical functional roles in biological and pathological
regulation and is extensively expressed throughout the body in the skin, gastrointestinal, the central
nervous system (CNS), cardiovascular, in bone, kidney, breast, and the parathyroid tissues[249-252].
The CaSR primary function is to regulate Ca2+ homeostasis and disease related mutations can cause
loss of function familial hypocalciuric hypercalcemia (FHH) and neonatal severe
hyperparathyroidism (NSHPT) which reduce CaSR’s sensitivity to [Ca2+]o, whereas over
activating mutations for a gain of function lead to autosomal dominant hypocalcemia (ADH).
Additionally, CaSR mutation and dysfunction has also been linked to carcinomas, osteoporosis,
hyperparathyroidism, hypoparathyroidism, renal failure, and cardiac disease. The primary agonist
for CaSR is Ca2+ for the regulation of Ca2+ homeostasis but has been shown to respond to various
other cations such as Mg2+, Gd3+, and Tb3+ [22, 253, 254]. We are interested in if we can correlate the
changes between the WT CaSR and disease related mutations using bacterially expressed CaSR
for structural, binding, and expression information in comparison to functional and signaling
information gained from cellular CaSR studies in order to expand our understanding in diseasemediated function differences[287].
Since CaSR is a transmembrane protein it has the issues associated with transmembrane protein
expression for binding, function, and structure studies in that transmembrane proteins are
notoriously difficult to stably express and crystallize. As such, we initially analyze the functional
domain alone, in lieu of the full protein omitting the transmembrane domain, in the case of CaSR
the main functionality is within the ECD. We looked at bacterially expressed CaSR since
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mammalian expressed CaSR has the issues of glycosylation can hinder binding studies using
fluorescence spectroscopy, expression and purification is more time extensive, and we found that
TNCA was bound to mammalian expressed CaSR thus being a holo ECD form. Bacterial
expressed CaSR has the benefit of no post-translational modifications, is quick and cost-effective,
and as such does not have the time for TNCA formation through the Pictet-Spengler reaction, but
does have the issue of potential incorrect protein structure formation from the foreign bacterial
expression system for the human CaSR ECD.

Figure 3.1 – CaSR mutations made for functional studies in cells.
Five binding sites on the CaSR ECD with a dimer Mg2+/Ca2+ binding site(E228, E231,
S240, and E241), a hinge region TNCA/Mg2+/Ca2+ binding site (S147, A168, S170,
A214, D216, Y218, S272, D275, and E297), a new top Mg2+/Ca2+ binding site (I81, S84,
L87, L88, L91), and a bicarbonate binding site (R66, R69, W70, R415, I416, and
S417). Mutations made for functional studies are in red Y218K, E297I, S272I, D275I,
and E228I.

We also wanted to correlate the functional effects the disruption mutations have on expression,
structure, and binding of the CaSR ECD by utilizing a bacterial expression system. This way we
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can visualize the effects of not only functional signaling and functional cooperativity in cell
studies[287] but also the effects on the ECD alone without taking into effect the full-length CaSR
as a dimer for binding and binding cooperativity. For our functional studies, we examined the
mutations affecting the binding of the hinge domain by creating either hydrophobic or charged
residues in the binding pocket to disrupt binding with mutations Y218K, E297I, S272I, and D275I
(Figure 3.1) [287]. We saw that these four critical hinge region binding mutations expressed on the
cell surface but led to a complete loss of functional response even up to 30 mM [Ca2+]i (Figure
2.15) [287]. The other mutation we made was to dimerization region of CaSR at E228 to disrupt the
binding with a hydrophobic residue E228I (Figure 3.1) [287]. This mutation led to a loss of function
effect reducing the binding of Mg2+ which was able to be recovered by TNCA (Figure 2.16) [287].

3.2

Results
3.2.1

bCaSR Expression Development

To optimize correct CaSR ECD structure and disulfide bonds we looked at removing cys residue
regions which could hinder correct CaSR ECD structure expression in a non-native bacterial
expression system. We removed the mammalian shuttle region, called the signal peptide region
(sp), as this would remove one cys residues and is unnecessary in a bacterial expression system
since the CaSR will not need to be transported to the cell surface as in a mammalian expression
system.
We also removed the cys-rich domain (CRD) since there are 9 cys residues in the CRD which
could form incorrect disulfide bonds and potentially an incorrectly folded unstable protein prone
to degradation (Figure 3.2). Thus, cys and sp were removed from bCaSR ECD together or separate
(Figure 3.3).
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Figure 3.2 – bCaSR WT versus bCaSR deletions using Rosetta-gami.
A – Western blot of WT bCaSR ECD expressed in Rosetta-gami cells and tagged with
ADD CaSR antibody. B – Western blot of bCaSR ECD with signal peptide region
deletion (sp-) with or without cys rich domain deleted (cys+/cys-) expressed in
Rosetta-gami cells and tagged with ADD CaSR antibody. bCaSR ECD is
approximately 65 kDa.

Removal of both cys and sp (cys-/sp-) lead to the best protein expression without degradation, but
also a loss of protein concentration and yield (Figure 3.2).
In order to improve the yield as well as maintain the stable expression, we further mutated four
cys residues to ala residues, which would also keep the CaSR ECD in monomer form and could
assist in CaSR stability. Additionally, we used an optimized E. coli expression system of SHuffle
cells over Rosetta-gami which is optimized for correct disulfide bond formation. SHuffle and
Origami, which Rosetta-gami was derived from, both have suppression of thioredoxin reductase
(trxB) and glutathione reductase (gor) which break down disulfide bonds.
This allows these E. coli cells to form disulfide bonds, thus allowing more accurate protein folding.
These also contain a mutant of alkyl hydroperoxide reductase subunit C (AhpC), which assist on
the detoxification of reactive oxygen species, this mutant, AhpC*, removes lethality of trxB and
gor suppression by mimicking their roles by the ability to reduce glutaredoxin 1 (Grx1), restoring
reducing power to the cells (Figure 3.4).
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Figure 3.3 – CaSR sequence.
Each letter denotes an amino acid. Red bars represent α-helicies, blue arrows
represent β sheets, and gray bars represent loop regions. The ECD is shown above
the gray membrane, the TMD is shown overlapping gray membrane, the amino acids
with the TMD that extend above and below the membrane are the TMD loops, and
the ICD is below the gray membrane. The two magenta C amino acids connected by
a magenta bar represent the disulfide bond location for homodimer formation.
Yellow background colored N amino acids represent potential N-linked glycosylation
sites. Purple C amino acids represent the 9 cysteines in the cys-rich domain of the
ECD. Amino acids are numbered every 10 amino acids.
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Origami forms disulfide bonds indiscriminately since it has periplasmic DsbA (Disulfide bond
isomerases family C) that leads to mis-oxidized and inactive proteins even though they present
with correct molecular weight (MW) on gels.

Figure 3.4 – The difference of SHuffle compared to Rosetta-gami.
The western blot performed with ADD CaSR antibody.

While SHuffle has cytoplasmically over-expressed DsbC under the rRNA promoter rrnB which
improves correct folding. Rosetta-Gami is an Origami derivative with enhanced expression of
eukaryotic proteins containing specific codons.

3.2.2

Disease Related Mutations of CaSR

With the discovery of our CaSR crystal structure, we saw new avenues of mutational CaSR
research to be investigated[287]. Namely, with the confirmation of the main Ca2+/Mg2+ and agonist
binding sites we could look into disease mutations on these binding regions in order to further
understand how these mutations affect CaSR binding and binding cooperativity between the
binding sites which could further lead us to therapeutic targets to address these loss and gain of
function disorders of Ca2+ homeostasis. We investigated the three main cation/TNCA binding sites
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(BS) as well as the bicarbonate/anion/pH BS for disruption or disease related mutations (Figure
3.5).

Figure 3.5 – CaSR disease mutations for ECD.
Green are mutations already done previously. Purple are planned mutations and if
they have disease relevance they are noted in parentheses.

We made mutations for bCaSR so far of R66H (Anion/pH BS for FHH), D216N (Anion/pH BS
for disrupt/cancer), E241K (Dimer BS for ADH), S272A (Hinge BS for disruption), E297K (Hinge
BS for FHH/NSHPT), H254A (Anion/pH BS for disruption), E228Q and E228K (Dimer BS for
ADH), these mutations were successfully made using the KOD DNA polymerase (Table 3.1).

79

Table 3.1 – CaSR disease mutations.

Planned mutations in black, bCaSR in red, hCaSR in blue, and both in green.

3.2.3

Expression and Purification of bCaSR

After the successful PCR point mutations were made we did a small scale expression of 25 mL
and a large scale expression of 600 mL to see if the bCaSR WT and variants were having protein
expression in the SHuffle cells (Figure 3.6). We saw that bCaSR WT, D216N, E241K, H254A,
S272A, and E297K had expression after IPTG treatment on small scale but that R66H, E228K,
and E228Q did not have CaSR expression and that trend remained upon large scale expression
(Figure 3.6).
We then purified the large scale expression of bCaSR WT and the eight mutants and showed that
bCaSR WT was able to be purified using a His-tag column on FPLC (Figure 3.7A). The
purification for bCaSR ECD WT eluted with one single large peak between 20-60% imidazole and
was desalted using a size exclusion column (Figure 3.7A). We then attempted mutation
purification for the bCaSR mutations and found that R66H, E228K, and E228Q had no protein
present after purification based on the UV below 100, the lack of protein bands on the western blot
and no detectable protein concentration (Figure 3.7-Figure 3.8).
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Figure 3.6 – Coomassie blue SDS-PAGE gel of bCaSR WT and mutants expression.
A 25 mL small scale was done followed by a 600 mL large scale of bCaSR WT (1),
and mutations R66H (2), D216N (3), E228K (4), E228Q (5), E241K (6), H254A (7),
S272A (8), and E297K (9). BI is before induction with IPTG, AI is 16 hours after
induction with IPTG, and M is the marker.

The other mutants which were able to express were also purified from the large-scale expression
and all had protein purified using FPLC as well as detectable protein concentration after
concentrating the purified protein.

Figure 3.7 – bCaSR WT and representative mutant purification from SHuffle cells.
His-tag FPLC purification of bCaSR WT (A), R66H (B), D216N (C) and S272A (D)
from SHuffle bacterial cells.

81

D216N and the WT bCaSR both showed great expression and purification with good single peak
elution at imidazole of 20-60% and bands at 65 kDa on coomassie blue and western blot SDS page
gels (Figure 3.7-Figure 3.8). The mutant D216N does show some lower bands below the 65 kDa
band whereas the WT bCaSR does not, these bands could be degradation of the D216N protein or
fragmented parts of the protein (Figure 3.8).
This could also imply that this mutation is detrimental to the structure and stability of the bCaSR
ECD. The elution peak for S272A is shifted to the right and seems to be a wider peak which begins
eluting out around 40% imidazole gradient and completes at approximately 85% imidazole
gradient whereas the WT and D216N bCaSR elution’s presented around 20-60% imidazole
gradient (Figure 3.7).

Figure 3.8 – Western blot gel ADD antibody for bCaSR WT and mutants purification.
Western blot results for histag and desalting peaks for bCaSR WT, R66H, E228K,
E228Q, S272A, D216N, E241K, H254A, and E297K mutants. R66H, E228K, and
E228Q had little to no protein present while H254A and E297K had not enough
protein present.

This change in elution time could indicate a structural change of the protein which allows for the
polyhistidine chain of bCaSR S272A to bind more tightly or efficiently to the column thus needing
more imidazole to remove from the column. Similarly, to the D216N bCaSR mutant, we see the
S272A protein at 65 kDa but also see lower bands not present with the WT bCaSR gels implicating
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some degradation or fragmented protein contaminants (Figure 3.8). While S272A and D216N had
suitable concentrations at 9.9 and 10.9 µM, respectively, which is more than the WT at 8.5 µM the
other mutants had lower concentration of 7.6 µM for E241K, 3.7 µM for H254A, and 2.8 µM for
E297K which shows these mutations lowered protein expression and overall yield (Figure 3.7Figure 3.8). We thus performed biophysical studies with WT bCaSR, S272A, and D216N since
they had the highest protein concentrations enabling triplicate studies for multiple binding
experiments.

3.2.4

Biophysical Studies of CaSR

Expressing protein in a bacterial or mammalian system can allow for further binding studies using
fluorescence spectroscopy, circular dichroism, NMR, SPR, etc. These instruments can be vital in
not only further confirming cellular experiments but elucidating additional information about
structural changes and drug affinities. We examined CaSR ECD binding, binding cooperativity,
and structure utilizing ANS hydrophobicity binding, Trp fluorescence spectroscopy, Tb3+/Trp
FRET with Tb3+ titration and Ca2+ competition, as well as circular dichroism (CD). Further
potential drug targets can also be titrated to examine if the binding Kd, cooperativity, and/or
structure is altered.

3.2.5

Circular dichroism

Circular dichroism (CD) is an excellent technique for analyzing the secondary structure of a
protein. It can show if the protein is predominately α-helices, β-sheets, loops, turns, or a
combination between them. In the case of the CaSR ECD, it is mostly α-helices thus we expect to
see the typical α-helix spectrum of a slight W. The WT bCaSR ECD has the expected α-helices
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shape where the black line is with no calcium addition. As the calcium concentration increases,
the shape is changed with more calcium indicating a change in the conformation of the protein
with the binding of calcium (Figure 3.9). The older defrosted bCaSR ECD sample is less stable
than the fresh purified bCaSR ECD sample and has a loss of structure upon calcium titration
(Figure 3.9). It is also possible that the observed conformational change is originally from the
dimerization or aggregation of CaSR ECD.

Figure 3.9 – Circular dichroism Ca2+ titration on bCaSR ECD WT.
A&B – 2 µM bCaSR ECD WT expressed in SHuffle in 5/25/14 and 8/28/14,
respectively, but both run on 8/28/14 and titrated with increasing [Ca2+] in 10 mM
Tris-HCl, pH 7.4.

3.2.6

Trp fluorescence spectroscopy

Calcium titration using fluorescence spectroscopy is an excellent way to analyze conformational
change and binding by titration. Trp fluorescence spectroscopy does not show the secondary
structure shape but rather fluorescence peak shifts. Trp fluorescence looks at the fluorescence
excitation and emission from Trp residues in the sample. Our sample is CaSR ECD protein with
Trp inside we see a fluorescence peak correlating to bCaSR ECD Trp fluorescence. Thus, upon
titration of Ca2+ or other compounds we should see a change in the fluorescence if the Trp in the
protein get either closer together or further apart leading to a fluorescence intensity change which
indicates the titrant bound to the protein which induced a conformational change on the protein
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near Trp locations. We can see that bCaSR ECD has Trp spread throughout the structure with
several near the binding sites for the CaSR ECD (Figure 3.10).

Figure 3.10 – Trp residues in CaSR ECD.
Structure of CaSR ECD showing all Trp residues highlighted in green sticks, with
Ca2+ in red spheres, and TNCA in pink sticks.
We used our purified 2 μM bCaSR ECD WT to do Ca2+ titration Trp fluorescence spectroscopy in
triplicate and saw a decrease in fluorescence signal upon Ca2+ titration (Figure 3.11A). The Kd for
Ca2+ was 5.3 ± 0.2 mM with a Hill number of 1.6 ± 0.1, implying there is cooperative binding of
Ca2+ to CaSR ECD (Figure 3.11D).
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Figure 3.11 – Trp fluorescence Ca2+ titration on 2 μM bCaSR ECD WT.
This experiment was done in 10 mM Tris-HCl with a pH of 7.4 and 2 μM of bCaSR
in triplicate. A – Representative plot of Ca2+ titration, buffer alone is shown near the
bottom. B – Kd of each run. C – Previous member’s data for comparison, which also
goes down but normalized to be up. D – Kd plot for the triplicate trials plotted.

We next examined the effect of anion binding by titrating in PO4. We wanted to investigate the
effect of PO4 on bCaSR since the Geng et al. paper showed a PO4 binding site similar to our
bicarbonate binding site[284, 287]. Since PO4 is not stable at neutral pH and the binding must be
done around pH 7.4 for CaSR stability, we used the stable analog K2HPO4. We saw a decrease in
signal in Trp fluorescence with bCaSR in response to Ca2+ titration with a Kd of 4.8 ± 0.1 mM and
a Hill number 1.3 ± 0.04. When bCaSR ECD WT is titrated with K2HPO4 there is a decrease in
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Trp fluorescence in response with a Kd of 10.6 ± 0.4 mM and a Hill number of 0.9 ± 0.04 (Figure
3.12).

Figure 3.12 – Trp fluorescence Ca2+ and PO4 titration on 2 μM bCaSR ECD WT.
This experiment was done in 10 mM Tris-HCl with a pH of 7.4 and 2 μM of bCaSR
in triplicate. Top – Ca2+ and PO4 titration representative plots. Bottom –Kd plot for
the trials the Kd values. Red is KCl Kd value.

Since TNCA and Trp have overlapping excitation and emission profiles, being that TNCA is a Trp
derivative, the titration of TNCA under Trp fluorescence spectroscopy cannot be performed since
TNCA will give an increase in fluorescence and therefore a false-positive result.
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We investigated the effect of disease and disruption related mutations of D216N and S272A would
have upon Ca2+ titration using Trp fluorescence spectroscopy (Figure 3.13).

Figure 3.13 – Trp fluorescence Ca2+ titration on bCaSR WT, S272A, and D216N.
This experiment was done in 10 mM Tris-HCl with a pH of 7.4 and 2 μM of bCaSR
in triplicate. A-C – WT (A), S272A (B), and D216N (C) bCaSR representative raw
data titration. D – WT, S272A, and D216N normalized plot for Kd for triplicate runs
with error bars and insert of Kd values are shown for each. E – Bar graph depicting
the average ΔF from 0 mM Ca2+ to 50 mM Ca2+ titrated for WT (black), D216N (blue)
and S272A (red).
Both of these mutations are located in the hinge pocket where Mg2+/TNCA/Ca2+ bind since this is
a critical pocket for CaSR function we expect a substantial disruption in the signal change. In fact,
when doing mutations in cells, the hinge site mutations such as Y218K and E297I led to a loss of
cellular functional activity of hCaSR while the cell surface expression was maintained[287]. While
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doing the Ca2+ titration on the bCaSR D216N mutation the 2 µM of protein in solution was stable
but after 10 mM of Ca2+ the protein began to precipitate leading to jumping around of the signal
and high error bars (Figure 3.13D). Although we did have precipitation issues, the protein did at
least still decrease in response to Ca2+ (Figure 3.13C-E). We saw that the S272A mutation also
decreased in response to Ca2+ titration (Figure 3.13B). Both of these mutations did lead to a
decrease in the Kd compared to the WT, where the WT was 4.8 ± 0.1 mM Ca2+ while the mutants
were higher with S272A having 7.2 ± 0.3 mM Ca2+ and D216N having 6.0 ± 0.3 mM Ca2+. We
also wanted to examine the mutations to Tb3+ titration using Tb3+/Trp FRET compared to the
bCaSR WT and began with the S272A mutant since it was more stable in solution than D216N
and did not precipitate at low calcium concentrations in titration or aggressively (Figure 3.21).

3.2.7

ANS binding fluorescence spectroscopy

8-anilino-1-naphthalenesulfonic acid (ANS) is a commonly used fluorescent probe for the
characterization of protein binding sites. A blue shift and an increase of fluorescence intensity are
generally attributed to the hydrophobicity of a binding site and the restricted mobility of ANS.
The main differences from mCaSR and bCaSR is that mCaSR would have glycosylation and would
have retained the signal peptide region as well as the 4 Cys residues allowing mCaSR to be fully
dimer and not monomer/dimer mixture as with bCaSR. When we performed ANS binding using
2 μM of mCaSR, though, we were surprised to see that the Ca2+ had little effect on mCaSR
conformational changes even up to 30 mM Ca2+ (Figure 3.14).
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Figure 3.14 – ANS binding Ca2+ titration of mCaSR ECD WT.
A – Representative plot of the titration of Ca2+ with 2 μM mCaSR up to 30 mM B –
Plot showing the triplicate data of mCaSR titration where little to no change is
observed even up to 30 mM with fully bound already at 2-3 mM Ca2+.
The mCaSR had very little change in response to Ca2+ titration and seemed to be immediately
bound to Ca2+ much tighter than bCaSR and without any cooperativity, as indicated by the Hill
number at 1.02 ± 0.24 (Figure 3.10).
Upon bCaSR ECD WT titration of Ca2+ we saw that the ANS fluorescence signal decreased
(Figure 3.15). The Kd for Ca2+ titration using ANS fluorescence spectroscopy was 5.8 ± 0.25 mM,
with a Hill number of 2.2 ± 0.22 (Figure 3.15). Since we were examining the ANS fluorescence
signal during titration onto bCaSR ECD, we did not have an overlap of TNCA signal and were
able to do TNCA titration onto bCaSR ECD using ANS fluorescence spectroscopy. To confirm
that the TNCA excitation at 370 nm for ANS would not affect the signal response of ANS we
examined the emission of 0.5 mM of TNCA over 400-600 nm and found there was emission in
response to TNCA with the emission peak at 450 nm whereas bCaSR WT ANS binding Ca2+
titration has the peak at 470 nm (Figure 3.16A). Since TNCA can activate CaSR in cells at lower
concentrations than 0.5 mM we also titrated TNCA into the buffer without ANS or bCaSR present

90

to see at what concentration did TNCA have emission response to 370 nm excitation and observed
that the 450 nm peak began to resolve after 50 µM of TNCA was added in, thus the TNCA titration
on bCaSR ECD for ANS fluorescence spectroscopy would need to be below 50 µM TNCA (Figure
3.16B).

Figure 3.15 – ANS binding Ca2+ titration on 2 μM bCaSR ECD WT.
This experiment was done with 40 μM of ANS in 20 mM Tris-HCl and 50 mM KCl
with a pH of 7.4 and 2 μM of bCaSR in triplicate. Protein and ANS were allowed to
incubate in the dark at 4°C for 1 hour prior to Ca2+ titration. A – Representative
plot of Ca2+ titration, ANS alone in gray near the bottom. B – The plot of the peak
for Kd of each run. C – Previous member’s data for comparison of decrease. D – Kd
plot for the triplicate trials.
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Thus, any Kd plots from TNCA titration ANS binding can only go to 40 μM TNCA so we examined
TNCA binding upon bCaSR ECD with ANS fluorescence spectroscopy in comparison to Ca2+
titration upon bCaSR ECD (Figure 3.16C-F and Figure 3.15).

Figure 3.16 – ANS binding TNCA titration on 2 μM bCaSR ECD WT.
This experiment was done with 40 μM of ANS in 20 mM Tris-HCl and 50 mM KCl
with a pH of 7.4 and 2 μM of bCaSR in triplicate. Protein and ANS were allowed to
incubate in the dark at 4°C for 1 hour prior to TNCA titration. A – TNCA excitation
alone. B – TNCA titration without protein. C – TNCA titration with bCaSR up to 1
mM TNCA. D – Representative TNCA titration on bCaSR ECD up to 50 µM with
ANS titrated with TNCA without bCaSR at the bottom. E – The plot of the peak for
Kd of each run. F – Kd plot for the triplicate trials.
We observed that the TNCA titration also decreased the ANS binding similar to Ca2+, but the Kd
was much lower for TNCA versus Ca2+ alone, with Ca2+ average of 6 trials being 4.4 ± 0.2 mM
and TNCA for 3 trials being 2.3 ± 0.3 μM. Additionally, the Hill numbers for Ca2+ and TNCA
were different with Ca2+ Hill number at 1.9 ± 0.2 showing cooperative binding and potentially
multiple binding sites while TNCA Hill number was 0.6 ± 0.1 which shows TNCA does not have
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cooperative binding with TNCA for bCaSR WT and potentially only a single binding site as
confirmed by the CaSR determined structure. This binding experiment shows that TNCA does
cause a hydrophobic conformational change on bCaSR WT (Figure 3.16).

Figure 3.17 – ANS binding PO4 and Ca2+ titration on 2 μM bCaSR ECD WT.
This experiment was done with 40 μM of ANS in 20 mM Tris-HCl and 50 mM KCl
with a pH of 7.4 and 2 μM of bCaSR in triplicate. Protein and ANS were allowed to
incubate in the dark at 4°C for 1 hour prior to titration. Top – Ca2+ and PO4 titration
representative plots. Bottom –Kd plot for the trials the Kd values.

We further investigated the PO4 effect on bCaSR utilizing ANS fluorescence spectroscopy to
correlate the responses we observed with Trp fluorescence (Figure 3.12 and Figure 3.17). Ca2+
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and PO4 were able to induce a conformational change on bCaSR with similar binding Kd values
with Ca2+ being 2.9 mM and PO4 being 2.2 mM (Figure 3.17). Thus, the PO4 binding at 2.2 mM
is stronger than Ca2+ but with drastically different Hill numbers. The PO4 Hill number was 1.0 ±
0.1 which implies non-cooperative binding and a single PO4 binding site for bCaSR WT which is
correlated by the single bicarbonate binding site found in the CaSR crystal structure (Figure 3.17).
While Trp fluorescence and ANS binding fluorescence spectroscopy both give a multitude of
bCaSR binding information they are both more indirect binding assays since we are not examining
the fluorescence of the titrator but are instead looking at the change of the protein structure for Trp
fluorescence or the exposure of hydrophobic regions of the protein for ANS binding. We,
therefore, decided to also look at the Tb3+/Trp Förster/fluorescence resonance energy transfer
(FRET) and further competition with Ca2+ to examine more direct fluorescence changes of Tb3+
binding and release.

3.2.8

Terbium/Trp FRET and Ca2+ competition

Terbium(III) itself is fluorescent with a yellow color resulting from a green emission line. Tb3+
has been used as a fluorescent probe for calcium binding sites in proteins since they are both
positively charged cations with similar molecular radiuses, where Ca2+ is 187 pm and Tb3+ is 200
pm. Tb3+ behaves similarly to but is more potent (50-fold) than Ca2+ which combined with its +3
charge makes it better for studying metal binding properties of proteins with weak Kd values since
the Tb3+ will bind tighter than Ca2+ in the same binding pockets. Terbium titration using
fluorescence spectroscopy is a good way to analyze conformational changes and binding affinity
on top of binding cooperativity when using the Hill number from the Hill equation.
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Additionally, using Tb3+/Trp FRET leads to a more accurate signal since the Tb3+ or Trp signals
themselves cannot give a peak at emission spectra at 500-600 nm when excited at 282 nm and
only has a large fluorescence change over 500-600 nm when FRET between Tb3+ and Trp occurs,
implying that Tb3+ is bound to the interested protein with a Trp near enough to the binding pocket
for FRET (Figure 3.18).

Figure 3.18 – Tb3+/Trp FRET diagram for CaSR.
Terbium titration into bCaSR after excitation at 282 nm for Trp excitation leads to
energy exchange between Tb3+ and Trp to have an emission peak at 545 nm. Trp
alone does not emit at 545 nm and Tb3+ alone has low fluorescence at 545 nm without
FRET signal.
The Tb3+ FRET was done on bCaSR ECD WT, which led to an increase in signal and an interesting
trend of the beginning part of the titration being linear before becoming sigmoidal (Figure 3.19).
This biphasic response has been seen previously[269] and could indicate multiple binding sites are
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present but not as readily seen for the weaker binding of Ca2+. The strong initial binding for Tb3+
was 6.1 ± 0.4 μM with slight binding cooperativity indicated by the Hill value of 1.5 ± 0.2. The
Tb3+ Kd was found to be 50.7 ± 0.6 μM for the weaker secondary sigmoidal binding, so the Ca2+
competition of Tb3+ was done at 40 μM just below the Kd. The Hill number for the second binding
curve was much higher at 7.4 ± 0.6.

Figure 3.19 – Tb3+/Trp FRET with Tb3+ titration on 2 μM bCaSR ECD WT.
This experiment was done in 20 mM PIPES and 10 mM KCl with a pH of 6.8 and 2
μM of bCaSR in triplicate. A – Buffer with Tb3+ titrated. B – Representative plot of
Tb3+ titration with background subtracted. C – Kd plot for the triplicate trials with
strong binding up to 20 µM Tb3+. D – Kd plot for the triplicate trials with a weaker
second binding curve and the strong binding curve from C.
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In order to investigate whether Ca2+, the main binding partner for CaSR, was able to displace Tb3+
for CaSR binding we titrated Ca2+ onto bCaSR ECD WT which was pre-treated with 40 μM of
Tb3+. Ca2+ was able to successfully compete out the Tb3+ at a Kd of 6.1 ± 0.2 mM, which is slightly
higher than the Kd of Ca2+ alone, as expected for a competition assay since the Ca2+ needs to first
overcome the bound substituent before binding itself thus skewing the Kd value (Figure 3.20).
These results again parallel previous lab member’s results (Figure 3.20C) confirming the success
of this bCaSR WT version with cys-/sp- expressed in SHuffle cells in binding and that the removal
of these regions does not affect the binding sites for Ca2+.

Figure 3.20 – Tb3+/Trp FRET with Ca2+ competition titration on bCaSR ECD WT.
This experiment was done in 20 mM PIPES and 10 mM KCl with a pH of 6.8 and 2
μM of bCaSR in triplicate. 40 μM Tb3+ was added before Ca2+ was titrated in. A –
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Buffer with 40 μM Tb3+. B – Representative plot of Ca2+ titrated into bCaSR with 40
μM Tb3+. C – Kd plot for the triplicate trials in comparison to previous member’s
data. D – Kd plot for the triplicate trials averaged.
We next examined Tb3+ FRET titration on the bCaSR S272A mutant which is a hydrophobic
mutation of the main hinge binding site for Ca2+ and TNCA (Figure 3.21). These results of biphasic
binding were also seen in our subdomain studies where Tb3+ titration upon subdomain 1 which
includes the main hinge binding site also presented with biphasic binding as well as disruption
mutations caused a change in this biphasic binding pattern[269].

Figure 3.21 – Tb3+/Trp FRET with Tb3+ titration on 2 μM bCaSR WT and S272A.
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This experiment was done in 20 mM PIPES and 10 mM KCl with a pH of 6.8 and 2
μM of bCaSR WT (black) and S272A (red) in triplicate. A – Representative titration
curve for S272A. B – Bar graph depicting the average ΔF from 0 µM Tb3+ to 100 µM
Tb3+ (WT black, S272A red) or to 20 µM Tb3+ (WT gray, S272A pink) titrated. C –
The full Tb3+ FRET titration curve showing the second binding for WT and the lack
of the sigmoidal curve for S272A. D – Show the zoomed-in first 20 μM Tb3+ titration
for WT and S272A.

Unlike the bCaSR ECD WT response though, the S272A response was not sigmoidal but instead
was 1:1 binding with a linear response after initial binding past 20 µM (Figure 3.21).

Figure 3.22 – Tb3+/Trp FRET with Tb3+ titration of CaSR ECD subdomains[269].
A – Subdomain 1 has previous proposed binding site 1 (S147, S170, D190, Y218,
E297), site 2 (D215, L242, S244, D248, Q253), and site 3 (E224, E228, E229, E231,
E232) with mutation 1 (D190A/E297I), mut 2 (D215A/D248A), and mut 3
(E224I/E228I/E229I/E231I/E232I). C – Subdomain 3 has previous proposed binding
site 4 (E350, E353, E354, N386, S388) and site 5 (E378, E379, T396, D398, E399) with
mut 4 (E350I/E353I/E354I) and mut 5 (E378I/E379I/D398A/E399I)[269].
The S272A mutant had drastic effects upon Tb3+ titration binding where the first binding process
is much quicker and has greater fluorescence changes where 20 µM of Tb3+ can illicit a
fluorescence increase of 350000 compared to the bCaSR ECD WT increasing to only 85000 in the
same amount of titrant (Figure 3.21B&D). The binding for this first curve for the bCaSR S272A
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mutant was much tighter as indicated by the Kd of 0.8 ± 0.2 µM Tb3+, but the cooperativity for the
first process is similar with a Hill number of 1.5 ± 0.4.
Table 3.2 – Summary of bCaSR WT binding titrations.
Tb3+/Trp FRET
bCaSR

Trp

ANS

3+

Tb /Trp
Ca2+

Titrant
WT

Fluorescence

Fluorescence

FRET
Competition

5.0 ± 0.1

4.4 ± 0.2

(n = 6)

(n = 6)

Tb3+ (μM)

N/A

TNCA (μM)

PO4 (mM)

2+

Ca (mM)

N/A

6.1 ± 0.3

N/A

50.7 ± 0.6

N/A

N/A

2.3 ± 0.3

N/A

N/A

10.6 ± 0.4

2.2 ± 0.2

N/A

N/A

1.5 ± 0.1

1.9 ± 0.2
N/A

1.3 ± 0.1

Kd

Ca2+

Hill

(n = 6)

(n = 6)

Tb3+

N/A

N/A

6.2 ± 0.4

N/A

TNCA

N/A

0.6 ± 0.1

N/A

N/A

PO4

0.9 ± 0.04

1.0 ± 0.1

N/A

N/A

number

N/A – not applicable. n = 3 if not listed otherwise.
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The S272A mutant also dramatically affects the cooperativity of the second binding process where
the WT had a sigmoidal curve and a Hill number of 7.4 ± 0.6, the S272A mutant has a 1:1 binding
curve with a Hill number of 0.5 ± 0.1. Additionally, S272A reduced the binding strength of the
second binding process from 50.7 ± 0.6 µM Tb3+ for WT to 61.1 ± 8.0 µM Tb3+ for S272A.

3.3

Discussion

Previously the mutations have been unsuccessful, but with research we found the correct primer
formation and PCR protocols to successfully produce bCaSR and hCaSR mutants. Using the
correct DNA polymerase for the size of the plasmid and protein for site-directed mutagenesis is
critical. Although the primers and protocol are optimized, this does not necessitate that the
mutations will effectively work during PCR. There are many factors influencing primers and PCR,
most notably temperature, run cycles, and primer design. Thus, looking at alternative reasons and
going back to protocols when we were successful is vital. By doing this we have found out the
KOD DNA polymerase is better for larger plasmids and that primer design can also matter for
plasmid size. Using the new primers and KOD polymerase resulted in a successful mutation.
We were able to PCR three mutations for hCaSR and bCaSR of E297K (FHH), S272A, R66H
(FHH). With the maintenance of our epifluorescence microscope for almost a year, we focused
on bCaSR mutation binding assays. We were able to purify each mutant and the WT for bCaSR,
although R66H both times had such a low concentration of protein through purification that
binding studies were not possible. The WT bCaSR and E297K and S272A mutants went forward
with binding studies. We first optimized our binding study protocols where we did not utilize
EGTA since the Ca2+ present was negligible and adding EGTA can lead to saturation or pH
changes. Also increasing the amount of titration added from 1-2 µL to ~4 µL helped to
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significantly reduce error, by keeping the volume closer to 4-5 µL we can also reduce dilution
effects of the bCaSR.
We looked at Trp fluorescence, ANS hydrophobicity binding fluorescence, Tb3+/Trp FRET, and
Tb3+/Trp FRET with Ca2+ competition on the WT with Ca2+, TNCA, and PO4 to investigate the
normal response, the drug effects of TNCA in bCaSR binding and the possible bicarbonate binding
site using PO4 (Table 3.2).
We saw that for WT bCaSR with Ca2+ Trp fluorescence decreases with a Kd of 5.0 ± 0.1 mM and
a Hill of 1.5 ± 0.1 showing weak binding and high cooperativity. These results are further
correlated by ANS binding having a Kd of 4.4 ± 0.2 mM and a Hill number of 1.9 ± 0.2 and the
Tb3+/Ca2+ competition having a Kd of 6.1 ± 0.3 mM and Hill number of 1.3 ± 0.1 (Table 3.2). We
could not use TNCA in any binding assay besides ANS since Trp and TNCA overlap in
fluorescence excitation and emission and would lead to false positives. Additionally, we could
not use higher than 50 μM TNCA for ANS binding since the fluorescence of TNCA also partially
overlaps with TNCA fluorescence, where higher than 50 μM shows on the fluorimeter. TNCA
and Ca2+ together with ANS binding showed that TNCA acts as an agonist for CaSR where the Kd
was decreased to 2.3 ± 0.3 µM, although the binding of TNCA does disrupt the cooperativity of
Ca2+ indicated by the Hill number of 0.6 ± 0.1. We know that mCaSR was found in crystallization
to be bound to TNCA to the hinge region of CaSR and that TNCA and Ca2+ act as competitive coagonists, this helped to explain this unusual results we saw with mCaSR ANS binding since the
ECD was likely already occupied by TNCA as confirmed by crystal and mass spectrometry
studies[287]. Therefore, studies need to be done using mCaSR as a comparison after Phe removal to
ensure that the mCaSR is an unoccupied form.
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While PO4 did show effects on bCaSR binding the PO4 form of K2HPO4 show that the K2HPO4
binding site is not a strong as the Ca2+ binding sites since the binding strength is lower considering
the higher Kd of 10.6 ± 0.4 mM Additionally, the Hill number greater than 1.0 implies cooperative
binding for Ca2+ and potentially multiple binding sites while the Hill number lower than 1.0 at 0.9
± 0.04 for K2HPO4 implies there is only a single binding site, which is the bicarbonate binding site
(Figure 3.12). We also tested the effect of KCl on bCaSR using Trp fluorescence to see if the
K2HPO4 effects were from the PO4 binding or the K2 binding (data not shown). The KCl was also
able to cause a decrease in signal upon titration with 2 μM bCaSR. The Kd of KCl was,
problematically, almost identical to the K2HPO4 binding at 11.9 ± 0.9 mM There was a difference
between KCl and K2HPO4 in their Hill numbers, where K2HPO4 has a Hill number less than 1.0
indicating non-cooperative binding and a single binding site KCl also has a Hill number of 1.2 ±
0.1 which implies KCl has cooperative binding and potentially multiple binding sites. We found
that the KCl and K2HPO4 were both able to induce a conformational change of CaSR. While KCl
is able to induce changes similarly to K2HPO4 more studies need to be done to determine if these
changes are related to K, Cl, or PO4.
While our purification of the bCaSR mutants S272A, D216N, and E241K was successful this,
unfortunately, did not translate to all of our mutations. R66H, E228K, and E228Q saw a complete
loss of expression while H254A and E297K both had diminished expression and purification of
CaSR with only 20-30% protein yield in comparison to the WT. This shows that R66 and E228
residues are critical for correct protein expression since mutation of these sites led to a loss of
protein expression potentially from protein misfolding. The E297K mutation had much lower
expression than the WT and was not enough protein for biophysical studies, this site is in the hinge
site 1 and disruption of this site could also show a loss of correct or stable conformation which can
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also be seen by the smeared degradation band for western blot. When we tried any of the binding
studies on the S272A and D216N mutants, they invariably had precipitation around 1-6 mM Ca2+
with D216N being much more susceptible to precipitation than S272A and as such the data would
broadly fluctuate from the diffraction on the precipitation. This indicates that these residues are
critical for structural stability. Additionally, S272A and D216N both reduced the binding Kd for
Ca2+ upon Trp fluorescence titrations with S272A having 7.2 ± 0.3 mM Ca2+ and D216N having
6.0 ± 0.3 mM Ca2+ compared to WT at 4.8 ± 0.1 mM Ca2+. Since D216N had precipitation issues
early on in titration we decided to look at S272A for Tb3+/Trp FRET titration. We saw that the
WT CaSR ECD under Tb3+/Trp FRET has two binding processes a quick initial tight binding at
6.1 ± 0.4 µM Tb3+ and slight cooperativity with a Hill number of 1.5 ± 0.2 and a slower extremely
cooperative binding process with a Kd of 50.7 ± 0.6 µM and a Hill number 7.4 ± 0.6. The S272A
mutant had drastic effects upon Tb3+ titration where the first binding process is much quicker and
has more considerable fluorescence changes where 20 µM of Tb3+ can illicit a fluorescence
increase of 350000 compared to WT increasing to only 85000 in the same amount of titration. The
binding for this first curve was much tighter as indicated by the Kd of 0.8 ± 0.2 µM Tb3+ but the
cooperativity for the first process is similar with a Hill number of 1.5 ± 0.4. The S272A mutant
also dramatically affects the cooperativity of the second binding process where the WT had a
sigmoidal curve and a Hill number of 7.4 ± 0.6, the S272A mutant has a 1:1 binding curve with a
Hill number of 0.5 ± 0.1. Additionally, S272A reduced the binding strength from 50.7 ± 0.6 µM
Tb3+ for WT to 61.1 ± 8.0 µM Tb3+ for S272A. This indicated that either FRET was not occurring
with Tb3+ binding to the protein in the higher Tb3+ concentrations or that there was only one
binding site in the protein. This could be because the protein is unfolded or degraded or that the
binding site was disrupted so much that the Tb3+ was not able to interact with the Trp just floating
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around outside of the protein structure thus increasing linearly or because disrupting the major
hinge binding site allowed for only one or no binding site to be present in the bCaSR S272A protein
(Figure 3.21). Since we have previously shown that Tb3+ itself cannot increase on such a large
scale we hypothesize this linear increase in FRET between unbound Tb3+ and nearby stable,
denatured, or precipitated bCaSR S272A. We did see a slight 1:1 binding curve for the beginning
change of S272A Tb3+ titration as we have seen with the WT, but the error bars were much higher
past a few μM of Tb3+ due to precipitation not seen in the WT (Figure 3.21). This tells us that the
hinge region binding site is not only critical for binding of Ca2+/Tb3+ but is also the epicenter of
cooperative binding throughout the CaSR ECD and disruption of this region leads to a loss of
binding, a reduction and loss in cooperative binding in other binding sites, as well as a loss of
structure stability as seen by precipitation issues of D216N. This also correlates with our hCaSR
functional studies since the hinge region mutations of Y218K, S272I, D275I, and E297I all led to
a loss of functional response while still expressing the protein on the cell surface.
We need to perform CD on the mutants to see if this is just a loss of CaSR function issue or if the
CaSR structure is greatly disturbed by the mutations. Additionally, we want to look at the binding
effects of the other mutants which can be purified E297K, H254A, E241K, as well as repeating
S272A and D216N for Trp fluorescence, ANS binding, and Tb3+/Trp FRET. It would also be
critical to investigate if TNCA is able to recover the binding effects seen between the WT and
mutants since previously the E228I mutant under functional cell imaging was able to be recovered
by TNCA. We would expect to see that the stabilization and cooperativity of TNCA binding in
the hinge site would recover the binding loss from mutation of the hinge site as well as the dimer
site. Overall the bCaSR binding studies have the advantages of no post-translational modifications
such as glycosylation as found in mCaSR expression systems, and additionally does not have
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TNCA already bound to the CaSR ECD in bCaSR expression from shorter expression time frames.
Although there are advantages to bCaSR expression the major drawback is a non-native expression
system can lead to incorrect protein structure leading to aggregation and degradation which causes
a loss of protein stability in solution. Efforts previously have been done to optimize these
conditions by using glycerol to stabilize the protein. Further optimization can be done to help
stabilize the WT and mutants for precipitation in titration spectroscopy studies using aides such as
5-30% glycerol or sucrose and adjusting pH or salt concentrations.

3.4

Materials and Methods
3.4.9

Plasmid extraction

Ampicillin positive agarose plates were streaked with Invitrogen™ MAX Efficiency™ DH5α
competent cells with the CaSR and CaSR mutants. These plates were incubated overnight at 37°C.
Then tubes of 10 mL Fisher BioReagents™ LB Miller broth with 1:1000 of Ampicillin were
inoculated with one colony each and put into a shaker overnight at 220 rpm and 37°C. The samples
were centrifuged, and DNA extracted per QIAprep spin miniprep kit protocol. The plasmid
utilized for mammalian CaSR mutational studies was human CaSR-pcDNA3.1 (+) (gift from Dr.
Edward Brown from Brigham and Women’s Hospital, Boston) and for bacterial studies the
plasmid was pET-17b.
3.4.10 Primer construction
The base pair (bp) sequence was utilized of the CaSR to make mutation primers at possible cation,
bicarbonate, and compound binding sites. The primers were a 27-35 base pairs around the targeted
amino acid. The primers were a minimum of 25 bp and adhere to the equation for Tm > 78°C using
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the equation Tm = 81.5 + (0.41*%GC) - (675/(#bp total)). All of the full-length CaSR mutants
were generated by site-directed mutagenesis on the basis of the sequence of CaSR.
3.4.11 Polymerase chain reaction (PCR)
PCR site directed mutagenesis was performed using either G-Biosciences Pfu DNA polymerase
or Sigma-Aldrich KOD DNA polymerase according to the manufacturer’s instructions. Briefly, a
pair of complementary primers were designed for generating each mutant with the mutation placed
at the middle of the primers. The template CaSR DNA was amplified using with these primers for
30 cycles in a polymerase chain reaction instrument (Techne). After digestion of the template
DNA with New England Biolabs Dpn1, the amplified mutant DNA was transformed and amplified
using Agilent XL10-Gold ultracompetent cells. All the DNA sequences were verified by Genewiz
(www.genewiz.com).
3.4.12 Agarose gel electrophoresis
The agarose gel for visualization of the PCR product was made using 50 mL of Thermo
Scientific™ TAE Buffer (Tris-acetate-EDTA) at 1x concentration with 0.8% agarose. This
mixture was heated for 90 seconds until boiled and fully dissolved. The mixture was then allowed
to cool until warm to the touch so 1:10,000 ratio of SYBR Safe DNA Gel Stain (10,000 x DMSO)
could be added to the mixture and poured into the UV transparent gel tray and left in the dark until
solidified. The samples were run on agarose gel using gel electrophoresis at 80-120 V and imaged
using UV light.
3.4.13 Inoculation and expression
Cells were streaked on an Ampicillin positive agarose plate using extracted CaSR plasmid, then
incubated overnight at 37°C. 600mL of Fisher BioReagents™ LB Miller broth was prepared at a
25 g/L ratio and then autoclaved for sterility. Tubes of 10 mL Fisher BioReagents™ LB Miller
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broth with 1:1000 Ampicillin were inoculated with one colony each and put into a shaker overnight
at 220 rpm and 37°C. After a minimum of 12 hours, 1.5 mL was added to each 600 mL flask of
Fisher BioReagents™ LB Miller broth with 1:1000 Ampicillin and shaken at 220 rpm at 30°C.
Measured O.D. using UV until approximately 0.600 absorbance for expression. Added isopropyl
β-D-1-thiogalactopyranoside (IPTG), to trigger lac operon and allow the protein to express
overnight at 220 rpm at 25°C. After a minimum of 12 hours the sample was centrifuged at 15000
× g for 30 min at 4°C and the pellet was collected.
3.4.14 CaSR ECD purification
Prepared Buffers as follows; Buffer A: 50 mM Tris-HCl, 250 mM NaCl, 20 mM Imidazole, pH
7.5. Buffer B: 50 mM Tris-HCl, 250 mM NaCl, 500 mM Imidazole, pH 7.5. The protein pellet
was resuspended in Lysis buffer with cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail.
The cells were broken up using a sonicator and cell disruptor. The sample was then filtered and
run using a His-tag column on Fast protein liquid chromatography (FPLC). The target protein will
bind to the beads while in buffer A and then dissociated by the high concentration of Imidazole in
buffer B, increasing steadily from 0 to 100%. The purified protein is desalted using size exclusion
column GE Healthcare HiTrap™ Chelating HP Columns in 10 mM Tris with pH 7.4.
3.4.15 SDS-PAGE and western blot
Samples were incubated in Bio-Rad Laemmli Sample Buffer with or without Sigma-Aldrich 2Mercaptoethanol and boiled for 10 minutes. The proteins were separated on an 8.5% SDS-PAGE
gel. After electrophoresis, the gel was either stained with coomassie blue or transferred to a 0.45
µm nitrocellulose membrane for western blot. The nitrocellulose membrane was blocked with 5%
Bio-Rad Blotting-Grade Blocker non-fat milk in Tris Buffered Saline and then incubated with first
mouse anti-CaSR ADD antibody (1:4000) for 1 hour at room temp or overnight at 4°C. After
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being washed three times with TBS with 0.1% tween (TBST), the membrane was incubated at
room temperature for 1 hr with goat anti-mouse secondary antibody diluted with TBST (1:4000).
The detected protein signals were visualized by Bio-Rad enhanced chemiluminescence reaction
system.
3.4.16 Circular dichroism spectroscopy
The circular dichroism spectra were recorded from 190 to 260 nm on a Jasco-810
spectropolarimeter purged with N2 and equipped with a temperature control system CTC-345.
Spectral dependent measurements were performed at a bandwidth of 2 nm using a U-type quartz
cell of path length 0.1 mm with protein concentrations ranging from 8 to 10 µM in 10 mM TrisHCl, pH 7.4. The spectra were recorded at a scan rate of 50 nm/min and response time of 1s. The
cuvette was sealed with parafilm to prevent solvent evaporation. The spectra were deconvoluted
using the selcon method after subtracting the spectrum of the buffer as the blank and the CD data
were depicted in units of molar ellipticity per residue.
3.4.17 Intrinsic tryptophan fluorescence spectroscopy
A PTI lifetime fluorimeter was used to record the fluorescence spectra at room temperature using
a 1-cm path length cell. Intrinsic tryptophan emission spectra were recorded from 300 to 400 nm
with the excitation wavelength at 282 nm. The slit widths were set at 1-4 nm for excitation and 38 nm for emission, respectively. The calcium titration was performed in 10 mM Tris with the
protein concentration of 2.0 µM at pH 7.4 by adding known amount of CaCl2.
3.4.18 Terbium FRET spectroscopy
For the Trp-sensitized Tb3+ Forester’s resonance energy transfer (FRET) assay, protein samples
(2.0 µM) were in 20 mM PIPES-10 mM KCl at pH 6.8. The emission spectra were collected from
500-600 nm with the excitation at 282 nm. The slit widths were set at 1-4 nm for excitation and
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3-8 nm for emission, respectively. Secondary Rayleigh scattering was circumvented by using a
glass filter with a cutoff of 320 nm. The Tb3+ titration was performed by adding various volumes
of Tb3+ stock solutions stepwise into the cuvettes. The Ca2+-Tb3+ competition experiments were
performed in solutions containing 40 µM Tb3+ and 2 µM protein as the starting point. The stock
solution of CaCl2 was gradually added into the mixture. The background fluorescence intensity
was subtracted using logarithmic fitting and the Tb3+ binding affinity of the protein was calculated
by fitting normalized fluorescence intensity data using the Hill equation, S =

[M ]n
K d + [M ]n
n

,

where ΔS is the total signal change in the equation, Kd is the apparent binding affinity, n is the Hill
coefficient, and [M] is the free metal concentration.
3.4.19 ANS-binding spectroscopy
For the ANS (8-anilino-1-naphthalenesulfonic acid) binding assay, protein samples were
incubated with 40 µM ANS in 50 mM Tris-HCl and 100 mM KCl (pH 7.4) for 1 hr prior to
measurement. The excitation wavelength was set at 370 nm, and the emission spectra were
acquired from 400 to 600 nm. For the Ca2+ titration, the protein concentration was 2 µM and the
Ca2+ concentration was increased in 20 mM Tris- HCl and 50 mM KCl, pH 7.4.
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4
4.1

Structure Based Drug Design

Introduction

Therapeutics targeting GPCRs account for over a third of the available Food and Drug
Administration (FDA) approved drugs on the market and developing compounds targeting GPCRs
is an ever-expanding niche with revenue from these FDA approved GPCR targeted drugs amassing
over $180 billion annually[292-295]. Family C GPCRs consist of eight metabotropic glutamate
receptors (mGluR1-8), a calcium-sensing receptor (CaSR), two heterodimeric aminobutyric acid
B (GABAB) receptors, three taste receptors (T1R), an amino acid receptor (GPRC6A), and five
orphan receptors. Additionally, therapeutics targeting the family C of GPCR is low with only 2
compounds, one targeting GABAB receptors called baclofen and one which has been developed
for CaSR targeting, cinacalcet, for treatment of hyperparathyroidism[296]. Furthermore, only one
drug so far has been targeted to the CaSR ECD, AMG416, which is currently going through FDA
approval[297-299]. Intermittent increases in parathyroid hormone (PTH) result in bone formation
whereas chronically elevated levels lead to bone loss, thus finding a CaSR antagonist could lead
to the treatment of osteoporosis as well as hypoparathyroidism[300]. Many antagonists for CaSR
have been developed such as NPS-2143, ronacaleret, and encaleret but none of these have made it
to FDA approval because of the bone formation and loss were equivalent or no marked
improvement in human trials[301].
After our discovery of the novel CaSR binding partner TNCA found bound to the CaSR structure
we drove forward with structure-based drug design utilizing TNCA as our lead compound in order
to find potential agonists or antagonists for CaSR[287]. Since TNCA is a naturally occurring
compound formed from Trp through the Pictet-Spengler reaction it cannot be used as a patentable
drug target[302]. Currently, almost all drugs which have been designed for CaSR targeting have
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been thought to be bound to the loops of the transmembrane domain (TMD) or inside of the TMD
channel themselves. These studies were done by mutation of proposed binding sites based on
homology models of the CaSR TMD[303,

304]

. Since the full length of CaSR had yet to be

crystallized there is the possibility that these drugs target different regions of the CaSR structure
so finding TNCA bound to the CaSR ECD structure gives us a lead compound to do drug design
based off of TNCA. Since TNCA itself is naturally occurring in the body it cannot be used as a
drug itself but modifications of TNCA could induce a novel therapeutic as a calcimimetic or
calcilytic. Therefore, we set out to do structure-based drug design utilizing TNCA as a lead
chemical compound in order to identify selective CaSR agonists and antagonists with improved
binding and pharmacokinetic profiles.

4.2

Results
4.2.1

Lead Drug Compound Design

We compared TNCA to other CaSR drugs that were designed which did not make it to FDA
approval and also the only CaSR drug that was successfully FDA approved, cinacalcet (Table 4.1).
Many of the compounds have a commonality of multiple aromatic rings in their structure and often
have an extended structure.
We tested several compounds, CSR-101 to CSR-106, from our collaborator Dr. Binghe Wang in
their stock of synthesized compounds for other projects that were similar in structure to TNCA
(Figure 4.1). These compounds have structural similarity to TNCA, and we were interested in the
effects these modifications to the TNCA backbone would have on the CaSR functional activity
and functional cooperativity in comparison to Ca2+ and TNCA.
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Table 4.1 – Compounds of CaSR agonists (calcimimetics) or antagonists (calcilytics).

These CSR-101 to 106 compounds did not have good docking scores to the ECD binding pocket
of CaSR using Sybyl and additionally had no significant changes on the CaSR function or
cooperativity in HEK293 cells using single-cell imaging and cell population (Figure 4.10). We
performed lead drug design and docking studies to decide which drug synthesis route to attempt
based on TNCA structure and preliminary structure binding pocket analysis we designed eight
lead backbones to begin with as possible templates (Table 4.2). We investigated Lead A and
replaced R2 with other charged oxygen species for the tight binding in the negatively charged
binding pocket. We also examined if a smaller sized TNCA compound would bind stronger to
CaSR, so we also looked at Lead A without the third aromatic ring.
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Figure 4.1 – CSR-101 to 106 compound structures and molecular weights.
The first six compounds were given to us by the Wang lab from their stock of
synthesized compounds since they were similar to the TNCA structure.

Utilizing a lead drug design software LADI, a library building software, designed by Mengyuan
Zhu in Dr. Wang’s research group (https://github.com/MengyuanZhu/LADI) we generated
analogs/lead co-conformers based on TNCA and other leads designed (Table 4.2).
Table 4.2 – Lead drug design templates based on TNCA structure.
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LADI functions by uploading the protein structure file into Sybyl docking software and uploading
the compound interested in LADI and then marking which areas on the compound can be altered,
called R groups as labeled in Lead A compound (Table 4.2).

Figure 4.2 – LADI program and R group replacements.
Example of marking the compound interested in with an R group (yellow stick/ball)
in LADI and examples of all the R groups then attached to the compound and docked
to the interested protein using Sybyl in conjunction with LADI.
LADI then takes these compounds and replaces the marked R groups with atoms or functional
groups from a library of possible R groups in LADI (Figure 4.2).

Figure 4.3 – LADI and Sybyl compound results for a lead compound for CaSR.
We used LADI on our potential lead compound backbones to dock the different R
groups in Sybyl. A – Original TNCA backbone. B – TNCA backbone with carboxylic
acid replaced with sulfonamide. C – TNCA backbone with carboxylic acid replaced
with sulfur dioxide. D – TNCA backbone with aromatic ring removed to shorten
structure length. The hit rate is shown in percent of successful R groups which bound
to CaSR. The binding score is shown with a higher score being stronger binding to
CaSR ECD binding pocket.
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Then in conjunction with Sybyl and LADI these compounds with each R group modification is
bound to CaSR using Sybyl docking software. Sybyl then gives the relative binding efficiency
rate of all the R groups in percent, called the hit rate, and the relative binding score, an arbitrary
value which indicates the strength of binding into the pocket where the higher the value the higher
the binding strength (Figure 4.3).

Figure 4.4 – Specs compounds bound to CaSR.
Using OEDocking FRED software from OpenEye the Specs potential compounds
were docked into CaSR binding site to investigate their score and these 10 had the
best binding as shown above.

The three ring structures were too bulky in comparison to the two ring structure which had a 100%
hit rate and the highest score of approximately 15 on average (Figure 4.3D). The R groups added
on to the TNCA unaltered backbone had a 54% hit rate and a score of approximately 8 on average
(Figure 4.3A). The sulfonamide replacement of the carboxylic acid on the TNCA backbone had a
hit rate of 16% and a score of approximately 7 on average (Figure 4.3B). The sulfur dioxide
replacement of the carboxylic acid on the TNCA backbone led to no binding and a score of
approximately 4 on average (Figure 4.3C).
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Table 4.3 – Specs compounds ordered for CaSR targeting after computational evaluation
of Specs library.
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With these binding results we were able to begin the synthesis process through both the lead
pathways of TNCA R-group replacement as well as the two ring backbone R-group replacement
(Figure 4.3A and D). Since compound synthesis is a long process, we also simultaneously began
looking at other readily available compounds with good binding scores we could test on CaSR to
examine their effects and direct our lead drug design further. Therefore, we turned to the Specs
compound library which offered over 200,000 compounds available for testing.
Specs compound library of over 200,000 compounds was examined for potential compounds with
adequate Sybyl CaSR ECD binding similar to our examined LADI compounds. Using an OpenEye
program called FRED we docked the 200K+ Specs library and then took top 2000 structures to
model in Sybyl. From our Sybyl docking results, we took the best 20 compounds and then looked
at each one docked into CaSR to pick the best 10 to order from Specs, CSR-107 to CSR-116
(Figure 4.4 and Table 4.3).

4.2.2

TNCA and Determined Related Compounds Optical Properties

The TNCA absorbance, excitation and emission is similar to Trp since TNCA is a derivative of
Trp (Figure 4.5). TNCA, previously referred to as CaSRL, has and excitation shift compared to
Trp from 300 nm to 280 nm but only a couple nm shift for emission (Figure 4.5A&B). The
absorbance plots for TNCA and Trp were almost entirely identical (Figure 4.5C). We saw that a
TNCA concentration greater than 0.5 mM in water saw shards of undissolved TNCA and thus was
the highest concentration possible for imaging studies (Figure 4.5D).
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Figure 4.5 – TNCA optical properties.
CaSR ligand (CaSRL) was the initial term given for TNCA. A-C – Excitation scan at
360 nm emission (A) and emission scan at 280 nm excitation (B) and absorbance (C)
scan of TNCA (blue) versus Trp (black). D – 0.75 mM TNCA in cell imaging showing
TNCA shards and that TNCA is not dissolvable in water higher than 0.5 mM.

We investigated the optical properties of the CSR series of compounds from Specs, CSR-107 to
116. The CSR compounds had variable absorbance, excitation and emissions with none showing
dissonance with Fura-2 Ca2+ dye at 340/380 nm excitation and 510 nm emission (Figure 4.6-Figure
4.7).
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Figure 4.6 – CSR-107 to CSR-115 absorbance properties.
A – Absorbance of CSR-107 to 115 over 220 to 500 nm in comparison to Trp (black)
in full zoomed-out scale. B – CSR-107 to 109 and Trp zoomed in to show more clearly.
C – CSR-111 to 115 and Trp zoomed in to show more clearly.

For CSR-107 we excited with 280, 318, and 416 nm and saw an emission peak at 310 and 356 nm,
although these peaks were all under 500,000 fluorescence making their overlap peak higher than
emission/excitation peaks indicating no true fluorescence present for those wavelengths (Figure
4.7A). CSR-108, CSR-109, and CSR-111 also did not have any peaks above 500,000 fluorescence
making their overlap peak higher than emission/excitation peaks indicating no actual fluorescence
present for those wavelengths either (Figure 4.7B-D). CSR-114 and CSR-115 did have a response
to excitation with CSR-114 being similar to Trp with an excitation at 280 nm producing a peak
≈2,800,000 fluorescence intensity with an emission peak at 370 nm, which then produces an
excitation peak back at 280 nm with the same fluorescence intensity (Figure 4.7E). CSR-115 had
emissions to two excitations of 237 and 271 nm with an overlapping emission peak at 382 nm with
a fluorescence intensity ≈3,400,000 and when the excitation scan was done at 382 nm there was
an excitation peak also at the same intensity at 271 nm with a smaller side peak on the curve at
245 nm (Figure 4.7F).
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Figure 4.7 – CSR-107 to CSR-115 excitation and emission properties.
Emission and excitation scans from 220 to 500 nm for each CSR compound based on
the absorbance plots with Trp (black) as comparison. CSR-107 (A), CSR-108 (B),
CSR-109 (C), CSR-111 (D), CSR-114 (E), CSR-115 (F).

We did not see any overlap with the CSR compounds or Fura-2 for excitation and emission spectra
meaning any signal changes seen on hCaSR with Fura-2 and compound additions will be real
changes and not fluorescence intersection.
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4.2.3

Determining Drug Effectiveness Using Single Cell Imaging

We performed CSR drug testing using single-cell imaging and cell population. TNCA is unable to
activate CaSR alone without first activating CaSR with Ca2+ first (Figure 4.8A).

Figure 4.8 – TNCA live-cell imaging with hCaSR in HEK293 cells.
A – Fura-2 cell imaging of hCaSR with increasing TNCA at sub-activating Ca2+ levels
the CaSR does not react, but with Ca2+ levels higher than 3 mM the cell is able to
respond. B – The oscillation frequency bar graph in peaks/min for these cells. C –
The number of cells which responded and did not respond in percent.
The oscillations with TNCA and Ca2+ were at a much higher frequency for hCaSR as compared to
the WT frequency (Figure 4.8-Figure 4.9). Although there was an increase in oscillation frequency
for TNCA treated hCaSR cells over the Ca2+ only cells, the EC50 of CaSR remained the same with
2.6 and 2.7 mM, respectively (Figure 4.9 & Figure 4.8B). While the oscillations of hCaSR with
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Ca2+ only and TNCA do have an overlap for their frequency of peaks per minute the TNCA
oscillations range to high-frequency oscillations (Figure 4.9& Figure 4.8C).

Figure 4.9 – Ca2+ and TNCA live-cell imaging with hCaSR in HEK293 cells.
A – Fura-2 cell imaging of hCaSR with 0.25 mM TNCA at increasing [Ca2+]o. B – The
EC50 of WT hCaSR without (black) and with 0.25 mM TNCA (red). C – The
oscillation frequency bar graph in peaks/min for WT hCaSR (black) versus with 0.25
mM TNCA (blue).
While TNCA does not have an effect on the EC50 of Ca2+ induced hCaSR response, TNCA does
affect Mg2+ induced hCaSR response as well as recovery of inactivating disease mutations[287].

Figure 4.10 – Ca2+ and CSR-101 live-cell imaging with hCaSR in HEK293 cells.
A – Fura-2 WT hCaSR imaging with increasing [Ca2+]o elicits an oscillation response.
B – CSR-101 is unable to elicit a response on WT hCaSR alone. C – 20 μM CSR-101
with increasing [Ca2+]o on WT hCaSR using Fura-2. D&E – CSR -101 (blue) shows
no difference from WT hCaSR (black) in EC50 or oscillation responses, respectively.
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The CSR-101 solubility in water was 100 μM with toxicity present at 20-40 μM, so we tested 20
μM on hCaSR with Ca2+ increasing to avoid cell toxicity (Figure 4.10). CSR-101 to 106 did not
show any effects on hCaSR cell imaging alone or with Ca2+ increasing and had no additional
effects on oscillation frequency such as TNCA had, data shown is just CSR-101 for a
representative plot (Figure 4.10D&E).

4.2.4

Screening Potential Drugs Using Cell Population Assay

Single-cell imaging can give a plethora of information such as oscillation frequency, oscillation
start and end times, EC50, and cellular response rates. The tradeoff being that only a few cells are
imaged at a time and several trials need to be done to get a high enough n number to confirm the
reliability of the results. Cell population, on the other hand, images an area on the slide which can
contain thousands if not hundreds of thousands of cells per experiment, leading to much more
reliable, consistent, and quicker results. Cell population analyzes the IP3 oscillation signal on a
much larger scale utilizing n=1,000 to 1,000,000 as opposed to single-cell imaging where n=20200. For cell population we do not see oscillations since with the thousands of cells present we
can see the initial Ca2+ release from the ER as a sharp increase but as all the cells begin to oscillate
as slightly varying frequencies, as shown in the single-cell imaging, these varied frequency peaks
lead to cancellation of signal to get an average signal line which is called destructive wave
interference.
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Figure 4.11 – Representative cell population data for WT hCaSR.
A – Raw data of Ca2+ additions to WT hCaSR using Fura-2 with Ca2+ binding to Fura2 intracellularly leading to an increase in signal at 340 nm and a decrease in the signal
at 380 nm simultaneously. B – The ratio of 340/380 nm of A. C – the EC50 plot of
normalized fluorescence intensity ratio versus the increase in Ca2+ to WT hCaSR
where the values are calculated from the plateau of the Fura-2 signal.
hCaSR treated with increasing levels of Ca2+ leads to a sharp increase and a just as rapid decrease
to a plateau with each increasing Ca2+ addition leading to less recovery for the plateau back to
baseline as more and more Ca2+ saturates the cytosol and Fura-2 signal (Figure 4.11). The
functional EC50 for Ca2+ is 3.6 ± 0.16 mM with high functional cooperativity with a Hill number
of 3.1 ± 0.41.
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Figure 4.12 – EC50 cell population data for WT hCaSR with control compounds.
Cell population EC50 response plots calculated from the cell population data with the
WT hCaSR alone (black), 10 μM cinacalcet (blue), 500 μM TNCA (red), or 10 μM
NPS-2143 (purple) in either raw or log scale in HEK5001 cells at n ≥ 3. Cinacalcet is
an agonist calcimimetic and NPS-2143 is an antagonist calcilytic.
We tested the WT (Ca2+ only), TNCA, known agonist cinacalcet, and known antagonist NPS-2143
as controls for what an antagonistic and agonistic result would present as to determine the potential
CSR efficacy (Figure 4.12). 500 µM TNCA and 10 µM cinacalcet are agonists with an EC50 of
1.74 ± 0.22 mM and 1.14 ± 0.04 mM and reduced functional cooperativity with Hill numbers of
1.3 ± 0.24 and 1.1 ± 0.05, respectively which would be helpful for disease mutations which shift
the CaSR activity to the right, such inactivating diseases as FHH and NSHPT (Figure 4.12).
Additionally, 10 µM NPS-2143 is an antagonist with an EC50 of 12.85 ± 0.41 mM and reduced
functional cooperativity with a Hill number of 2.7 ± 0.22 for CaSR (Figure 4.12).
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Figure 4.13 – EC50 for WT hCaSR with possible lead compounds.
Cell population EC50 response plots calculated from the cell population data with the
WT hCaSR alone (black) and 50 μM of Specs compounds (CSR series), 10 μM
cinacalcet (blue), 500 μM TNCA (red), 50 μM TNCA (brick red), or 10 μM NPS-2143
(purple) in log scale in HEK5001 cells at n ≥ 3. Cinacalcet is an agonist calcimimetic
and NPS-2143 is an antagonist calcilytic. The best three potential targets are shown
in raw scale with controls, 50 μM CSR-110 (green), and 10 μM Crizotinib (magenta).

Cinacalcet and NPS-2143 show us the standard of drug activity for agonists we would expect at
least an EC50 ≤ 2.5 mM and for antagonists we would expect at least an EC50 ≥ 5 mM Ca2+ for our
potential lead compounds. Additionally, cinacalcet and NPS-2143 are effective at 10 μM and we
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expect the CSR compounds to be at least effective at 50 μM to be considered agonists or
antagonists. CSR-107 to CSR-116 at 50 μM each are mostly similar to the hCaSR Ca2+ only
response (Figure 4.13). 50 μM CSR-110 has an EC50 at 4.6 ± 0.24 mM and a Hill number of 1.5 ±
0.13. While chemotherapy agent Crizotinib at 10 μM has an EC50 at 1.9 ± 0.2 mM and a Hill
number of 2.1 ± 0.5 (Figure 4.13). The rest of the CSR series did not have statistically significant
differences in comparison to hCaSR Ca2+ alone and can be considered nonreactive.

4.3

Discussion

We were able to find 16 compounds similar to TNCA for initial drug studies. These compounds
CSR-101 to 116 were acquired from Dr. Wang lab and the Specs compound library. We tested
these compounds using single-cell imaging or cell population assay in HEK5001 cells stably
transfected with hCaSR. We did increasing levels of [Ca2+]o alone or with 10 μM cinacalcet, 500
μM TNCA agonist, 10 μM NPS-2143, 50 μM of each of the CSR series of compounds, and 10 μM
of a chemotherapy agent Crizotinib. Agonists TNCA and cinacalcet, as well as antagonist NPS2143, showed drastic responses compared to Ca2+ alone. TNCA and cinacalcet both decreased the
EC50 of Ca2+ alone from 3.6 ± 0.16 mM to 1.74 ± 0.22 mM and 1.14 ± 0.04 mM, respectively, with
cinacalcet being a stronger agonist than TNCA (Figure 4.12). Both TNCA and cinacalcet also
reduce the functional cooperativity of Ca2+ alone based on the Hill number reduction of 3.1 ± 0.41
to 1.3 ± 0.24 and 1.1 ± 0.05, respectively, showing that both of these agonists lead to an overactivated form of CaSR upon binding where cooperativity is reduced since the Ca2+ are able to
bind more readily and cooperativity is no longer as critical (Figure 4.12). NPS-2143, on the other
hand, reduced the functional activity and functional cooperativity of hCaSR compared to Ca2+
alone with an EC50 of 12.85 ± 0.41 mM and a Hill number of 2.7 ± 0.22 (Figure 4.12). This
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reduction of cooperativity is not as extreme as seen with the agonists since instead of no longer
needing as much functional cooperativity in the case of over-activated agonist bound hCaSR the
antagonist is actually disrupting the potential functional cooperativity which further potentiates the
loss of function of hCaSR as seen by the decrease in functional activity by the lower EC50 value.
The CSR compounds did show some effects on hCaSR using cell population studies which showed
CSR-110 as an antagonist with a decrease in functional activity as seen by the weaker EC50 of 4.6
± 0.24 mM as well as having a reduction in functional cooperativity similar to NPS-2143 but even
more disruptive to functional cooperative binding with and a Hill number of 1.5 ± 0.13 (Figure
4.13). Additionally, Crizotinib an agonist, but still weaker than TNCA or cinacalcet with an EC50
of 1.9 ± 0.2 mM and since this over activated form in intermediate between cinacalcet and Ca2+
alone the functional cooperativity is still necessary for this bound hCaSR version as seen by a Hill
number of 2.1 ± 0.5 (Figure 4.13). Both of these compounds are good potential calcimimetic and
calcilytic drug lead potential to further potentiate their activity and effect on hCaSR with further
compound modification.
Future research can be done to follow these routes of lead optimization. We did use the LADI
library program to design potential lead drugs and found that modification of the R group on TNCA
and a reduction of TNCA from three rings to two rings had the best Sybyl docking scores (Figure
4.3). Future collaborative efforts will be targeted to synthesizing these compounds to test new
potential CaSR therapeutic targets.
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4.4

Materials and Methods
4.4.5

Cell culture and transfection

Monolayer cultures of HEK293 cells were purchased from American Type Culture Collection
(ATCC CRL-1573) and maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and high glucose (4.5 g/L) at 37°C. WT CaSR
or its mutants were transfected into HEK293 cells using Lipofectamine 2000 or 3000 (Life
Technologies) by following the manufacturer’s instructions. Coverslips are incubated in
transfection solution 4-6 hr. Transfection solution is aspirated and fresh DMEM is added and
imaging is performed 24-48 hr later.
4.4.6

Measurement of [Ca2+]i changes in single CaSR-transfected cells

The CaSR WT was transiently transfected into HEK293 cells grown on coverslips and cultured
for 48 hr at 37°C. 1 μM Fura 2-AM is added into physiological Ringer buffer (10 mM HEPES,
121 mM NaCl, 2.4 mM K2HPO4, 0.4 mM KH2PO4, 1.2 mM MgCl2, 1.2 mM CaCl2 and pH 7.4).
The addition of the non-ionic detergent Pluronic ® F-127 can assist in the dispersion of the
nonpolar AM ester in aqueous media. The cells are incubated in the Fura-2 AM and F-217 solution
for 15–20 minutes at 37°C. The cells were washed twice with Ringer buffer, without calcium.
The coverslips were mounted on a bath chamber and placed on the stage of a Leica DM6100B
inverted microscope with a cooled EM-CCD camera. The cells were alternately illuminated with
340 or 380 nm light using a Till Polychrome V monochromator and xenon lamp, and the
fluorescence at emission wavelength 510 nm was recorded in real-time as the [Ca2+]o and/or
[Mg2+]o was increased in a stepwise manner in the presence or absence of 0.25 mM TNCA in
buffer (10 mM HEPES, 155 mM NaCl, 5 mM KCl, 2 mM NaH2PO4, and 0.5 mM MgCl2) (pH
7.4).

The ratio of the emitted fluorescence intensities resulting[23] from excitation at both
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wavelengths was utilized as a surrogate for changes in [Ca2+]i and was further plotted and analyzed
as a function of [Ca2+]o. All experiments were performed at room temperature. The signals from
2 to 100 single cells were recorded for each measurement. Oscillations were identified as three
successive fluctuations in [Ca2+]i after the initial peak.
4.4.7

Intracellular calcium concentration in cell population by fluorimetry

The [Ca2+]i responses of wild type (WT) CaSR and its mutants were measured as described by
Huang et al.[259]. Briefly, CaSR-transfected HEK293, or stably transfected HEK5001, cells were
grown on 13.5 × 20 mm coverslips. After the cells reached 90% or higher confluency, they were
loaded by incubation with 2 μM Fura-2 AM in 20 mM HEPES, containing 125 mM NaCl, 5 mM
KCl, 0 mM CaCl2, 0.5 mM MgCl2, 1 mM NaH2PO4 (pH 7.4) for 15 mins at 37°C and then washed
twice with Ca2+-free Ringer’s buffer. The coverslips with transfected, Fura-2-loaded HEK cells
were placed diagonally in 3-mL quartz cuvettes containing Ca2+-free Ringer’s buffer. The
fluorescence spectra at 510 nm were measured during stepwise increases in [Ca2+]o with alternating
excitation at 340 or 380 nm on a QM1 fluorescence spectrophotometer (Photon Technology
International). The ratio of the intensities of the emitted light at 510 nm when excited at 340 or
380 nm was used to monitor changes in [Ca2+]i. The EC50 and Hill constants were fitted using the
Hill equation, S =

[M ]n
K d + [M ]n
n

, where ΔS is the total signal change in the equation, Kd is the

apparent binding affinity, n is the Hill coefficient, and [M] is the free metal concentration. The
emission ratio of 340/380 was calculated and used to reflect the changes in [Ca2+]i when different
concentrations of [Mg2+]o were applied to the cells. To examine the coactivation of CaSR by
TNCA and [Mg2+]o or [Ca2+]o, different concentrations of TNCA were placed in the experimental
buffer with a fixed concentration of [Ca2+]o and varying concentrations of [Mg2+]o, or vice versa,
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as described in the Results section. The effects of other ligands were analyzed by comparing the
changes in [Ca2+]i produced by [Mg2+]o alone or by co-application of Mg2+ with other ligands. The
EC50 of [Mg2+]o obtained during incubation with various concentrations of TNCA is compared
with that observed in the presence of [Mg2+]o alone. The EC50 changes were plotted as a function
of TNCA concentration, and the curve was fit to the Hill equation, S =

[M ]n
K d + [M ]n
n

, where ΔS

is the total signal change in the equation, Kd is the apparent binding affinity, n is the Hill
coefficient, and [M] is the free metal concentration. The activation of CaSR by the TNCA,
functioning as a co-agonist with [Mg2+]o, was indicated by the increasingly left-shifted EC50 for
[Mg2+]o as the concentration of TNCA increases.
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5
5.1

Visualizing Subcellular Ca2+ Dynamics Using Designed Ca2+ Sensors

Introduction

The endoplasmic/sarcoplasmic reticulum (ER/SR) are the primary internal calcium storage for
cells with concentrations in the mM range and regulates cellular calcium dynamics. In addition to
regulating Ca2+ dynamics, the ER also is responsible for protein synthesis, modification,
trafficking, lipid synthesis, and drug metabolism. Protein synthesis imbalance from the demand
of synthesis and the capacity for protein storage in the ER can lead to ER stress, from the accrual
of misfolded or unfolded proteins, which then causes cellular apoptosis[305-307]. There are three key
players for ER Ca2+ dynamic regulation the ryanodine receptor (RyR) for Ca2+ release down to the
ms range, the inositol (1,4,5)-trisphosphate receptor (IP3R) for Ca2+ release to the second range,
and the sarco/endoplasmic reticulum calcium-ATPase (SERCA) pump for Ca2+ refilling in the ER
in the sub-second range (Figure 5.1). Being able to examine the distinct Ca2+ dynamics through all
three of these major players and at the kinetic rates they each present with as well as cell-specific
kinetic rates such as heart and skeletal muscles in the 1-100 ms range is critical for further
understanding of the ER/SR Ca2+ dynamics. These receptors and pump which regulate Ca2+
dynamics have been found to have heterogeneous expression and differential Ca2+ dynamics
depending on expression in ER/SR as well as the varying cell types. The morphology of the ER/SR
was initially considered to be a uniform system which could communicate and send Ca2+
throughout but has recently been found to be more heterogeneous not only in protein distribution
but also in pockets of Ca2+ signaling either due to binding of CaBPs or having Ca2+
microdomains[308-310].
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Figure 5.1 – ER/SR calcium signaling inside the cell.
Ca2+ signaling dynamics in the cell to communicate the Ca2+ homeostasis between the
high [Ca2+] extracellularly in the mM range and the low [Ca2+] intracellularly in the
µM range is regulated by a multitude of proteins as well as by the internal organelle
Ca2+ storage in the ER/SR in the mM range. These proteins operate in a variety of
differing rates of Ca2+ transport from the millisecond (ms) to seconds (s) range. On
the plasma membrane are channels that either remove Ca2+ from the cytosol to
maintain the µM [Ca2+]i or that bring Ca2+ back into the cytosol from the [Ca2+]o. The
plasma membrane Ca2+ ATPase (PMCA), the sodium-calcium exchanger (NCX), and
the potassium-dependent sodium-calcium exchanger (NCKX) are just a few proteins
which pump Ca2+ out of the cell in exchange for energy adenosine triphosphate (ATP)
or gradient transfer (Na+/K+). On the other hand, proteins such as store-operated
channels (SOCs), transient receptor potential (TRP) channels, and voltage-gated
calcium channels (VGCCs) deliver Ca2+ from the extracellular into the cytosol.
[Ca2+]i concentration is also further regulated by ER proteins such as the IP3R, RyR,
and SERCA pump with either release Ca2+ from the ER/SR into the cytosol or pump
Ca2+ back into the ER/SR, respectively. Additionally, GPCRs such as CaSR can sense
[Ca2+]o and lead to a production of IP3 which then binds the IP3R and release ER/SR
[Ca2+] into the cytosol. The [Ca2+]i is also regulated by the mitochondria by the
mitochondrial calcium uniporter (MCU) and the NCX/hydrogen-calcium exchanger
(HCX) whereas the Golgi is regulated by IP3R, RyR and secretory pathway Ca2+ATPase (SPCA).

The RyR, IP3R, and SERCA pump, as well as ER Ca2+ signaling, are critical for cellular function
and stability where dysfunction leads to a multitude of disease states and cell death. ER Ca2+
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dysregulation has been linked to multiple neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, schizophrenia, etc. Mutations on the RyR, IP3R, and SERCA pump are
associated with malignant hyperthermia, arrhythmias, skin disease, central core disease, deafness,
and diabetes[153,

311-318]

. The complex and not fully understood ER/SR morphology, Ca2+

microdomains, and protein subcellular distribution differences provide challenges in further
understanding the Ca2+ dynamics of the ER/SR as well as the relation to disease states.
Table 5.1 – Expression of ER/SR proteins in different cell lines.
Cells
IP3R
RyR
SERCA pump
C2C12

Type 1 and 3

Type 1 and 3

Type 1, 2a, 2b

Cos-7

Type 1-3

TBD

TBD

HEK293

Type 1-3

Type 1 and 2

Type 2b, 3d, and 3e

HeLa

Type 1-3

Type 2

Type 2b, 3d, and 3e

TBD = To be determined

Examining multiple common cell types utilizing antibody staining, western blot, or DNA/mRNA
level analysis shows RyR, IP3R, and the SERCA pump are expressed in each cell type with varying
isoforms (Table 5.1)[44,

319-329]

. Many cell lines have yet to be investigated for these protein

expressions, isoform type, and expression patterns. Research is continually evolving and showing
new discoveries in isoforms of these ER/SR proteins as wells as illuminating their expression
levels in a multitude of cell types. Thus this is an ongoing field of study for a better understanding
of cellular protein expression. In order to investigate these crucial gaps in ER Ca2+ dynamics, we
designed a Ca2+ sensor targeted to the ER/SR with fast kinetics capable of capturing fast ms range
responses as well as slower seconds to minutes range as well as having a Kd in the mM range for
cellular imaging studies.
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Although FRET pairs are the more commonly used type of Ca2+ sensor, their distance dependence
allows room for intrusion from other molecules in physiological conditions.

Due to the

electrostatic nature of Ca2+ ions, Ca2+ binding sites are formed by residues with oxygen atoms,
especially charged residues such as Asp and Glu[330]. Using our established expertise for designing
novel Ca2+ sensors, by utilizing a diverse number of charged ligand residues (2-5) in the intended
metal binding site in EGFP, our group engineered several novel EGFP-based sensors, Ca-G1 and
CatchER (Calcium sensor for detecting high concentration in the ER), as well as a modified
improved version of CatchER called CatchER+ (Figure 5.2)[331-334]. Ca-G1 was created by the
addition of a single EF-hand motif and is valuable as a ratiometric sensor, but has a small dynamic
range and slow kinetics[335]. CatchER and CatchER+ exhibit the largest Ca2+ induced fluorescence
changes over other available sensors, a comparable Kd for ER/SR measurements, and fast
kinetics[331-334]. The electrostatics of the binding site, the area around it, and the subsequent effect
on the chromophore influence the fluorescent and kinetic properties of CatchER and CatchER+[331334]

. CatchER has a large dynamic range at 510 nm when excited at both 395 and 488 nm (Figure

5.2)[331-334]. CatchER exhibits an unparalleled Ca2+ off rate of 700 s-1 allowing CatchER and
CatchER+ to measure Ca2+ release from the ER/SR in various cell types[331-334, 336]. CatchER+ had
three mutations, S175G, Y39N, and S30R, to improve thermostability and brightness at 37°C for
enhanced use in situ experiments (Figure 5.2). All of our designed sensors are advantageous for
several reasons, because they are able to be readily targeted to cellular compartments containing
Ca2+, they have fast kinetics and affinities to cover the broad range of [Ca2+] in different organelles,
and a direct Ca2+ binding site not using a CaBP binding motif which improves the kinetic rate of
binding and releasing Ca2+.
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Figure 5.2 – CatchER+ sensor design and improvement process.
Shows that the design process for CatchER and CatchER+. A – We identified common
Ca2+ binding motifs based on natural Ca2+ binding proteins, then designed algorithms
to calculate potential Ca2+ binding sites (GG, MUG, and MUGC). B&C – We applied
the Ca2+ binding site prediction onto EGFP to create CatchER, with retention
sequences KEDL and calreticulin for ER/SR retention. C – Mutations S175G, Y39N,
and S30R to CatchER to generate the improved CatchER+. D – Improvement
mutations made between CatchER and CatchER+ at 37°C.
We confirmed that the CatchER+ sensor can be successfully transfected into a cell and is uniformly
expressed throughout the ER using confocal imaging in comparison to our CatchER+ sensor and
ER Tracker Red (Figure 5.3).

Figure 5.3 – CatchER+ confocal imaging in C2C12 with ER Tracker.
Pearson’s coefficient for colocalization of ER Tracker red 555 dye (orange) and
CatchER+ (green) 488 nm.
The Pearson’s correlation coefficient (PCC) shows the relationship between two variables where
a value of 1 is a perfect positive correlation, and a value of 0 is no linear correlation. Here we see
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with a PCC value of 0.91 that CatchER+ and ER Tracker Red have a high correlation showing that
CatchER+ is successfully targeted to the ER and is uniformly expressed throughout (Figure 5.3).
With the successful design, targeting, and imaging of our CatchER+ sensor we could then begin
testing it in live-cell imaging.

5.2

Results
5.2.1

Using Epifluorescence Imaging to Analyze CatchER+ Function

We examined CatchER+ in C2C12 mouse myoblast muscle cells, HEK293 human embryonic
kidney cells, Cos-7 fibroblast-like monkey kidney cells, and HeLa human epithelial
adenocarcinoma cells. We looked at 4-cmc to initiate a release of Ca2+ through the RyR from the
ER leading to a signal decrease of CatchER+ (Figure 5.4A). We also treated with CPA to reversibly
inhibit the SERCA pump which refills the ER and while inhibited leads to a decrease in Ca2+ from
the ER without able to refill the ER until washed away (Figure 5.4B). Lastly, we looked at
activating the IP3R indirectly since IP3 is not cell permeable we instead had to activate a GPCR to
produce IP3 by either ATP for the purinergic receptor (P2YR) or with HeLa cells histamine for the
histamine receptor (H1R) (Figure 5.4C). Since this method of Ca2+ release is an indirect release of
Ca2+ from the ER then the signal is lower than direct compounds which illicit direct release from
the ER. Since ATP must go through a GPCR to illicit IP3 production, then the amount of IP3R
activation is less than just adding IP3 itself would be. Since IP3 does not pass the plasma
membrane, then this indirect method must be utilized. With this method, we can only see a 5-15%
release of Ca2+ from the ER. This is much lower than the 20-50% release we see with 4-cmc and
CPA, which leads to a higher signal to noise (S/N) ratio.
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Figure 5.4 – CatchER+ epifluorescence in response to 4-cmc, CPA, and ATP.
A – Small volume 200 μM of 4-cmc was added to initiate a release of Ca2+ from the
ER in HEK293 cells with a representative plot. Below is the schematic of 4-cmc
activation on the RyR, which releases Ca2+ from the ER. B – Small volume 15 μM of
CPA was added to initiate a release of Ca2+ from the ER in C2C12 cells with a
representative plot. Below is the schematic of CPA inhibition of the SERCA pump,
which reduces ER Ca2+ since the ER [Ca2+] cannot refill. C – Small volume 100 μM
of ATP was added to initiate a release of Ca2+ from the ER in Cos-7 cells with a
representative plot. Below is the schematic of ATP indirect activation on the IP3R,
which releases Ca2+ from the ER after production of IP3 from P2YR activation.

These representative plots are not only for the overall responses seen in HEK293, C2C12, and
Cos-7 cells in response to each drug but also for the overall responses seen for each drug over each
cell line. All of these cell lines responded similarly to each compound under epifluorescence
conditions (Table 5.2).
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Table 5.2 – Epifluorescence ΔF/F0 responses in each cell type to 4-cmc, CPA, and ATP.
Epifluorescence Imaging
Cell Type
Drug Type
[Drug] (µM)
ΔF/F0 (%)
# of cells
C2C12

4-cmc

200

18.6 ± 1.1

43

Cos-7

4-cmc

200

7.3 ± 0.6

19

HEK293

4-cmc

200

12.0 ± 0.8

8

HeLa

4-cmc

ND

ND

ND

C2C12

CPA

15

24.2 ± 1.6

35

Cos-7

CPA

15

26.0 ± 1.9

10

HEK293

CPA

15

21.0 ± 0.8

14

C2C12

ATP

100

10.3 ± 1.0

14

Cos-7

ATP

100

13.0 ± 1.0

9

HEK293

ATP

100

6.0 ± 1.5

4

Data represents mean ± SEM error. ND – No data. Data collected at room temperature.
ΔF/F0 – change in fluorescence intensity over initial intensity.

There were some differences such as RyR response to 4-cmc being the highest at 18.6 ± 1.1% for
C2C12 since, as a mouse muscle cell line, there is a higher expression of RyR in order for muscle
contraction to occur (Table 5.2). All three cell lines were very similar and within error of each
other for CPA responses while the ATP responses were similar for C2C12 and Cos-7 but almost
half the response for HEK293 cells which may be due to less P2YR expression (Table 5.2).
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5.2.2

Highly Inclined and Laminated Optical Sheet (HILO) Microscopy

Analyzing the Ca2+ dynamic changes of CatchER using epifluorescence we noticed consistent
changes in Ca2+ release between cells and trials, but we were not able to resolve subcellular
changes throughout the structure of the ER due to the low imaging quality in epifluorescence as
well as the contamination in light from the other layers of the cell. There is an array of imaging
available to analyze processes on the cellular level. Getting high-resolution images to examine
subcellular ER/SR morphology as well as potential microdomains on live cells is not simplistic.
Often to achieve high resolution with confocal microscopy fixatives are required, which can
damage or alter the organelles wanting to be investigated. Additionally, when wanting to examine
a very narrow area of the cells more advanced microscopy is needed than simple light or
fluorescence microscopy can provide, both which often give the overall signal of the cell and not
in specific organelles. Total Internal Reflection Fluorescence (TIRF) microscopy excites only a
narrow slice of tissue (~100 nm) which can reduce background and enhance visibility to organelle
and membrane-localized processes. A significant drawback of confocal and TIRF microscopy is
the cost of the system. Since TIRF has the restriction of only penetrating 20-100 nm into the
surface of the cell because of the angle of reflection, there is a lack of distinguishing the full
features of the ER/SR within the cell which would encompass the entirety of the cell from top to
bottom, and that a cell diameter can average 25 µm. Thus, we switched gears to another
microscopy technique called highly inclined and laminated optical sheet (HILO) microscopy[337]
(Figure 5.5). Both confocal microscopy and TIRF microscopy can provide high imaging capability
to resolve ER structure details. Nonetheless, none of them are appropriate for imaging calcium
dynamics probed by the CatchER+ expressed in organelles and the microdomains in the subcellular
regions of the ER[338-340].
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Figure 5.5 – CatchER+ captures a highly defined ER-network pattern using HILO.
A – Model of differences in light angles between epifluorescence, TIRF, and HILO
imaging. B-D – Bright field (B), epifluorescence 488 nm (C), and HILO 488 nm (D)
images of C2C12 cell transfected with CatchER+, respectively. E) Enlargement of
white box area from C-D of the ER network under epifluorescence (bottom) and
HILO (top) conditions.

The former lacks the required temporal resolution for imaging fast calcium dynamic responses,
and the latter is only useful for imaging biological events within a few hundreds of nanometers
from the coverslip. The ER is best expressed throughout the whole cell that includes the center of
the cell around the nucleus, which would be several µm into the cell. It is critical to see the ER
structure details for any future microdomain studies where there might be an uneven distribution
of CaBPs throughout the lumen of the ER.

For the limitations mentioned on confocal,

epifluorescence, and TIRF microscopy, we turned to HILO microscopy[337] to best accomplish
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visualization of ER details at a depth of 10 µm while retaining the high spatial resolution and
temporal resolution.

Figure 5.6 – Epifluorescence and HILO imaging comparison.
A – Cross-section along the same region and same cell under epifluorescence imaging
(blue) or HILO imaging (red). B – The average signaling response to 1 mM 4-cmc
over the same time points using HILO (red) and epifluorescence (blue).

This technique also reduces the fluorescence background and images at high S/N by selectively
exciting the sample within submicron thickness allowing the capability to examine microdomains
of the ER without Z-axis signal perturbation[341, 342]. Epifluorescence, TIRF, and HILO microscopy
all rely on the same optical settings with the difference being in their respective incidence angles
of the laser where epifluorescence is ideal for full cell analysis, TIRF is better for near cell surface
analysis, and HILO is preferable for central cellular analysis without other regions overlap such as
with epifluorescence (Figure 5.5).
Immediately, we could observe clearly defined ER network patterns when imaging CatchER+ in
C2C12 cells under HILO conditions as compared to the epifluorescence conditions with the same
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gain, exposure and instrument settings, with the only variance being the angle of incidence of the
laser (Figure 5.5).

Figure 5.7 – Epifluorescence and HILO cross-sectional 3D response comparison.
Cross-sections of the signaling response to 1 mM 4-cmc in HILO (A) and
epifluorescence (B) in C2C12 cells.

To quantitatively compare the imaging quality from the epifluorescence and HILO conditions, we
further used cross-section analysis of the ER network in the same region of a C2C12 cell. Clearly,
we can see that the epifluorescence cross-sectional intensity profile of ER network is less defined
and has a loss of peak differentiation from the overlapping of all the regions of the ER throughout
the cell (Figure 5.6A). On the other hand, the cross-sectional CatchER+ intensity profile in the
HILO configuration had sharper defined peaks since due to the single section of CatchER+ being
examined elucidating the Ca2+ microdomains throughout the ER as well as the S/N ratio using
HILO imaging being much higher (Figure 5.6A). Under the same conditions, epifluorescence had
an overall lower ER Ca2+ release compared to HILO and lower fluorescence intensity distribution
in addition to the loss of defined ER-network regions (Figure 5.6B). When we further look at these
cross-sectional subcellular differences in CatchER+ signaling on a time scale in response to
treatment with 1 mM 4-cmc we can drastically see more differences between epifluorescence and
HILO imaging techniques (Figure 5.7).
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Figure 5.8 – CatchER+ HILO in response to 4-cmc, CPA, and ATP.
A – Perifusion of 1 mM of 4-cmc was added to initiate a release of Ca2+ from the ER
in C2C12 cells with an average of 21 cells. Below is the schematic of 4-cmc activation
on the RyR, which releases Ca2+ from the ER. B – Perifusion of 50 μM of CPA was
added to initiate a release of Ca2+ from the ER in Cos-7 cells with an average of 30
cells. Below is the schematic of CPA inhibition of the SERCA pump, which reduces
ER Ca2+ since the ER [Ca2+] cannot refill. C – Perifusion 500 μM of ATP was added
to initiate a release of Ca2+ from the ER in C2C12 cells with an average of 9 cells.
Below is the schematic of ATP indirect activation on the IP3R, which releases Ca2+
from the ER after production of IP3 from P2YR activation.
Once again we can not only see the initial subcellular Ca2+ differences of CatchER+ fluorescence
in HILO which is lost in epifluorescence but can further see that while the release of Ca2+ from the
ER for the cross-section is similar to the Ca2+ recovery subcellular distribution visualized using
CatchER+ fluorescence signal is a different pattern of distribution than the starting Ca2+
distribution pattern (Figure 5.7). This shows us that there is indeed microdomains of Ca2+ through
this cross-section of the ER and that the differences in initial Ca2+ and Ca2+ recovery could be from
distribution differences of RyR and SERCA pumps as well as pockets of Ca2+ microdomains.
We initially examined the CatchER+ to monitor changes in ER [Ca2+] in C2C12 myoblasts, Cos-7
cells, HEK293 cells, and HeLa cells under HILO microscope settings examining the global whole-
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cell signal in response to 4-cmc, CPA, ATP, and histamine. We show the representative responses
of CatchER+ using HILO imaging with the perifusion of 1 mM 4-cmc in C2C12 myoblast cells
(Figure 5.8A), 50 µM CPA in Cos-7 cells (Figure 5.8B), and 500 µM ATP in C2C12 myoblast
cells (Figure 5.8C). Additional imaging was conducted in C2C12, Cos-7, and HEK293 cells with
4-cmc, CPA, and ATP as well as in HeLa cells with 4-cmc and histamine, as represented in Table
5.3. Since the C2C12 have a higher expression of RyR, they show the most potent response to 1
mM 4-cmc treatment which produced a 45.5 ± 1.3% change in the fluorescence intensity of
CatchER+ which correlates with a 45.5% decrease in ER/SR [Ca2+] (Table 5.3).
Cos-7 and HEK293 cells were more sensitive to 1 mM 4-cmc and led to cell stress, so we treated
them with 0.5 mM 4-cmc which had a release of 12.3 ± 0.8 and 22.0 ± 1.6%, respectively. HeLa
cells had a release of 23.5 ± 0.8% in response to 1 mM 4-cmc (Table 5.3). In Cos-7 cells, the
addition of 50 µM CPA led to a 17.0 ± 0.9% release upon inhibition of the SERCA pump (Table
5.3). C2C12 and HEK293 cells had a release of 25.7 ± 1.5 and 23.3 ± 1.2%, respectively, in
response to the addition of 50 µM CPA (Table 5.3). C2C12 cells treated with 500 µM ATP caused
a 14.0 ± 1.1% release upon indirect activation of the IP3R (Table 5.3). Cos-7 and HEK293 cells
had a release of 12.3 ± 1.7 and 15.6 ± 1.1%, respectively, in response to the addition of 500 µM
ATP (Table 5.3).

146

Table 5.3 – Epifluorescence and HILO CatchER+ ΔF/F0 for each cell and drug type using.
Epifluorescence
HILO
Cell Type

Drug Type

[Drug]

# of

[Drug]

cells

(µM)

ΔF/F0 (%)
(µM)

# of
ΔF/F0 (%)
cells

C2C12

4-cmc

200

18.6 ± 1.1

43

1000

45.5 ± 1.3

32

Cos-7

4-cmc

200

7.3 ± 0.6

19

500

12.3 ± 0.8

36

HEK293

4-cmc

200

12.0 ± 0.8

8

500

22.0 ± 1.6

40

HeLa

4-cmc

ND

ND

ND

1000

23.5 ± 0.8

10

C2C12

CPA

15

24.2 ± 1.6

35

50

25.7 ± 1.5

18

Cos-7

CPA

15

26.0 ± 1.9

10

50

17.0 ± 0.9

31

HEK293

CPA

15

21.0 ± 0.8

14

50

23.3 ± 1.2

18

C2C12

ATP

100

10.3 ± 1.0

14

500

14.0 ± 1.1

12

Cos-7

ATP

100

13.0 ± 1.0

9

500

12.3 ± 1.7

13

HEK293

ATP

100

6.0 ± 1.5

4

500

15.6 ± 1.1

24

HeLa

Histamine

ND

ND

ND

100

12.6 ± 0.8

33

Data represents mean ± SEM error. ND – No Data, ΔF/F0 – change in fluorescence signal
over initial fluorescence in response to drugs. Data collected at room temperature.

Lastly, HeLa cells were treated with 100 µM histamine to activate the histamine receptor (H1R) a
GPCR which also produces IP3 upon activation similarly to ATP with P2YR[343]. HeLa cells had
a release of 12.6 ± 0.8% in response to treatment with 100 µM histamine, a result that was similar
to the release observed for the activation of IP3R in the other cell types with ATP (Table 5.3).
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5.2.3

Examining Microdomains using CatchER+ and HILO Imaging

Another major reason to utilize HILO imaging is the ability to measure the fluorescence in a small
slice of the cell as opposed to all the layers of the cell in epifluorescence. In order to examine
subcellular microdomains of Ca2+ signaling in the cell throughout the ER/SR network we needed
a high-resolution imaging capability and using epifluorescence is inadequate since the signal in a
microdomain would be canceled out by the signal in overall ER/SR signaling on the other layers
around the microdomain.
Using HILO microscopy, we can see if different regions of the ER/SR on the slice we are recording
have differential Ca2+ expression implying microdomains of Ca2+ signaling and also of differential
protein expression. Overall the global ER Ca2+ dynamics in the whole cell is pretty consistent in
response to 4-cmc in C2C12 cells with 45.5% release and a deviation of ±7.35% in 32 whole cells
(Figure 5.8A, Figure 5.9D and Table 5.3). Analyzing the raw data plots for every 50 by 50 pixel
region (Figure 5.9A) over the field of view for the cells transfected with CatchER+ (Figure 5.9B)
we can see that there is variance in the initial Ca2+ levels by fluorescence intensity as well as the
ending levels (Figure 5.9A). Interestingly, there is little variance in the actual release percentage
over the cells disregarding the background response and examining the plateau of release around
45.5% with ±7.35% deviation (Figure 5.9C&D).
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Figure 5.9 – CatchER+ HILO imaging in C2C12 in response to 1 mM 4-cmc.
A – Raw plotted data for each 50x50 pixel region. B – CatchER+ 488 nm was excited
in C2C12 cells. C – The ΔF/F intensity map. D – The normalized plot for each whole
cell labeled accordingly. E – ΔF/F intensity release values plot of each plot in A.

Since C2C12 cells are mouse skeletal muscle cells they will present with ER as well as an SR and
the SR is known to have regions of microdomains of expression of proteins in addition to Ca2+
concentration differences along the junctional SR in communication with the plasma membrane
for E-C coupling. Examining the whole cell, regions of interest (ROIs) 1 and 2, in comparison to
smaller potential subcellular microdomains throughout the cell, ROIs 3-27 the raw fluorescence
data once again shows different starting fluorescence intensities, valley release intensities, and
recovery intensities (Figure 5.10A&D). If we assume the starting Ca2+ was similar and normalize
to T0 secs we see that the ΔF/Fo at 300 secs was 53.5 ± 11.4% release which is similar to the global
signal for 32 cells at 45.5 ± 7.35% release although with slightly more variance in the standard
deviation which implies microdomains of RyR distribution and/or Ca2+ levels. Furthermore, the
recovery region at T500 secs the signal recovered to 18% with a deviation of 66.8% showing a
dramatic difference in areas of Ca2+ uptake and/or SERCA pump distribution (Figure 5.10C&F).
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Figure 5.10 – Analyzing subcellular microdomains using CatchER+ and HILO
imaging.
A&D – Raw plots of the ROIs in G. B&E – ROIs in G normalized to the valley
intensity at 300 secs. C&F – ROIs in G normalized to the initial intensity at 0 secs. G
– Cells being analyzed and the ROIs, whole-cell ROI #1-2.

If we instead assume that the release fluorescence is generally consistent as shown by lower
deviation from global cell analysis and by the ΔF/Fo heat map and plot (Figure 5.9C&E) and

150

normalize the data at T300 secs we see that the recovery at 500 secs fluctuates 18% between each
ROI while the initial intensities at 0 secs fluctuates 22.8% (Figure 5.10B&E).

Figure 5.11 – CatchER+ HILO imaging in C2C12 with different normalization.
Representative plots of the ROIs normalized to the valley intensity at 300 secs (top 3
plots) or to the initial intensity at 0 secs (bottom three plots) and the ROIs being
analyzed.

Even by analyzing 3 ROIs in one cell, we can see each ROI has different release and recovery
responses, implying Ca2+ and/or protein distribution subcellular microdomains (Figure 5.11). In
order to confirm if these differences are due to Ca2+ microdomains or protein distribution
differences, we analyzed protein distribution utilizing confocal microscopy.

5.2.4

Confocal Imaging of Global CatchER+, RyR, and SERCA Distribution

There is an array of imaging available to analyze processes on the cellular level. Getting highresolution images to examine intracellular morphology and ER/SR protein distributions on cells
are not as simplistic and need fluorescence labeling of proteins through immunohistochemistry
techniques and then high-resolution imaging utilizing confocal microscopy. We transfected the
cell with CatchER+, which is uniformly expressed throughout the cell in comparison to ER Tracker
Red and a PCC of 0.91 (Figure 5.12). Additionally, we stained the nucleus with DAPI, and the
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cellular actin structures were stained with phalloidin 633 dye in order to see the overall cellular
assembly which is critical for multinuclear cells (Figure 5.12-Figure 5.13).

Figure 5.12 – CatchER+ confocal imaging in C2C12 with ER Tracker.
Pearson’s correlation coefficient (PCC) plot of ER Tracker red 555 dye (orange) and
CatchER+ (green) 488 nm. Also stained Phalloidin 633 dye for actin (magenta) and
DAPI nucleus stain (blue) 405 nm. The large panel is the merge of all four
wavelengths merged. Figure 5.3 shows a zoomed-in version of CatchER+ with ER
Tracker.

In order to examine the subcellular distribution of RyR, we labeled C2C12 cells transfected with
CatchER+ with primary RyR and secondary 555 nm antibodies (Figure 5.13A&B). Interestingly,
and most pronounced on the tubule, we can see that the RyR antibody was more distributed on the
edges of the ER where we would expect RyR1 to congregate along the junctional SR for E-C
coupling with dihydropyridine receptor (DHPR) on the plasma membrane, as can be seen by the
orange outlines on the ER/SR structures (Figure 5.13B). There are still some RyR throughout the
ER/SR though since RyR is still necessary throughout but based on the poor PCC value of 0.40
the RyR is not expressed uniformly throughout the ER/SR (Figure 5.13D).
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Figure 5.13 – CatchER+ confocal imaging in C2C12 with RyR antibody.
A&B – RyR 555 antibody (orange), CatchER+ (green) 488 nm, stained Phalloidin 633
dye for actin (magenta) and DAPI nucleus stain (blue) 405 nm. B – Merge of all four
wavelengths. C – RyR expression for blasts (single nuclei), immature tubule (2-3
indistinct nuclei), and mature tubule (≥ 3 distinct nuclei). D – Pearson's correlation
coefficient (PCC) plot of RyR and CatchER+.

Since the tubules have a higher expression of RyR from the localization of RyR to the junctional
SR in communication with DHPR at the PM we also noticed that the tubule antibody staining for
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RyR was significantly higher than the single nuclei blasts by 2.8 fold and that the mature tubule
was still 1.9 fold higher than the forming tubule with 3 indistinct nuclei (Figure 5.13C).
With the low RyR expression we looked again at RyR expression but on lower confluency cells
for C2C12 cells to confirm that the antibody was adequately binding to the cells and that the
overlap of cells and high cell number were not altering the data (Figure 5.14).

Figure 5.14 – RyR confocal imaging in C2C12.
A – Confocal image of RyR 633 antibody (red) and DAPI nucleus stain (blue) and
surface plot under color spectrum where green is high signal and red is the low signal.
A – Confocal image of RyR 633 antibody and surface plot under rainbow RGB colors
where green is high signal and blue is the low signal.
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The RyR does seem to be expressed throughout the ER in the cell but that the distribution
throughout the ER was not uniform and that there are microdomains of higher expression
throughout the cell (Figure 5.14). There does not seem to be a pattern of microdomain distribution
as seen by the varying peak heights on the surface plots, and some cells have fewer microdomains
than others (Figure 5.14).

Figure 5.15 – SERCA1 and SERCA2 confocal imaging in C2C12.
A – Confocal image of SERCA1 and SERCA2 633 antibody (red) and DAPI nucleus
stain (blue). B – Confocal image of SERCA 633 antibody and surface plot under
rainbow RGB colors where red is high signal and blue is the low signal. C – A single
cell from B under spectrum colors where purple is high signal and red is the low
signal. D – Confocal image of SERCA1 and SERCA2 633 antibody (red) and DAPI
nucleus stain (blue). E – Confocal image of SERCA 633 antibody and surface plot
under rainbow RGB colors where red is high signal and blue is the low signal. F – A
single cell from D under spectrum colors where purple is high signal and red is the
low signal.
Since ER Ca2+ recovery is regulated by the SERCA pump, we also examined the SERCA pump
distribution through antibodies targeting both SERCA1 and SERCA2 together (Figure 5.15). The
SERCA pump expression was much stronger than RyR even though the same secondary antibody
was utilized, which could indicate higher overall expression of SERCA pumps than RyR (Figure
5.15). Additionally, the expression distribution of SERCA pumps was much more highly
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concentrated in and around the nucleus (Figure 5.15). Not only was there differential expression
distributions between RyR and SERCA pumps there was also microdomains of SERCA pump
expression in the nucleus region as well as distal regions as seen by the varying peaks in the surface
plots (Figure 5.15). While these discoveries corroborate our results using live-cell imaging, we
need to develop ways to image with CatchER+ and examine these target proteins simultaneously
or sequentially so we can compare the release kinetics to local protein microdomains. This can be
done with advanced dual imaging methodologies as well as with localized targeted CatchER+
variants.

5.2.5

Comparison of Localized CatchER+-JP45 vs. Global CatchER+ Sensors

In order to confirm the subcellular changes and protein distribution we were able to examine using
CatchER+ we collaborated with Dr. Zorzato in Italy in order to design a membrane-bound localized
skeletal muscle sensor CatchER+-JP45 which we could investigate the localized versus the global
ER/SR Ca2+ dynamics. We constructed a targeted CatchER+ protein attached to the ER membrane
internally by attaching junctional protein 45 (JP45) to the N-terminus of CatchER+. This newly
designed targeted sensor was named CatchER+-JP45 (Figure 5.16). CatchER+-JP45 has the JP45
protein, attached to CatchER+ sensor, which co-localizes to the RyR1 in the SR of cells. The
CatchER+-JP45 protein faces inside of the SR next to the RyR1 luminal opening. In SR the RyR
co-localizes with JP45 when communicating with the DHPR protein on the plasma membrane of
the cell in order to shuttle Ca2+ quickly between the SR to the cytosol and also from extracellularly
to the cytosol for voltage-gated action potentials necessary for muscle contraction and release
(Figure 5.16) [344-346].
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Figure 5.16 – CatchER+-JP45 sensor design and SR expression.
Diagram showing communication of DHPR and RyR1 in muscle cells for the
simultaneous release of Ca2+ from the SR through RyR1 and CaSQ Ca2+ release and
through DHPR from the extracellular both into the cytosol upon voltage on the
plasma membrane for muscle contraction. Insert upper left shows the design of
CatchER+-JP45 sensor.
In order for the SR Ca2+ concentration to not be unnaturally large a CaBP calsequestrin (CaSQ)
binds Ca2+ and then binds JP45 colocalized to the RyR1 in this junctional zone to keep a higher
[Ca2+] in this region for muscle contraction (Figure 5.16). Currently, the exact function and disease
relevance of JP45 and CaSQ have not been fully elucidated and the CatchER+-JP45 sensor can
help us with these discoveries.
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We were interested in comparing the global CatchER+ signal and response in C2C12 myoblast and
myotubules with targeted local CatchER+-JP45 to further elucidate the subcellular microdomains
seen with HILO imaging. We first did this by transfecting both into myoblast C2C12 cells to
examine the response differences in regards to ER Ca2+ dynamics using epifluorescence (Figure
5.17). While we do see the response, the intensity is dimmer for CatchER+-JP45 which is to be
expected since this sensor is only colocalized with RyR instead of being uniformly expressed
throughout the whole ER/SR as for CatchER+. The release of Ca2+ from the ER for CatchER+ in
response to 4-cmc is 18.6 ± 7.4% while the CatchER+-JP45 is around 8.8 ± 6.5% where the
localized CatchER+-JP45 releases and recovers similar to CatchER+ (Figure 5.17).

Figure 5.17 – CatchER+ and CatchER+-JP45 in myoblasts of C2C12 cells with 4-cmc.
CatchER+ (left) and CatchER+-JP45 (right) with 200 μM of 4-cmc added to initiate a
release of Ca2+ from the ER from the RyR. The peak time and ΔF for each experiment
and a diagram illustrating the pathway of release from ER through RyR after
addition of 4-cmc.
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Figure 5.18 – CatchER+ and CatchER+-JP45 in myoblasts of C2C12 cells with CPA.
Top – CatchER+ (left) and CatchER+-JP45 (right) with 200 μM of 4-cmc added to
initiate a release of Ca2+ from the ER from the inhibition of the SERCA pump. Bottom
– The peak time and ΔF for each experiment and a diagram illustrating the pathway
of release from ER through SERCA pump blocking not allowing the refilling of the
ER after addition of CPA.
CatchER+-JP45 shows quicker ER/SR emptying upon SERCA pump inhibition by CPA and
interestingly can recover much more rapidly and efficiently the Ca2+ concentration in this localized
microdomain much more readily that the global Ca2+ refills while CPA is inhibiting the SERCA
pump (Figure 5.18). This could be due to CaSQ binding to high levels of Ca2+ in the junctional
SR which is then released from CaSQ for junctional SR refilling of Ca2+ circumventing the slower
SERCA pump refilling of the ER/SR.
We allowed C2C12 cells to differentiate from myoblasts into myotubules, which is the early stage
of muscle fiber formation marked by having 3 or more distinct nuclei in one cell. When the
myotubules and muscle fibers form there is more SR present and thus a higher number of RyR1
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for JP45 to co-localize with for our localized CatchER+-JP45 studies. Since myotubules are
resistant to transfection we transfected the C2C12 three times over one week in order to ensure
expression of the CatchER+ and CatchER+-JP45 sensors in the myotubules.
We investigated the effect of 500 μM 4-cmc treatment on myotubules between global CatchER+
and localized CatchER+-JP45 (Figure 5.19).

Figure 5.19 – CatchER+ and CatchER+-JP45 HILO imaging in C2C12 tubule cells.
The normalized plot for CatchER+ (black) for n = 6 cells and CatchER+-JP45 (blue)
for n = 3 cells is shown on the right after exposure to 500 μM 4-cmc.

Additionally, since there is such a high expression of RyR1 in myotubules over myoblasts we
decreased the 4-cmc concentration to 0.5 mM as to not fully saturate the release of Ca2+ from the
ER/SR allowing for the comparison of release by the global and localized sensors. The release
slope for global CatchER+ in tubules in response to 500 μM 4-cmc treatment is much more linear
with slower kinetics as opposed to the myoblasts with the myotubules not reaching a plateau even
at ~400 seconds (Figure 5.8 & Figure 5.19). On the other hand the localized CatchER+-JP45 sensor
had a markedly different response to 4-cmc treatment in the localized junctional SR microdomain
where the Ca2+ fully releases and plateaus at 28.4 ± 0.8% and 80% of this change occurs in 42.7 ±
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3.9 secs whereas CatchER+ does not plateau and reaches 24.6 ± 2.2% global Ca2+ release and 80%
of this change takes 413.7 ± 17.9 secs (Figure 5.19). Additionally, when the 4-cmc is washed away
localized CatchER+-JP45 can immediately recover back to baseline and 80% of this recovery
happens in 114.3 ± 24.7 secs whereas global CatchER+ cannot fully recover the ER/SR Ca2+ back
to baseline (Figure 5.19).

Figure 5.20 – CatchER+ and CatchER+-JP45 FDB fiber analysis.
A – Expression of CatchER+ and CatchER+-JP45 in mouse flexor digitorum brevis
foot muscle. B – Cross-section distribution pattern of fluorescence intensity for
CatchER+ (black) and CatchER+-JP45 (red) from A with the doublet peak red arrows
corresponding to red arrows in A. C – 100 Hz electrical stimulation of transfected
FDB mouse fibers for CatchER+ (black) and CatchER+-JP45 (red).
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We wanted to further see the application of our localized CatchER+-JP45 sensor in comparison to
our global CatchER+ sensor for analyzing subcellular microdomains on a tissue scale as opposed
to single-cell studies, so we transfected both sensors into mouse flexor digitorum brevis (FDB)
muscle fibers (Figure 5.20A). We saw that the global CatchER+ sensor was uniformly expressed
throughout the ER/SR of the FDB skeletal muscle and when examining a cross-section of the
muscle we can see the uniform single peaks of CatchER+ expression in each fiber of the FDB
muscle (Figure 5.20A-B). Interestingly, we see that the localized CatchER+-JP45 sensor had a
differential expression pattern and can be seen on the cross-section by a doublet peak as the sensor
is expressed co-localized to RyR1 at the plasma membrane contacts with the junctional SR as
indicated by the red arrows (Figure 5.20A-B).
Furthermore, these FDB muscles were exposed to 100 Hz of electrical stimulation for 300 ms to
activate skeletal muscle E-C coupling through the activation of voltage-gated DHPR on the plasma
membrane which have the allosteric interaction with RyR1 on the junctional SR colocalized with
JP45 leading to a release of Ca2+ from the SR to the cytoplasm[344-346]. For the global CatchER+
sensor there was a 40% release of Ca2+ in 100 ms whereas the localized CatchER+-JP45 sensor
had over 85% release of Ca2+, two-fold greater than the global signal, in less than 50 ms (Figure
5.20C).
For imaging the complex and dynamic structure of the ER a microscopy technique was needed
that would overcome the resolution limit from the diffraction of light. Since light diffraction limits
the resolution and the distance at which two items can be distinguished to approximately half of
the wavelength of light[347]. Thus we not only utilized epifluorescence, confocal, and HILO
imaging but also did photon switch imaging using the stochastic optical reconstruction microscopy
(STORM)[348] technique. STORM can image in the 20-40 nm range by utilizing photo switchable
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fluorescent molecules which can be switched on and off thousands of times before being
photobleached.

Figure 5.21 – CatchER+ STORM imaging in C2C12 mouse muscle cells.
GFP/EGFP antibody that is Rabbit polyclonal to GFP (ab6556) with a secondary
Donkey Anti-Rabbit IgG H&L (ab6701). CatchER+ at 488 nm (white) and 647 nm
(cyan).

Most commonly utilized is the cyanine dye (Cy5) switched between a fluorescent and dark state
by alternating red (638 nm) and green (532 nm) laser pulses, this switching between fluorescent
and non-fluorescent is readily reversible and easily controlled through laser pulsing[348, 349]. This
reconstruction technique makes sub-diffraction imaging of the ER structure possible by avoiding
the limitation of the wavelength of light and instead utilizing the photons emitted.
We can more clearly visualize the ER network pattern by utilizing STORM imaging (Figure 5.21).
We can see in comparison to the epifluorescence image at 488 nm for CatchER+ that the 647 nm
STORM image is much clearer and background fluorescence from other layers of the cell are
removed (Figure 5.21).
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Figure 5.22 – CatchER+-JP45 STORM imaging in C2C12 mouse muscle cells.
GFP/EGFP antibody that is Rabbit polyclonal to GFP (ab6556) with a secondary
Donkey Anti-Rabbit IgG H&L (ab6701). CatchER+-JP45 at 488 nm (white) and 647
nm (cyan).
We also simultaneously looked at the CatchER+-JP45 in C2C12 cells at 488 nm epifluorescence
in comparison to 647 nm GFP tagged photo-switchable antibody for STORM imaging (Figure
5.22-Figure 5.23).

Figure 5.23 – CatchER+-JP45 STORM imaging in C2C12 mouse muscle cells.
GFP/EGFP antibody that is Rabbit polyclonal to GFP (ab6556) with a secondary
Donkey Anti-Rabbit IgG H&L (ab6701). CatchER+-JP45 at 488 nm (white) and 647
nm (cyan).
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The signal for CatchER+-JP45 in epifluorescence seems to have higher intensity around the
nucleus from all of the cell layers but that upon examining the 647 nm STORM signal we can see
that the signal is actually most highly concentrated for localized CatchER+-JP45 near the edges of
the cell structure where the ER/SR would have plasma membrane contacts (Figure 5.22-Figure
5.23).

5.3

Discussion

The HILO imaging technique is an improvement over epifluorescence imaging in that there is an
excellent separation of signal from the background as well as an overall higher dynamic range.
We found for C2C12 cells that 1 mM of 4-cmc had a release of 45.5 ± 1.3% for 32 cells, 50 μM
of CPA had a release of 25.7 ± 1.5% in 18 cells, and 500 ATP had a release of 14.0 ± 1.1% in 12
cells (Table 5.3). HEK293 cells were more sensitive to higher drug concentrations, so we did 500
μM of 4-cmc that had a release of 22.2 ± 1.6% for 40 cells, 50 μM of CPA had a release of 23.3 ±
1.2% in 18 cells, and 500 ATP had a release of 15.6 ± 1.1% in 24 cells. HEK293 was comparable
in response to C2C12 for CPA and ATP while only lower for 4-cmc because of the lower
concentration. Cos-7 cells were also more sensitive to drug concentrations and also had did 500
μM of 4-cmc that had a release of only 12.3 ± 0.8% for 36 cells, 50 μM of CPA had a release of
17.0 ± 0.9% in 31 cells, and 500 ATP had a release of 12.3 ± 1.7% in 13 cells. Cos-7 was
significantly lower in the response of all three drugs in comparison to the other cell lines, with
ATP being only remotely close to the other two. Overall it seems that the Cos-7 cells have lower
ER responses. Lastly, we tested 4-cmc and histamine on HeLa cells. HeLa cells, unlike the other
cell lines we investigated, do not have a P2YR activated by ATP but instead has the histamine
receptor (H1R) which is activated by histamine. Many other sensors test the IP3R activity through
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the H1R activation by histamine since the activation of H1R in HeLa cells leads to oscillations of
Ca2+ from the ER. Thus, we were interested in seeing if we were able to see these oscillations with
CatchER+. Similarly, to the Cos-7 cells the ΔF/F for 1 mM 4-cmc was lower than in C2C12, at
~25% as opposed to ~45%. This is most likely due to the much higher RyR expression in C2C12
cells since they are skeletal muscle cells versus HeLa cells which are cervical cancer tumor cells.
We also did a photobleaching test on CatchER+ to we could see if the downward slope of some of
our responses was indeed real signal change or if the sensor was photobleaching over time with
the two fps collection by the HILO laser with a constant laser exposure at 0.7 mW power and 0.5
exposure. The cells did not show any significant change in fluorescence over 2500 seconds, which
is much longer than any experiments we currently perform. Thus, any downward sloping of the
sensor in our imaging is due to the real constant release of Ca2+ from the ER and not
photobleaching of the sensor.
We saw that the overall whole-cell signal for 4-cmc response in C2C12 cells was consistent but
when analyzing the individual regions of interest in the cell for potential subcellular microdomains
we saw significant variance on the starting Ca2+ fluorescence, the release and recovery
fluorescence as well. When we normalized the results to the initial time point at 0 secs and the
release plateau time point of 300 secs, we saw additional significant variances in the recovery,
release, and initial fluorescence signals for Ca2+ bound to CatchER+. This indicates that the
variance between each ROI in release and recovery is not merely due to an increase in errors in
normalization but that there are actual microdomains present. Variance in RyR distribution, as
well as Ca2+ concentrations in those ROIs, account for the variability in the release valley
differences at 300 secs. While the distribution of SERCA pump and the Ca2+ nearby for SERCA
pump to uptake in the cytosol account for the variable recovery rates at 500 secs. We confirmed
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that there is differential expression of RyR between a blast C2C12 cell and myotubule using
confocal microscopy. Additionally, we confirmed that the RyR expression was distributed
throughout the ER but examining the surface plots of the cells we saw peaks of differential
expression microdomains throughout the cell (Figure 5.14). We also examined SERCA pump
distribution and expression using confocal imaging to correlate the kinetic recovery differences
(Figure 5.15). Interestingly we see that the SERCA pump not only has microdomains of expression
indicated by the peak height differences on the surface plot but that the SERCA pumps are overall
mainly expressed in the ER around and in the nucleus of the cell (Figure 5.15). Overall the SERCA
pump antibody signal was brighter than the RyR signal for the same ratio and secondary antibody
which could because the SERCA pump uptake of Ca2+ to the ER is a much slower process requiring
an ATP for each Ca2+ shuttled so having higher expression of SERCA pumps could overcome the
slower kinetics of SERCA pumps for ER Ca2+ dynamics by having more in place to function. We
can then further perform confocal or STORM imaging on the same cells to see if the ROIs have
differential receptor expression or if these variances are solely from Ca2+ concentration
microdomains.
We further analyzed potential localized subcellular microdomains by designing a targeted
CatchER+ variant which is attached to JP45 and col-localizes with RyR1 at the PM for E-C
coupling with DHPR called CatchER+-JP45. We saw that the whole-cell signaling in C2C12 blast
cells for 4-cmc treatment was similar in release and recovery kinetics with the CatchER+-JP45
sensor being slightly dimmer due to the lower RyR expression in blasts cells as seen by the
confocal imaging. The whole-cell signaling in response to SERCA pump inhibition by CPA was
markedly different on the recovery kinetics where CatchER+ has slow recovery with a full recovery
after washing away CPA whereas CatchER+-JP45 is able to recover the Ca2+ almost as rapidly as
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released. This is most likely due to the CaSQ network at the junctional SR which binds high [Ca2+]
for storage for E-C coupling response and can release Ca2+ from CaSQ for SR release or to recover
the free SR [Ca2+], this response could also be due to other methods of ER/SR refilling in the
region of the junctional SR such as STIM/ORAI influx of Ca2+ from the extracellular space. Since
JP45 and RyR1 synthesis is upregulated in myotubules we also compared the global CatchER+ and
localized CatchER+-JP45 signal in response to 4-cmc in C2C12 myotubules and found that the
global ER/SR Ca2+ dynamics led to a slow release over 413.7 secs to 24.6 ± 2.2% Ca2+ release
whereas CatchER+-JP45 rapidly releases and plateaus Ca2+ from the SR at 28.4 ± 0.8% within 42.7
± 3.9 secs (Figure 5.19). CatchER+-JP45 shows that upon washing away of 4-cmc the junctional
SR Ca2+ can immediately recover back to baseline and 80% of this recovery happens in 114.3 ±
24.7 secs whereas global CatchER+ shows that the whole ER/SR cannot fully recover the ER/SR
Ca2+ back to baseline (Figure 5.19). When comparing these results to mouse FDB muscle electrical
stimulation with CatchER+ and CatchER+-JP45, we see the similar trend where CatchER+-JP45
shows significant Ca2+ release at 85% in 40 ms while CatchER+ indicates the global Ca2+ release
is only 50% and much slower at 100 ms although both are able to recover to baseline (Figure 5.20).
In the future, we will further investigate the microdomain visualization, especially in comparison
of CatchER+ and CatchER+-JP45 within myoblasts and myotubules of C2C12 cells. Furthermore,
STORM dual-color and confocal imaging of C2C12 cells and other cell lines are necessary to
confirm the microdomain protein expression to correlate the HILO imaging results. Also, we
should do a Ca2+ free trial of CatchER+ imaging using 100 μM La3+ in the 0 Ca2+ Ringer’s buffer
to prevent any Ca2+ in buffer/cell media from entering the cell, therefore preventing refilling of
ER/SR. La3+ is a Ca2+ chelator since it is a Ca2+ channel blocker. This can provide critical
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information about ER/SR refilling routes. There is also a need to target CatchER+ to other
organelles as well as designing versions of CatchER+ based on RFP, YFP, and CFP.

5.4

Materials and Methods
5.4.6

Cloning of CatchER+

Mutations were made using Pfu DNA polymerase (G-biosciences) by following the
manufacturer’s instructions and using primers 5’-AAGTTCAGCGTGCGCGGCGAGGGCGAG3’

and

5’-CTCGCCCTCGGCGCGCACGCTGAACTT-3’

for

S30R,

5’-

GGCGATGCCACCAACGGCAAGCTG-3’ and 5’-CAGCTTGCCGTTGGTGGCATCGCC-3’
for

Y39N,

and

5’-GAGGACGGCGGCGTGCAGCT-3’

and

5’-

AGCTGCACGCCGCCGTCCTC-3’ for S175G.
5.4.7

Cell culture and transfection of CatchER+

Cultures of C2C12 (CRL-1772), Cos-7 (CRL-1651), HEK293 (CRL-1573) and HeLa (CRMCCL-2) cells were purchased from American Type Culture Collection (ATCC) and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
and high glucose (4.5 g/L) at 37°C. CatchER+ was transfected into cells using Lipofectamine 3000
(Life Technologies) by following the manufacturer’s instructions. Seed HEK293, Cos-7 or HeLa
cells onto sterilized 22 mm x 40 mm glass microscope slides in 6 cm dishes, so they are ~70%
confluent the day of transfection. The next day cells were transfected using 2 µg of CatchER+
cDNA and a 1:3 (weight/volume) DNA: transfection reagent ratio in the reduced serum media
Opti-MEM at 20-100% Opti-MEM. DNA: transfection reagent mixture was incubated for 4-6 hr
at 37 °C and after cells are washed then incubated at 37 °C for 48 hr so CatchER+ can be expressed.
C2C12 myoblast cells were trypsinized, resuspended in DMEM, and seeded onto slides at a final
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confluence of 60%. Cells were transfected during resuspension as outlined above and then
incubated for 24 hr at 37 °C then washed and incubated at 37 °C for 48 hr so CatchER+ can be
expressed.
5.4.8

Confocal imaging of CatchER+

We used confocal laser scanning microscopy (CLSM) Zeiss LSM 800 on fixed cells and then used
Invitrogen™ Molecular Probes™ BODIPY™ ER-Tracker™ Red for staining the ER and
Invitrogen™ ProLong™ Gold Antifade Mountant with DAPI for staining the nucleus, CatchER+
was transfected into the cells two days before fixing. Cells were fixed with 3.7% Thermo
Scientific™ Pierce™ 16% Formaldehyde (w/v), Methanol-free, permeabilized with 0.1% Triton
X-100, and non-specific binding was blocked with 0.1% Bovine Serum Albumin (BSA) all in
phosphate buffered saline (PBS).
5.4.9

Epifluorescence imaging of CatchER+

CatchER+ was transiently transfected into cells grown on coverslips and cultured for 48 hr at 37°C.
Cells were washed twice with 2 mL of physiological Ringer buffer (10 mM HEPES, 121 mM
NaCl, 2.4 mM K2HPO4, 0.4 mM KH2PO4, 1.2 mM MgCl2, 1.8 mM CaCl2 at pH 7.4). The
coverslips were mounted on a Warner Instruments low profile open diamond bath imaging
chamber. The cells were illuminated with 488 nm, and the fluorescence at an emission wavelength
510 nm was recorded in real-time as the concentration of ER/SR Ca2+ was perturbed with 4-cmc,
CPA, or ATP. All experiments were performed at room temperature on a Leica DM6100B
inverted microscope with a Hamamatsu cooled EM-CCD camera and illuminated with a Till
Polychrome V monochromator and a xenon lamp.
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5.4.10 HILO imaging of CatchER+
HILO microscopy was accomplished based on a Nikon TiE inverted microscope. Briefly, a fiber
coupled 488 nm laser (Oxxius) was collimated and introduced into the optical train of the
microscope. The laser was then focused at the back focal plane of a 100X TIRF objective (N.A.
1.49, Nikon) by using an achromatic optical lens (Thorlabs) with 200 mm focal length. The laser
collimation system and focusing lens were both mounted a mechanic translation stage (Thorlabs)
so that its optical axis of incident laser could be laterally shifted to change the incident angle of
the laser at the cell-coverslip interface. The HILO imaging condition was achieved by operating
at sub-critical angles of the total internal reflection. Since the thickness of cells, as well as the
depth of ER structure, varied among individual cells, the best HILO imaging conditions were
achieved by carefully tuning the incident angle of the excitation laser.

Moreover, the

epifluorescence images used for comparison with HILO images were taken by setting the incident
angle at 0 degrees. Large scale data analysis was done with a self-written MATLAB script.
5.4.11 Preparing cells for STORM imaging
Cells were fixed in standard fixing solution: 3% paraformaldehyde (PFA) and 0.1% glutaraldehyde
(GA) in PBS. Cells were reduced with 2 mL of 0.1% NaBH4, prepared immediately before use
and washed with PBS. Cells were blocked in blocking buffer of 3% BSA and 0.1% Triton-X100
in PBS and then aspirated. Primary antibody 2 ug/mL was added in blocking buffer and incubated
for 30 mins at RT or O/N at 4°C. Cells were aspirated and washed three times with washing buffer
of 0.2% BSA and 0.05% Triton-X100 in PBS. Secondary antibody 2 ug/mL was added in blocking
buffer and incubated for 30 mins at RT while shaking and covered with foil to protect fluorophore
from light. Cells were aspirated and washed three times with washing buffer in the dark at room
temperature.
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6
6.1

Neuronal Application of CatchER+

Introduction

Neuron Ca2+ dynamics are a complex system between pre and post-synaptic neurons for
neurological communications. Presynaptic Ca2+ influx triggers exocytosis of neurotransmittercontaining synaptic vesicles.

Figure 6.1 – Calcium dynamics in neurons.
Ca2+ is a neurotransmitter secreted in the synaptic cleft through synaptic vesicles with
an unknown [Ca2+] inside of the synaptic cleft. The ER is the primary store of Ca2+ in
neurons at ~1 mM [Ca2+] while the cytosolic [Ca2+] is in the nM range. Multiple
channels and receptors shuttle Ca2+ into and out of the neurons as well as activating
Ca2+ release from the ER through downstream regulation, for example, the IP3R
being bound by IP3 from mGluR activation.
Ca2+ release depends on the ER Ca2+ dynamics in order for neuron Ca2+ signaling from the
presynaptic axon to the postsynaptic dendrite[350]. A transient rise in postsynaptic calcium in
dendritic spines is essential for the induction of activity-dependent synaptic plasticity. Intracellular
Ca2+ in neurons is 50-100 nM but can increase up to 100-fold upon generation of an action
potential. Many channels, pumps, receptors, and organelles are involved in the neuronal Ca2+
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dynamics. In order to regulate the Ca2+ homeostasis between the extracellular and intracellular
spaces, as well as the internal organellular stores and the synaptic cleft a multitude of proteins are
utilized to keep this intricate balance and Ca2+ communication functioning[351-370].
In order to shuttle [Ca2+]o to the cytosol the neurons utilize α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor (AMPAR), nicotinic acetylcholine receptors (nAchR), N-methylD-aspartate

receptor

(NMDAR),

voltage-gated/voltage-dependent

calcium

channel

(VGCC/VDCC), and transient receptor potential channel (TRP) proteins. All these proteins have
Ca2+ shuttling capabilities based on their activation cascades. AMPAR has four agonist binding
sites with the conventional agonist being glutamate, upon binding of at least 2 binding sites the
receptor’s central pore is opened enough through conformational change to allow cations of Ca2+,
as well as potassium and sodium to flow intracellularly, which ions go through AMPAR, is subunit
selective[351, 352]. This processes of AMPAR opening and closing occurs relatively quickly within
1 ms, which allows for the necessary CNS fast excitatory synaptic transmissions[351]. Similarly, to
AMPAR the NMDAR also allows cations to flow through its pore upon binding glutamate and
glycine (or D-serine), although the major cation in the case of NMDAR is sodium with lesser
amounts of calcium and potassium being able to flow into the cytosol[353-362]. nAchR is a nonselective cation channel which when in its open conformation allows the passage of cations to flow
in or out of the cytosol. nAchR undergoes a conformational change upon binding of its agonist
acetylcholine[363, 364]. VDCCs are one of the main ways to allow Ca2+ to quickly pass into the
cytosol, upon membrane depolarization the VDCC is activated and allows for the mM [Ca2+]o to
flow into the micromolar intracellular cytosolic calcium concentration ([Ca2+]i)[365,

366]

. TRP

channels have many stimuli leading to the transport of Ca2+ into the cytosol depending on cellular
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or species expression[367-370]. TRP channels have been found to be activated by cold or hot
stimulus, taste, pain, and other compounds[367-370].
In addition to proteins which directly transport Ca2+ into the cytosol, there are also proteins whose
signaling leads to Ca2+ release into the cytosol from the ER. The transmembrane GPCR proteins
CaSR and mGluR, upon binding to an agonist extracellularly, lead to IP3 production which in turn
binds to the IP3R in the ER membrane and releases oscillatory or transient Ca2+, respectively.
CaSR binds Ca2+ to achieve this purpose while mGluR binds glutamate or other drugs such as
dihydroxyphenylglycine (DHPG).
While these proteins all lead to the increase in [Ca2+]i, there must be proteins which help maintain
the cytosolic [Ca2+]i in the micromolar range. The proteins responsible for shuttling Ca2+ out of
the cytosol in neurons are the plasma membrane Ca2+ ATPase (PMCA) pump, the sodium-calcium
exchanger (NCX), the SERCA pump, and ion/neurotransmitter containing vesicles. PMCA pumps
Ca2+ against the gradient from the micromolar cytosol to the millimolar extracellular space, this
requires energy in the form of ATP to shuttle Ca2+. PMCA is essential in maintaining this
homeostasis, without which the neuron and body as a whole would be unable to continue with
Ca2+ signaling in the cell. PMCA has a high affinity for Ca2+ in the nanomolar range but requires
the hydrolysis of one ATP molecule per each Ca2+ ion moved extracellularly, making this process
slow and costly but accurate[371-374]. NCX, on the other hand, has a much lower affinity for Ca2+
than PMCA but is able to much more quickly shuttle Ca2+ extracellularly, up to 5000 Ca2+ ions per
second, at a much lower energy cost[375-377]. NCX relies on the gradient of Na+ versus Ca2+ and
can remove one Ca2+ per addition of 3 Na+ to the cytosol[376, 377]. The speed at which NCX
functions is critical for neuronal action potentials which need Ca2+ signaling recovery at rapid
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rates[375]. PMCA and NCX are the two primary methods for any cell to regulate the removal of
Ca2+ from the cytosol[374, 378].
Not only is neuron Ca2+ dynamics critical for neurological function, but it is also related to a
plethora of neuron related disease from dysregulation of Ca2+ dynamics as seen in Table 6.1. Thus,
being able to monitor these ER Ca2+ dynamics in response to potential disease mutations and
therapeutic targets can help us to better understand these diseases and treat them effectively.
Additionally, there are many disorders that can be affected by ER Ca2+ dynamics that have not
been understood or unearthed in their functionality, such as how ER Ca2+ dynamics are affected
in synaptic plasticity (Table 6.1).
Table 6.1 – ER/SR related diseases.
Sarco/endoplasmic
Inositol trisphosphate
Ryanodine receptor (RyR)

reticulum Ca2+-ATPase

receptor (IP3R)
(SERCA) pump
Alzheimer’s disease (AD)
Bipolar disorder (BPD)
Amyotrophic lateral
sclerosis (ALS)
Huntington’s disease
Schizophrenia
Spinocerebellar ataxias
Epilepsy

Alzheimer’s disease (AD)

Epilepsy
Depression
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The ER network not only surrounds the nucleus comprising the nuclear envelope but then extends
all the way to distal dendrites and dendritic spines. The ER network has higher concentrations at
branch points of dendrites to help produce necessary local proteins needed for function in dendrites
and synaptic activity in dendritic spines[379]. Neurons have a tortuously complex and continuous
ER network which is still currently being investigated[380-385]. The ER extends throughout the
whole neuron and is even found in some dendritic spines where synaptic activity can occur[379, 386390]

. Similarly, to other cells, the significant players for ER Ca2+ release and uptake are still IP3R,

RyR, and the SERCA pump. Additionally, neurons have calcium induced calcium release (CICR)
through the STIM/ORAI complex[391]. Presynaptic neurons can localize to the dendritic spines of
postsynaptic neurons for neurotransmitter communication.

Ca2+ release from the ER in

presynaptic neurons triggers spontaneous neurotransmitter release. The neurotransmitters then
bind to receptors on the surface of the postsynaptic neurons causing Ca2+ release from IP3R and/or
RyR as well as CICR, this can lead to long-term potentiation or depression (LTP or LTD)[391]. The
rough ER in neurons is found primarily in the soma and proximal dendrites and has ribosomes for
protein transcription[379, 391]. The smooth ER is found mainly in distal dendrites, dendritic spines,
and axons with some ribosomes for local protein transcription[379, 391]. The Golgi apparatus also
has satellite Golgi complexes that are in the dendrites for signaling and protein shuttling in these
regions[379].
Neuronal ER Ca2+ imaging is not a new field and has been investigated before. Henderson et al.
examined GCaMPer in neuroblastoma and rat cortical neurons using different drugs to stimulate
ER Ca2+ release[392]. They used 10 μM CPA to inhibit the refilling of the SERCA pump, thus
creating a decrease of ER Ca2+, and 300 nM thapsigargin to also irreversibly inhibit the SERCA
pumps[392]. With 10 μM CPA they saw a 40-60% release where we see a 30-50% release with 15

176

μM CPA depending on cell types. For rat cortical neurons they used 25 μM CPA to inhibit the
SERCA pump, 50-100 μM DHPG to bind mGluR1/5 and cause IP3 production which binds to the
IP3R and releases Ca2+ from the ER[392].

Additionally, they used 5 mM Caffeine on

cardiomyocytes to induce Ca2+ release from the RyR[392]. They saw a 40-50% release with CPA,
whereas we see a 30-50% release depending on cell type. Choi et al. used Fura-2 to investigate
the cytosolic changes in response to ER Ca2+ release in mouse midbrain dopamine neurons[393].
They used 20 mM Caffeine to induce the RyR to release Ca2+ from the ER, they also used 20 μM
DHPG to release Ca2+ from the IP3R and found that if they already emptied the ER using Caffeine
and then added DHPG there was no response since the Ca2+ was all already released[393]. They also
used MagFluo-4 dye to image the ER signal changes using 20 mM Caffeine to induce RyR Ca2+
release from the ER and 4 μM thapsigargin to irreversibly block ER Ca2+ refilling through the
SERCA pump[393]. They got a ~40-45% release with Caffeine and a ~60% release by thapsigargin.
Solovyova et al. used Mag-Fura-2 to image the ER signal changes using 20 mM Caffeine to induce
RyR Ca2+ release from the ER and 5 μM thapsigargin to irreversibly block ER Ca2+ refilling
through the SERCA pump in dorsal root ganglia neurons[394].
While imaging in neurons with and without looking directly at ER Ca2+ has been done previously
there is an unmet need for an imaging method capable of imaging specifically in the ER and within
these small dendritic spines with excellent spatial resolution and strong fluorescence signal. We
were also interested in the microdomains through the variable ER expression of neuronal systems,
so we applied our designed sensor CatchER+ in hippocampal neurons to see the differential
subcellular signaling in response to DHPG activation of mGluR1/5 to potentiate LTD.
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6.2

Results
6.2.1

CatchER+ HILO Imaging in Neurons

HILO imaging has shown to be successful for CatchER+ imaging studies for looking at differential
signaling, and subcellular microdomains throughout the ER network, which while not uniform in
a cell is less diverse than the neuron ER structure. In order to investigate the differential and
extensive neuronal ER structure, we utilized CatchER+ sensor and HILO high-resolution imaging
in hippocampal neurons (Figure 6.3) and cortical neurons (Figure 6.4) from post-natal mice as well
as GFP for negative control (Figure 6.2). GFP showed no response to DHPG as expected since it
was a negative control transfected into the cytosol of the neuron without Ca2+ sensing capabilities
(Figure 6.2).

Figure 6.2 – GFP control representative response in mouse hippocampal neuron.
The response to the perifusion of 50 and 100 μM DHPG is shown through the ΔF/F0
plot with a heat map of GFP transfected into the mouse hippocampal neuron cytosol.
The color of the lines corresponds with the regions highlighted by boxes in the heat
map.
Initially, we investigated the effect of 50 μM DHPG and subsequently 100 μM DHPG in the
hippocampal neurons to see the differing responses to pre- and post-threshold levels of DHPG to
see the differences between the long term depression effects of 50 versus 100 μM DHPG (Figure
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6.3). While we were able to see some regions of the neuron had full recovery back to baseline for
100 μM DHPG similar to the 50 μM treatment, we also saw that some regions had partial or no
recovery for 100 μM DHPG as opposed to the 50 μM treatment (Figure 6.3B). The response to 50
and 100 μM DHPG led to a significant spike in the signal, either through release or uptake, and
we also see a significant spike response to the washing of the ACSF buffer to remove the DHPG
which correlated to that regions DHPG response, either through release or uptake (Figure 6.3A).
Remarkably, the 4-cmc, thapsigargin, or CPA compounds being washed away with ACSF does
not trigger this response in the neurons and is unique to the DHPG wash step (Figure 6.3C and
Figure 6.4A). Another phenomenon we were able to observe was the differential Ca2+ signaling
throughout the ER of the neuron. In most regions of the ER in the neuron, we see the expected
Ca2+ release from the ER through the IP3R after addition of DHPG as well as the recovery of the
ER as the ER refills after release. Some areas of the neuronal ER though actually have an uptake
of Ca2+ in response to DHPG additions (Figure 6.3A). This is thought to either be a movement of
Ca2+ for signaling responses to different regions of the ER for local responses, CICR, or perhaps
activating pulling Ca2+ into the ER through the STIM/ORAI1 complex. In addition to looking at
the DHPG effects on the ER Ca2+ signaling in hippocampal neurons, we also looked at the RyR
response as a control since the 4-cmc response elicited from RyR has previously been consistent
and stronger than IP3R responses in non-neuronal cell lines.
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Figure 6.3 – DHPG and 4-cmc representative response in hippocampal neurons.
A&B – The response to the perifusion of 50 and 100 μM DHPG is shown through the
ΔF/F0 plot with a heat map of CatchER+ transfected into the mouse hippocampal
neuron. The color of the lines corresponds with the regions highlighted by boxes in
the heat map. C – The response to the perifusion of 1 mM 4-cmc is shown through the
ΔF/F0 plot with a heat map of CatchER+ transfected into the mouse hippocampal
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neuron. The color of the lines corresponds with the regions highlighted by boxes in
the heat map.

Thus we used 1 mM 4-cmc perifusion on the neurons either alone or after DHPG to see that the
ER release was occurring (Figure 6.3C). All of the regions of the ER in the neurons reacted
similarly in that they all had a release of Ca2+ upon 4-cmc treatment and some level of recovery
after washing with ACSF. The release of Ca2+ varies between areas of the neuron of around 1045% release. The other substantial difference throughout the neuron is the recovery rates. Some
regions can recover entirely while others recover past the baseline, partially recover, barely, or not
at all. While there is some variability in the 4-cmc response, it is still consistently a release of Ca2+
from the ER and none of the regions have an increase as seen in the DHPG treatments (Figure 6.3).
In addition to imaging hippocampal neurons we also imaged cortical post-natal mouse neurons.
We treated these neurons with DHPG and 4-cmc similarly to the hippocampal neurons (Figure
6.4). Similar to the hippocampal trials, we saw a decrease in signal in response to DHPG for most
regions of the neuron’s ER but an increase in some areas (Figure 6.4). We also added 200 μM 4cmc instead of 1 mM 4-cmc since we did not know how the cortical neurons would respond to
higher 4-cmc concentrations and did not want to lead to neuronal apoptosis (Figure 6.4A). The
neurons had a release but not recovery, possibly due to the long imaging time and multiple drug
treatments (Figure 6.4A).
The cortical neurons also seemed to exhibit an overall slow decrease in signal throughout the
experiment that would not be photobleaching since the CatchER+ sensor takes much longer to
actually photobleach and that the background/non-responsive plots had minor decreases in
comparison (Figure 6.4). Thus, this phenomenon of gradual decreasing in signal seems to be
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indicative of true signaling dynamics in the cortical neuron ER where Ca2+ is slowly depleting
over time.

Figure 6.4 – DHPG and 4-cmc representative response in mouse cortical neurons.
A-C – The response to the perifusion of 100 μM DHPG is shown through the ΔF/F0
plot with a heat map of CatchER+ transfected into the mouse hippocampal neuron.
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The color of the lines corresponds with the regions highlighted by boxes in the heat
map. A – The response to the perifusion of 1 mM 4-cmc is shown after the DHPG
response through the ΔF/F0 plot with a heat map of CatchER+ transfected into the
mouse hippocampal neuron. The color of the lines corresponds with the regions
highlighted by boxes in the heat map.
We then treated hippocampal neurons with 100 μM DHPG alone to see the response were similar
if the neurons were not pre-treated with 50 μM DHPG first (Figure 6.5A-B).

Figure 6.5 – DHPG and CPA representative response in mouse hippocampal neurons.
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A-B – The response to the perifusion of 100 μM DHPG is shown through the ΔF/F0
plot with a heat map of CatchER+ transfected into the mouse hippocampal neuron. C
– The response to the perifusion of 50 μM CPA is shown through the ΔF/F0 plot with
a heat map of CatchER+ transfected into the mouse hippocampal neuron. The color
of the lines corresponds with the regions highlighted by boxes in the heat map.
The 100 μM DHPG treatments showed responses similar to those treated with 50 and 100 μM
DHPG with the same differential ER Ca2+ response where some regions increase in ER Ca2+
concentrations whereas most of the neuron decreases and that the 100 μM treatment led to the ER
Ca2+ only partially recovering or having a slight plateau where the signal does not recoup and often
responds again upon washing with ACSF buffer as we have seen for all the DHPG treatments
(Figure 6.5A-B).
The CPA treatment induced a response pattern similar to 4-cmc in neurons and almost identical in
other CPA treated cell imaging experiments we have done using CatchER+ (Figure 6.5C). The
CPA in hippocampal neurons induces a 5-10% release of Ca2+ from the ER, which reaches a
plateau until washed away with ACSF thus returning to the baseline Ca2+ signal (Figure 6.5C).
This shows us that the SERCA pump distribution and signaling is not differential to those in other
cell types especially as compared to the differential signaling we see for the IP3R release through
DHPG as composed to ATP or Histamine IP3R activation in other cell types which only lead to a
decrease in the ER Ca2+ signal, not an increase, and at a much slower rate than seen in neurons.

6.3

Discussion

We were able to successfully image hippocampal neurons which were obtained from post-natal
mice using our fluorescence ER Ca2+ sensor CatchER+ in epifluorescence and HILO imaging
systems. We initially imaged CatchER+ in neurons on an epifluorescence 40x Leica microscope
in neurobasal media activating the ER response using 200 µM 4-cmc to activate the RyR Ca2+
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release, 50 µM DHPG or 10 mM Caffeine to activate mGluR1/5 to indirectly activate the IP3R
Ca2+ release, and lastly with 15 µM CPA to inhibit SERCA pump refilling. The low resolution of
our 40x objective and the overall fluorescence overlap of epifluorescence led us to change to HILO
imaging technique with a 100x objective on a Nikon microscope in order to see microdomain
changes throughout the neuron ER network and be able to visualize the soma, dendrites, and
dendritic spines accurately.
Therefore, we examined mouse hippocampal post-natal neuron imaging (Figure 6.2-Figure 6.3 and
Figure 6.5) as well as a batch of mouse cortical post-natal neuron wild type (WT) imaging (Figure
6.4), both with the HILO imaging system. We first examined that the GFP transfected neurons for
control had no signal change in response to treatment with 50 µM and 100 µM DHPG, which they
did not, confirming that any CatchER+ signal changes we examine within the neurons are actual
signal changes (Figure 6.2). We next looked at CatchER+ responses in hippocampal neurons in
response to 1 mM 4-cmc to activate the RyR Ca2+ release, 50 or 100 µM DHPG to activate
mGluR1/5 to indirectly activate the IP3R Ca2+ release, and lastly with 50 µM CPA to inhibit
SERCA pump refilling (Figure 6.3 and Figure 6.5). 1 mM 4-cmc is able to initiate a decrease in
fluorescence signal from a release of Ca2+ in the ER at 32.5 ± 1.7%, while 50-100 µM DHPG is
able to initiate a quick release/uptake and recovery of ±14.2 ± 2.3%, and 50 µM CPA inhibits
refilling of the ER leading to a release of 9.9 ± 2.5% (Figure 6.3 and Figure 6.5). While 4-cmc and
CPA only initiate a decrease in CatchER+ signal in response to treatment, DHPG can have a
decrease in most neuron regions, but some regions throughout the neuron are able to have an
increase in response to treatment (Figure 6.3 and Figure 6.5). Additionally, upon washing away
DHPG we also see the second response in the same manner as the DHPG treatment response that
is not seen with 4-cmc or CPA (Figure 6.3 and Figure 6.5). This response could be attributed to a
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phantom signal response from the movement of the drug again to re-activate the receptors before
being washed away or to be a depolarization effect from the change in Ca2+ levels extracellularly
after equilibration with the Ca2+ release initiated from the ER leading to another wave of Ca2+
release from the ER from calcium-induced calcium release (CICR).
We also imaged cortical mouse neurons simultaneously in response to 200 µM 4-cmc to activate
the RyR Ca2+ release and 100 µM DHPG to activate mGluR1/5 to indirectly activate the IP3R Ca2+
release (Figure 6.4). 200 µM 4-cmc can initiate a decrease in fluorescence signal from a release of
Ca2+ in the ER at 21.7 ± 2.4%, while 100 µM DHPG is able to initiate a quick release/uptake and
recovery of ±12.6 ± 2.5% (Figure 6.4). Similarly, to the hippocampal neurons, we also see the
bidirectional DHPG response in cortical neurons as well as the secondary ACSF response only in
DHPG washing. For 100 μM DHPG Henderson et al. saw ~40% release and only ~15% release
with 50 μM DHPG, where we see around 10% release using 50-100 μM DHPG in hippocampal
neurons[392]. Also, we have found that most other research looking at the ER Ca2+ release through
DHPG activation do not see the quick response we do on the seconds scale but instead only see
the slower DHPG response on the minutes scale. While we have let our experiment run for 800
seconds, we only see this quick response and recovery, which could be attributed to our sensor’s
superior fast kinetic on and off rate properties in the ms range.
Further research using inhibitors specifically for mGluR1, such as CPCCOEt, or for mGluR5, such
as 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP), in conjunction with DHPG activation, to
investigate the specific group I mGluR responsible for LTD. Furthermore, we also want to image
CatchER+ with a morphology fluorescence probe to confirm that the changes being seen are not
convoluted from neuronal dendritic movement during imaging. Moreover, designing CatchER+
for viral infection into mouse models to examine whole mouse brain and hippocampal responses
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with WT and relevant mutants in response to stimuli would expand the understanding of the effects
of ER Ca2+ dynamics in related disorders.

6.4

Materials and Methods
6.4.2

Generation of primary hippocampal neuron cultures and transfection

Mice were kept in standard housing with littermates, provided with food and water ad libitum and
maintained on a 12:12 (light-dark) cycle. Primary neuron culture was approved by the Georgia
State University Institutional Animal Care and Use Committee. Primary hippocampal neurons of
mixed sex were isolated from P0-1 mice as previously described[395]. At day in-vitro 11, neurons
were transfected with Lipofectamine 2000 (Thermo Fisher Scientific) as described previously[396]
and imaged 1-2 days later.
6.4.3

Epifluorescence imaging of CatchER+

CatchER+ was transiently transfected into cells grown on coverslips and cultured for 48 hr at 37°C.
Cells were washed twice with 2 mL of artificial cerebrospinal fluid (ACSF) buffer (124 mM NaCl,
3 mM KCl, 1.8 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 10 mM D-Glucose, pH=7.4). The
coverslips were mounted on a Warner Instruments low profile open diamond bath imaging
chamber. The cells were illuminated with 488 nm and the fluorescence at an emission wavelength
510 nm was recorded in real-time as the concentration of ER/SR Ca2+ was perturbed with 4-cmc,
CPA, or ATP. All experiments were performed at room temperature on a Leica DM6100B
inverted microscope with a Hamamatsu cooled EM-CCD camera and illuminated with a Till
Polychrome V monochromator and a xenon lamp.
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6.4.4

HILO imaging of CatchER+

HILO microscopy was accomplished based on a Nikon TiE inverted microscope. Briefly, a fiber
coupled 488 nm laser (Oxxius) was collimated and introduced into the optical train of the
microscope. The laser was then focused at the back focal plane of a 100X TIRF objective (N.A.
1.49, Nikon) by using an achromatic optical lens (Thorlabs) with 200 mm focal length. The laser
collimation system and focusing lens were both mounted a mechanic translation stage (Thorlabs)
so that its optical axis of incident laser could be laterally shifted to change the incident angle of
the laser at the cell-coverslip interface. The HILO imaging condition was achieved by operating
at sub-critical angles of the total internal reflection. Since the thickness of cells, as well as the
depth of ER structure, varies among individual cells, the best HILO imaging conditions were
achieved by carefully tuning the incident angle of the excitation laser.

Moreover, the

epifluorescence images used for comparing with HILO imaging was taken by setting the incident
angle at 0 degrees. Large scale data analysis was done with a self-written MATLAB script.
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7
7.1

Major Conclusions and Significance

CaSR Significance and Conclusions

The research we have done on CaSR address key gaps in our understanding of extracellular
signaling and the CaSR structure. The discovery of the parathyroid CaSR by Dr. Ed Brown et al.
in 1993 revealed the source for Ca2+ homeostasis and extracellular Ca2+ signaling[22]. Our research
into the structure of CaSR ECD exposes the crucial role of Ca2+ binding sites of the CaSR ECD in
diseases of [Ca2+]o sensing and also revealed the binding of a drug TNCA in the main binding
pocket of CaSR, thus opening a new research path of drug design previously untapped. More than
400 mutations have been found in the CaSR for a variety of diseases and disorders, over half of
these are related to disorders of Ca2+ dysfunction. Inactivating human mutations with familial
hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT) reduce
CaSR’s sensitivity to [Ca2+]o, whereas activating mutations of autosomal dominant hypocalcemia
(ADH) cause heightened sensitivity of [Ca2+]o and [Mg2+]o [397, 398]. Studies have reported that these
disease-associated mutations alter either the CaSR’s responses to [Ca2+]o and [Mg2+]o by shifting
of the responsiveness of CaSR or altering the cooperativity[399]. CaSR has also been shown as a
critical regulator for renal fibrosis[255, 400-406]. Remarkably, CaSR calcilytic R-568 showed in
mouse models to inhibit renal fibrosis[403] Our determined crystal structure of human CaSR ECD
exposed significant insights on the regulation and structural foundation of CaSR diseases as well
as the potential for drug development[287]. We initially optimized expression of CaSR ECD in order
to use this purified protein for crystallization studies. We optimized expression by removing the
7TMD, ICD, and cys-rich region from the CaSR ECD. We then removed the flag tag for staining
as to not further perturb the CaSR structure. Additionally, we expressed the CaSR ECD in a
mammalian expression system lacking GnT1 so that CaSR ECD would not be glycosylated with
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complex glycans and instead only with mannose glycans leading to easier deglycosylation using
Endo-F1.

We then ordered new Sepharose beads to use exclusively for mCaSR hist-tag

purification. Doing all of these steps allowed us to get a crystal formation under 200 mM Mg2+
and 10 mM Ca2+ with 2.1 Å resolution. We found in our determined CaSR ECD structure two
confirmed Mg2+ binding sites, two of which overlap with our predicted Ca2+ binding sites, and
then a novel drug binding site in the hinge region thought to be the main Ca2+ binding site based
on mutation studies (Table 2.3). The hinge TNCA binding site consists of residues S147, A168,
S170, Y218, and E297. Four of these residues overlap exactly with our predicted Ca2+ binding
site. The dimerization binding site of Mg2+, which is possible to also be Ca2+ since with weak
binding Ca2+ did not show on the crystal structure, are residues E228, E231, S240 and E341 from
the other monomer. Two of these residues overlap a binding site on the modeled structure. Lastly,
a new Mg2+ site was found that was not predicted using our modeled structure and also found in
another crystal paper which came out after ours, and these residues are I81, S84, L87, and L88.
With all of these binding sites known we can then be poised to examine the disease mutations at
these sites and find I81M (FHH), L87I (lung carcinoma), L87R (thyroid neoplasm), Y218S (FHH),
Y218C (FHH), E228Q (ADH), E228K (ADH), E297D (ADH), and E297K (FHH). There are many
more mutations affecting the residues directly around each residue number as well as in the region
of the binding pockets in general. Inactivating and activating mutations are primarily distributed
in the TNCA binding site at the hinge region as well as the dimerization interface binding site of
Mg2+. We found that the residues of E297 and Y218 were critical for CaSR function since
mutation of these residues to Ile and Lys, respectively, lead to a complete loss of CaSR function
in cell imaging. The E228 residue mutation to Ile led to a loss of CaSR signaling function only
able to be overcome by higher [Ca2+]o or TNCA treatment.
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Additionally, we use a multitude of methods for analyzing the CaSR; bacterial expression
(bCaSR), mammalian expression (mCaSR), and cellular imaging, cell population, binding studies,
ELISA, and crystallography. We utilized a bacterial E. coli expression system for the CaSR ECD
which has been optimized to have a higher yield and less degradation by removing the cys-rich
domain, the signal peptide region, and mutating 4 Cys residues to Ala in order to prevent incorrect
disulfide bond formation and thus give us a structure correctly formed. The benefits of bCaSR are
that there are no post-translational modifications like glycosylation, there is quicker cell growth,
in addition to being economical. We then used the SHuffle expression cell line in order to prevent
incorrect disulfide bonds from occurring. Using this methodology, we were able to get consistent
CaSR ECD expression and purification as confirmed by CD studies. Then we further created
mutations to disturb the binding sites or related disease mutations in order to correlate our
functional studies in the cell to binding studies using fluorimetry. We were able to make mutations
S272A to disturb hinge region binding, E228K/Q for ADH mutations affecting the dimerization
site, R66H FHH related mutation affecting the bicarbonate binding site, and D216N cancer
mutation near the hinge site. We found that mutation of R66H, E228K, and E228Q led to a loss
of CaSR expression and a complete loss of purification capacity. S272A and D216N both
successfully purified but their Trp fluorimetry results saw a decrease in Ca2+ binding induced
conformational effects and using Tb3+/FRET with S272A we saw disturbance of Tb3+ cooperative
binding effects with no apparent binding pattern and high precipitation showing a detrimental
effect of the mutation on CaSR stability.
While CaSR is an important therapeutic target there has so far only been one FDA approved
positive allosteric modulator named cinacalcet for treatment of hyperthyroidism. There is still a
pressing need for discovery of additional calcimimetics since cinacalcet causes adverse side effects
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of nausea and vomiting in 15–20% of patients, reduction of male testosterone levels in 15–30% of
patients and needing a twice-daily dosage schedule is often problematic. The long-term safety and
efficacy of the calcimimetics are also unclear. A recent trial in humans using cinacalcet showed a
slight, but statistically insignificant, improvement in cardiovascular disorders, a significant cause
of death in the dialysis population, which may be mitigated by further development of this class
of drugs. So far no CaSR calcilytics have been FDA approved since all have failed in animal trials
for the adverse effects of usage, this is still a critical target for future drug studies since antagonists
of CaSR have the potential to treat osteoporosis or forms of hypoparathyroidism[407, 408].
The revealed Trp derivative TNCA as a co-agonist improves CaSR activation through Ca2+ by
increasing oscillation frequency and by Mg2+ by decreasing the EC50 of [Mg2+]o[287]. These results
give us hope that TNCA can be used for further drug development. TNCA binds at the hinge
pocket adjacent to the proposed Ca2+ site, here TNCA either acts as a cooperative regulator or as
a competitive binding partner. Due to limitations of biopsy and lack of imaging agents, the
biodistribution of CaSR expression during biological and pathological states are not currently
defined. The first major gap in understanding human diseases is non-invasive mapping CaSR’s
expression in both physiological and pathological states. Our initial drug studies here reveal that
TNCA as a lead drug target is possible, and further drug design and collaborations need to be done
to provide more dramatic drug compounds to synthesize for testing. Our initial lead drug design
led us to find a couple of compounds which act as calcimimetics and calcilytics, but none yet which
are more effective than cinacalcet or NPS2-143, respectively.
The CaSR studies is an ever-growing and furthering field. Our future work in this research
includes more disease related mutations of the CaSR ECD to see effects on the functionality in
response to mutation as well as drug recoveries. Additionally, more lead drug target studies where
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TNCA based compounds can be made to find a potential CaSR therapeutic. The full-length CaSR
has also yet to be crystallized and crystallization of full-length human CaSR would greatly help in
identifying potential therapeutic directions since cinacalcet and many other designed CaSR drugs
are thought to be targeted to the CaSR TMD.

7.2

Calcium Sensors Significance and Conclusions

The discovery of Ca2+ binding dyes such as Fura-2 and then the additional discovery of fluorescent
proteins spearheaded the Ca2+ imaging field. While GECIs based on fluorescent protein scaffold
are critical in Ca2+ imaging today, there is still an ever-growing need for new sensor colors, kinetic
rates, binding modalities, and organelle/location targeting. Currently, only our CatchER is
available on the market which can bind a single Ca2+ per EGFP backbone, this capability gives
CatchER fast kinetics as well as being able to quantitate the signal as 1:1 binding using min/max
experiments. Our sensor is targeted to the ER/SR through KDEL and calreticulin retention
sequences but can also be targeted to the cytosol upon removal of those regions. CatchER does
have drawbacks of being bright at 30°C but dim at the commonly used 37°C for cell culture and
animal models. Therefore, we modified CatchER through thermostability, and fluorescence
mutations reported by others to create the improved CatchER+ which still has 1:1 binding and fast
kinetics in the ns-ms range.
In collaboration with Dr. Zorzato in an attempt to further comprehend the Ca2+ dynamics involved
within the ER/SR in skeletal muscle cells during E-C coupling at the junctional face membrane,
we created a fusion of CatchER+ with the newly discover JP45 which colocalizes with RyR1. This
new construct has JP45 at the N-terminus of CatchER+ so that CatchER+ remain inside the ER/SR,
we named this construct CatchER+-JP45.
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The adaptability of Ca2+ as an intracellular messenger is modulated by the distribution of CaBP
and Ca2+ regulating protein throughout the cell as well as its spatial and temporal properties. Ca2+
signaling is shown to be in differential microdomains. These microdomain of Ca2+ equips regions
of the cell to have dynamic Ca2+ signaling differences localized to that region of the cell which do
not necessitate full cell signaling for local processes. Ca2+ microdomains and regions of high
calcium gradients are present more frequently in areas of Ca2+ signaling usually under rapid
conditions for example near calcium channels for Ca2+ influx or near RyR1 for E-C coupling of
skeletal muscle contraction. Many of these microdomains are present in the major Ca2+ storage
organelles of the ER/SR and mitochondria. There have been many studies indicating that Ca2+
dysregulation in the ER/SR and the cell as a whole for homeostasis have significant effects on
diseases affecting the whole body. Ca2+ dysregulation from ER/SR proteins such as RyR, IP3R
and the SERCA pump alone have been attributed to Malignant hyperthermia (MH), Central core
disease of muscle (CCD), Multiminicore disease with external ophthalmoplegia (MMDO),
Catecholaminergic polymorphic ventricular tachycardia (CPVT), spinocerebellar ataxia 15 and 29
(SCA15/29, acrokeratosis verruciformis (AKV) and Darier disease (DD). Additionally Ca2+
dysfunction in the neuronal system alone has been linked to many neurodegenerative disorders
including Alzheimer’s disease (AD), bipolar disorder (BPD), amyotrophic lateral sclerosis (ALS),
Huntington’s disease (HD), schizophrenia, spinocerebellar ataxias, Parkinson’s disease (PD),
epilepsy, and fragile X syndrome (FXS) [146-163].
As such, there is a critical need to understand how disease states affect Ca2+ dynamics and
signaling in the ER/SR in a global and microdomain regions as well as the whole cell in multiple
body systems. Additionally, understanding how Ca2+ microdomains are precisely arranged to
assist in cellular function will aid us in comprehending disease states and treating them. In order
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to achieve this, our sensor CatchER+ along with HILO microscopy can examine the sources of
Ca2+ microdomains and then further examine these regions for targets of microdomain placement.
We have found that CatchER+ with HILO imaging can elucidate the differential Ca2+ dynamics
throughout the subcellular regions of the ER as indicated by the variance in release and recovery
rates throughout the ER in a single cell. By targeting our sensor to JP45, we could examine the
microdomain specifically in the junctional zone of the SR. CatchER+-JP45 can be used to monitor
the Ca2+ flux in this microdomain in skeletal muscle cells in neuromuscular diseases associated
with dysfunctional proteins. We find that not only does CatchER+-JP45 distribute in specific areas
of the ER/SR but that the response kinetics and dynamics are differential to global CatchER+. We
are therefore ideally placed to target our sensor to other proteins thought to be in microdomain
regions and examine the effects of Ca2+ signaling in these regions under normal and disease states.
In order to more fully understand these microdomains, we looked towards transfection of
CatchER+ into hippocampal neurons using HILO imaging to examine the differential ER responses
thought to occur throughout the neuronal structure where expression of the ER can vary from the
soma to dendrites and dendritic spines. We found that not only does the ER present with regions
of signaling and non-signaling Ca2+ dynamics but that different regions of the same neuron ER
have an increase or decrease response to 100 μM DHPG activation of the mGluR1/5 which
potentiate LTD.
Our research so far with CatchER+ and CatchER+-JP45 show that our sensor can be utilized in
multiple cell types including C2C12, HEK293, HeLa, Cos-7 and cultured neurons to monitor
ER/SR receptor-mediated Ca2+ responses in response to agonist or antagonist additions. We can
further continue our research by making mouse models expressing CatchER+, targeting CatchER+
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to other organelles such as the mitochondria, and developing other CatchER+ color variants using
RFP, YFP, and CFP backbones to apply a Ca2+ binding site to.
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8

APPENDICES

Appendix A – Optimizations
Removal of TNCA from mCaSR
When we elucidated the crystal structure for CaSR we also saw and TNCA bound in the hinge
region of the ECD. We need to remove that ligand in order to accomplish accurate binding studies
on the mCaSR. Thus, we used varying concentrations of Phe on the mCaSR to see which
concentration could displace TNCA. 150 mM Phe was the most proficient at TNCA removal
(Figure 8.1).

Figure 8.1 – TOF MS of mCaSR TNCA peak being competed out by Phe.
Left peaks are Phe, right peaks are TNCA.

We did the next expression batch of mCaSR ECD using 150 mM Phe. We initially did Phe
removal with multiple concentrations and at room temp but decided that the previous method for
MS analysis of Phe removal of TNCA was too harsh. Therefore, we elected to wash the
column/mCaSR with 150 mM Phe for 5-10 CVs after the protein was loaded O/N onto the column.
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Figure 8.2 – Expression and purification of mCaSR using Phe wash.
(A) 150 mM Phe only in buffer A pre-wash not in run of program buffer A or B. (B)
150 mM Phe in buffer A and B throughout purification. (C) Western blot done with
ADD antibody and SDS gel stained with Coomassie Blue.
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We did 150 mM Phe wash in Buffer A as to not shock the protein which is in mammalian buffer.
We also decided to do half of the purifications with Phe in Buffer A and B throughout, and half
with Phe only in the pre-running Buffer A and none in the elution (Figure 8.2). We saw that having
Phe only in buffer A led to a single mCaSR peak (Figure 8.2A) whereas having Phe throughout
the whole purification led to a doublet mCaSR peak (Figure 8.2B). Upon doing coomassie blue
and western blot gels we see that all of the peaks are the same kDa since TNCA is such a small
MW we do not expect to see changes on the gel. Mass spectrometry was performed on these peaks
but no TNCA was found in any of the peaks, while this may be true in actuality this could also
mean that the concentrations of the TNCA are just too low to detect but that TNCA is still present.
As such, using hCaSR for TNCA studies will be more ideal since we know there is no TNCA
bound in hCaSR.

Identifying CaSR Disease Mutations
Utilizing the CaSR database (CaSRdb) and the Catalogue Of Somatic Mutations In Cancer
(COSMIC) database which collects known cancer disease mutations from scientific
publications[409, 410]. We were able to extract all of the currently listed disease mutations known by
2017 to affect CaSR utilizing these two databases. These were then outlined in a table sorted by
the amino acid sequence and the type of mutation as well as the effect this mutation had (Table
8.1).
Table 8.1 – CaSR disease mutations using CaSRdb and COSMIC.
Domain

Amino Acid
Mutation

AA#

Histology

ECD

M1R

1

FHH

ECD

p.A2E

2

Carcinoma

CDS
Mutation

Primary Tissue

Pubmed
Id

c.5C>A

Skin

21984974
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ECD

p.C6R

6

Malignant melanoma

c.16T>C

Soft tissue

26168399

ECD

p.C6*

6

Ewings sarcoma

c.18C>A

Bone

25186949

ECD

C7ins/fsX47

7

FHH

ECD

p.V9I

9

Carcinoma

c.25G>A

Large intestine

25344691

ECD

p.L10I

10

Carcinoma

c.28C>A

Endometrium

-

ECD

L11S

11

FHH

ECD

L13P

13

FHH

ECD

T14A

14

FHH/Polymorphisms

ECD

p.W15*

15

Malignant melanoma

c.45G>A

Skin

26214590

ECD

Y20H

20

FHH/Polymorphisms

ECD

G21R

21

FHH

ECD

p.P22L

22

Malignant melanoma

c.65C>T

Skin

-

ECD

p.D23N

23

Carcinoma

c.67G>A

Lung

-

ECD

p.R25L

25

Carcinoma

c.74G>T

Ovary

-

ECD

R25X

25

FHH

ECD

Q27R

27

FHH

ECD

p.K28K

28

Malignant melanoma

c.84G>A

Skin

-

ECD

p.K28N

28

Malignant melanoma

c.84G>C

Skin

-

ECD

K29E

29

ADH

ECD

p.G30R

30

Malignant melanoma

c.88G>A

Skin

-

ECD

p.G30R

30

Carcinoma

c.88G>A

Skin

25303977

ECD

p.G30E

30

Malignant melanoma

c.89G>A

Skin

-
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ECD

p.G30E

30

Carcinoma

c.89G>A

Skin

25303977

ECD

p.D31N

31

Carcinoma

c.91G>A

Stomach

-

ECD

p.I33I

33

Chondrosarcoma

c.99C>A

Bone

23770606

ECD

p.I33I

33

Malignant melanoma

c.99C>T

Skin

-

ECD

p.I33I

33

Malignant melanoma

c.99C>T

Skin

-

ECD

p.G36V

36

Carcinoma

c.107G>T

Large intestine

25344691

ECD

p.P39S

39

Malignant melanoma

c.115C>T

Skin

-

ECD

p.P39S

39

Malignant melanoma

c.115C>T

Skin

-

ECD

p.P39S

39

Malignant melanoma

c.115C>T

Skin

26214590

ECD

p.P39S

39

Carcinoma

c.115C>T

Skin

25759019

ECD

P39A

39

FHH

ECD

I40F

40

FHH

ECD

p.F42F

42

Malignant melanoma

c.126T>C

Skin

-

ECD

F42S

42

FHH

ECD

K47N

47

ADH

ECD

p.S53L

53

Malignant melanoma

c.158C>T

Skin

26343386

ECD

S53P

53

FHH

ECD

P55L

55

FHH

ECD

C60F

60

FHH

ECD

R62M

62

FHH

ECD

p.F65F

65

Malignant melanoma

c.195C>T

Skin

-

ECD

p.R66H

66

Carcinoma

c.197G>A

Ovary

21720365

201

ECD

R66C

66

FHH

ECD

R66H

66

FHH

ECD

p.R69C

69

Carcinoma

c.205C>T

Endometrium

-

ECD

p.R69H

69

Carcinoma

c.206G>A

Lung

-

ECD

p.R69H

69

Carcinoma

c.206G>A

Salivary gland

27103403

ECD

p.F76C

76

Carcinoma

c.227T>G

Endometrium

-

ECD

p.E80K

80

Carcinoma

c.238G>A

Breast

-

ECD

I81M

81

FHH

ECD

p.P85L

85

Carcinoma

c.254C>T

Stomach

25042771

ECD

p.A86A

86

Malignant melanoma

c.258C>T

Skin

-

ECD

p.L87I

87

Carcinoma

c.259C>A

Lung

22980975

ECD

p.L87R

87

Other

c.260T>G

Thyroid

-

ECD

p.P89S

89

Malignant melanoma

c.265C>T

Skin

-

ECD

p.T92M

92

Carcinoma

c.275C>T

Large intestine

-

ECD

p.L93L

93

Glioma

c.279G>A

Central nervous
system

-

ECD

G94X

94

FHH

ECD

G94R

94

FHH

ECD

p.R96K

96

Malignant melanoma

c.287G>A

Skin

-

ECD

p.R96R

96

Malignant melanoma

c.288G>A

Skin

-

ECD

p.I97T

97

Carcinoma

c.290T>C

Liver

-

ECD

p.I97T

97

Carcinoma

c.290T>C

Liver

-

ECD

T100I

100

FHH

202

ECD

p.C101C

101

Carcinoma

c.303C>T

Pancreas

-

ECD

p.T103S

103

Carcinoma

c.308C>G

Breast

-

ECD

p.T103T

103

Carcinoma

c.309C>T

Skin

25303977

ECD

p.V104I

104

Carcinoma

c.310G>A

Kidney

-

ECD

p.K106K

106

Malignant melanoma

c.318G>A

Skin

-

ECD

p.A107T

107

Carcinoma

c.319G>A

Skin

25303977

ECD

A116T

116

ADH

ECD

A116P

116

ADH

ECD

p.N118fs*6

118

Carcinoma

c.350delA

Large intestine

-

ECD

N118K

118

ADH

ECD

p.I120M

120

Carcinoma

c.360T>G

Esophagus

-

ECD

p.S122Y

122

Carcinoma

c.365C>A

Endometrium

-

ECD

p.S122Y

122

Carcinoma

c.365C>A

Endometrium

-

ECD

A124K

124

ADH

ECD

L125P

125

ADH

ECD

L125F

125

ADH

ECD

E127K

127

ADH

ECD

E127G

127

ADH

ECD

E127A

127

ADH

ECD

p.F128L

128

Carcinoma

c.382T>C

Stomach

-

ECD

F128L

128

ADH

ECD

C129Y

129

ADH

203

ECD

C129F

129

ADH

ECD

C129S

129

ADH

ECD

C129R

129

ADH

ECD

p.N130I

130

Carcinoma

c.389A>T

Large intestine

24755471

ECD

p.N130I

130

Carcinoma

c.389A>T

Large intestine

24755471

ECD

C131Y

131

ADH

ECD

C131F

131

ADH

ECD

C131W

131

ADH

ECD

p.P136L

136

Malignant melanoma

c.407C>T

Skin

26214590

ECD

S137P

137

FHH/Dominant Neg

ECD

p.T138T

138

Malignant melanoma

c.414G>A

Skin

-

ECD

T138M

138

FHH

ECD

G143R

143

FHH

ECD

G143E

143

FHH

ECD

p.G146G

146

Carcinoma

c.438C>T

Large intestine

-

ECD

p.G148D

148

Malignant melanoma

c.443G>A

NS

24265153

ECD

p.V149I

149

Carcinoma

c.445G>A

Large intestine

22810696

ECD

p.S150S

150

Malignant melanoma

c.450C>T

Skin

-

ECD

T151M

151

ADH

ECD

T151R

151

ADH

ECD

G158R

158

FHH

ECD

L159P

159

FHH
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ECD

Y161C

161

FHH

ECD

p.I162M

162

Carcinoma

c.486T>G

Large intestine

-

ECD

p.P163S

163

Carcinoma

c.487C>T

Lung

-

ECD

p.P163S

163

Malignant melanoma

c.487C>T

Skin

-

ECD

P163R

163

FHH

ECD

Q164X

164

FHH

ECD

V165del/fsX1
88

165

FHH

ECD

S166G

166

FHH

ECD

p.S169F

169

Malignant melanoma

c.506C>T

Skin

22842228

ECD

p.S171G

171

Carcinoma

c.511A>G

Lung

-

ECD

S171N

171

FHH

ECD

p.R172K

172

Malignant melanoma

c.515G>A

Skin

22842228

ECD

R172G

172

FHH

ECD

L173P

173

FHH

ECD

L174R

174

FHH

ECD

p.N176N

176

Carcinoma

c.528C>T

Lung

-

ECD

N178D

178

FHH

ECD

F180C

180

FHH

ECD

p.S182T

182

Carcinoma

c.544T>A

Lung

22510280

ECD

p.F183Y

183

Carcinoma

c.548T>A

Lung

-

ECD

p.L184F

184

Malignant melanoma

c.550C>T

Skin

-

ECD

p.R185*

185

Malignant melanoma

c.553C>T

Skin

-
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ECD

p.R185Q

185

Malignant melanoma

c.554G>A

Skin

-

ECD

p.R185Q

185

Carcinoma

c.554G>A

Skin

25759019

ECD

R185X

185

FHH

ECD

R185Q

185

FHH and Dominant
Negative

ECD

p.T186T

186

Carcinoma

c.558C>A

Lung

20505728

ECD

p.E191E

191

Ewings sarcoma

c.573G>A

Bone

25186949

ECD

E191K

191

ADH

ECD

A194T

194

FHH

ECD

p.A196T

196

Malignant melanoma

c.586G>A

Skin

26286987

ECD

p.M197I

197

Malignant melanoma

c.591G>A

Skin

-

ECD

p.A198V

198

Other

c.593C>T

Liver

-

ECD

p.A198V

198

Other

c.593C>T

Liver

-

ECD

p.D199N

199

Malignant melanoma

c.595G>A

Skin

24838835

ECD

p.D199H

199

Carcinoma

c.595G>C

Lung

22941189

ECD

p.I200I

200

Malignant melanoma

c.600C>T

NS

23890154

ECD

p.I201I

201

Carcinoma

c.603C>T

Endometrium

-

ECD

p.F204F

204

Malignant melanoma

c.612C>T

Skin

26343386

ECD

p.F204F

204

Malignant melanoma

c.612C>T

Skin

26286987

ECD

p.F204F

204

Malignant melanoma

c.612C>T

Skin

26286987

ECD

p.F204F

204

Malignant melanoma

c.612C>T

Skin

26286987

ECD

p.F204F

204

Malignant melanoma

c.612C>T

Skin

26286987

ECD

p.R205C

205

Carcinoma

c.613C>T

Endometrium

-
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ECD

p.R205C

205

Carcinoma

c.613C>T

Liver

-

ECD

p.R205C

205

Carcinoma

c.613C>T

Liver

-

ECD

p.R205C

205

Lymphoid neoplasm

c.613C>T

Hematopoietic
and lymphoid

-

ECD

p.R205H

205

Carcinoma

c.614G>A

Stomach

-

ECD

p.R205L

205

Carcinoma

c.614G>T

Esophagus

26873401

ECD

p.R205R

205

Carcinoma

c.615C>T

Esophagus

26873401

ECD

p.W206*

206

Malignant melanoma

c.617G>A

Skin

-

ECD

W208S

208

FHH

ECD

I212S

212

FHH

ECD

I212T

212

FHH

ECD

D215G

215

FHH

ECD

p.D216N

216

Malignant melanoma

c.646G>A

Soft tissue

26168399

ECD

p.D216D

216

Glioma

c.648C>T

Central nervous
system

-

ECD

p.D216D

216

Carcinoma

c.648C>T

Endometrium

-

ECD

p.D216D

216

Glioma

c.648C>T

Central nervous
system

23917401

ECD

p.D216D

216

Carcinoma

c.648C>T

Stomach

-

ECD

p.D217G

217

Pulmonary blastoma

c.650A>G

Pleura

24909177

ECD

Y218S

218

FHH

ECD

Y218C

218

FHH

ECD

p.R220W

220

Malignant melanoma

c.658C>T

Skin

22842228

ECD

p.R220W

220

Carcinoma

c.658C>T

Upper
aerodigestive
tract

27693639
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ECD

p.R220Q

220

Carcinoma

c.659G>A

Breast

22722193

ECD

R220W

220

FHH

ECD

R220P

220

FHH

ECD

R220Q

220

FHH

ECD

P221L

221

ADH

ECD

P221Q

221

FHH

ECD

P221S

221

FHH

ECD

p.G222G

222

Malignant melanoma

c.666G>A

Skin

26286987

ECD

p.G222G

222

Malignant melanoma

c.666G>A

Skin

26286987

ECD

p.G222G

222

Malignant melanoma

c.666G>A

Skin

26286987

ECD

p.G222G

222

Malignant melanoma

c.666G>A

Skin

26286987

ECD

p.I223fs*34

223

Carcinoma

c.663delG

Large intestine

-

ECD

K225T

225

FHH

ECD

p.F226F

226

Malignant melanoma

c.678C>T

Skin

-

ECD

p.F226F

226

Malignant melanoma

c.678C>T

Skin

-

ECD

p.F226F

226

Malignant melanoma

c.678C>T

Skin

26214590

ECD

p.R227*

227

Carcinoma

c.679C>T

Endometrium

-

ECD

p.R227*

227

Malignant melanoma

c.679C>T

Skin

22842228

ECD

p.R227*

227

Carcinoma

c.679C>T

Stomach

-

ECD

p.R227*

227

Carcinoma

c.679C>T

Large intestine

25344691

ECD

p.R227*

227

Malignant melanoma

c.679C>T

Skin

26343386

ECD

p.R227Q

227

Carcinoma

c.680G>A

Lung

22980975

208

ECD

p.R227Q

227

Malignant melanoma

c.680G>A

NS

23890154

ECD

R227Q

227

FHH

ECD

R227L

227

FHH/Dominant Neg

ECD

E228Q

228

ADH

ECD

E228K

228

ADH

ECD

p.E232K

232

Malignant melanoma

c.694G>A

Skin

22842228

ECD

p.E232G

232

Carcinoma

c.695A>G

Endometrium

-

ECD

p.R233R

233

Malignant melanoma

c.699G>A

Skin

-

ECD

p.I237I

237

Carcinoma

c.711C>T

Large intestine

25344691

ECD

p.E241V

241

Carcinoma

c.722A>T

Liver

-

ECD

E241K

241

ADH

ECD

p.S244F

244

Malignant melanoma

c.731C>T

Skin

-

ECD

p.S244F

244

Carcinoma

c.731C>T

Skin

25303977

ECD

p.Q245K

245

Malignant melanoma

c.733C>A

Skin

-

ECD

p.Q245Q

245

Carcinoma

c.735G>A

Large intestine

22810696

ECD

Q245R

245

ADH

ECD

p.D248N

248

Carcinoma

c.742G>A

Urinary tract

-

ECD

p.D248H

248

Carcinoma

c.742G>C

Urinary tract

-

ECD

p.D248H

248

Malignant melanoma

c.742G>C

Soft tissue

26168399

ECD

E250K

250

FHH

ECD

p.E251E

251

Malignant melanoma

c.753G>A

Skin

26214590

ECD

p.T263M

263

Carcinoma

c.788C>T

Liver

-

209

ECD

p.T263M

263

Carcinoma

c.788C>T

Liver

25822088

ECD

T263M

263

FHH

ECD

p.A264T

264

Carcinoma

c.790G>A

Prostate

26000489

ECD

p.I267I

267

Malignant melanoma

c.801C>T

Skin

21499247

ECD

p.I267I

267

Malignant melanoma

c.801C>T

Skin

-

ECD

p.I267I

267

Malignant melanoma

c.801C>T

Skin

-

ECD

V268del/fsX2
73

268

FHH

ECD

p.F270L

270

Carcinoma

c.808T>C

Liver

-

ECD

p.F270L

270

Carcinoma

c.808T>C

Liver

-

ECD

p.F270L

270

Carcinoma

c.808T>C

Liver

25822088

ECD

S271F

271

FHH

ECD

P274S

274

FHH/Polymorphisms

ECD

p.D275N

275

NS

c.823G>A

NS

22722201

ECD

p.L276F

276

Malignant melanoma

c.826C>T

Skin

-

ECD

p.P278L

278

Carcinoma

c.833C>T

Skin

25303977

ECD

p.E282E

282

Malignant melanoma

c.846G>A

Skin

-

ECD

p.E282D

282

Carcinoma

c.846G>C

Cervix

-

ECD

I283T

283

FHH

ECD

p.R285R

285

Carcinoma

c.853C>A

Stomach

-

ECD

p.R285W

285

Carcinoma

c.853C>T

Endometrium

-

ECD

R285W

285

FHH/Polymorphisms

ECD

p.R286C

286

Lymphoid neoplasm

c.856C>T

Hematopoietic
and lymphoid

23415222

210

ECD

p.R286C

286

Carcinoma

c.856C>T

Biliary tract

-

ECD

p.I288I

288

Malignant melanoma

c.864C>T

Skin

-

ECD

p.T289T

289

Carcinoma

c.867G>T

Prostate

-

ECD

p.G290S

290

Malignant melanoma

c.868G>A

Skin

-

ECD

p.G290S

290

Carcinoma

c.868G>A

Skin

25303977

ECD

A295T

295

FHH

ECD

p.S296R

296

Malignant melanoma

c.886A>C

Skin

-

ECD

S296N

296

FHH

ECD

E297D

297

ADH

ECD

E297K

297

FHH

ECD

p.A300T

300

Carcinoma

c.898G>A

Skin

25759019

ECD

p.A300A

300

Glioma

c.900C>T

Central nervous
system

-

ECD

p.A300A

300

Glioma

c.900C>T

Central nervous
system

23917401

ECD

p.S302F

302

Carcinoma

c.905C>T

Upper
aerodigestive
tract

25275298

ECD

p.S303F

303

Malignant melanoma

c.908C>T

Skin

-

ECD

p.S303F

303

Malignant melanoma

c.908C>T

NS

23890154

ECD

p.S303S

303

Malignant melanoma

c.909C>T

Skin

26343386

ECD

p.I305I

305

Carcinoma

c.915C>T

Endometrium

-

ECD

p.F311V

311

Other

c.931T>G

Thyroid

-

ECD

p.G316S

316

Adenoma

c.946G>A

Prostate

23265383

ECD

p.F320I

320

Carcinoma

c.958T>A

Esophagus

26873401

211

ECD

p.F320F

320

Carcinoma

c.960C>T

Breast

-

ECD

p.F320F

320

Malignant melanoma

c.960C>T

Skin

-

ECD

p.F320F

320

Malignant melanoma

c.960C>T

Skin

-

ECD

p.F320F

320

Malignant melanoma

c.960C>T

Skin

-

ECD

p.F320F

320

Ewings sarcoma

c.960C>T

Bone

25186949

ECD

p.F320F

320

Malignant melanoma

c.960C>T

Skin

-

ECD

p.F320F

320

Malignant melanoma

c.960C>T

Skin

26214590

ECD

p.A321T

321

Carcinoma

c.961G>A

Lung

22980975

ECD

A321P

321

FHH

ECD

K323X

323

FHH

ECD

p.A324T

324

Carcinoma

c.970G>A

Skin

25303977

ECD

p.G325R

325

Carcinoma

c.973G>A

Kidney

-

ECD

p.I327I

327

Malignant melanoma

c.981C>T

Skin

-

ECD

p.G329S

329

Malignant melanoma

c.985G>A

Skin

-

ECD

p.R331W

331

Carcinoma

c.991C>T

Large intestine

22895193

ECD

p.R331R

331

Malignant melanoma

c.993G>A

Skin

-

ECD

p.E332K

332

Malignant melanoma

c.994G>A

Skin

26214590

ECD

p.E332K

332

Malignant melanoma

c.994G>A

Skin

26343386

ECD

p.E332K

332

Carcinoma

c.994G>A

Skin

25759019

ECD

p.L334P

334

Carcinoma

c.1001T>C

Stomach

24816253

ECD

K335_V337d
el

335

FHH

ECD

P339T

339

FHH

212

ECD

p.R340R

340

Malignant melanoma

c.1020G>A

Skin

-

ECD

p.R340R

340

Malignant melanoma

c.1020G>A

Skin

-

ECD

p.R340S

340

Carcinoma

c.1020G>T

Lung

22980975

ECD

p.S342F

342

Malignant melanoma

c.1025C>T

Skin

-

ECD

p.H344L

344

Carcinoma

c.1031A>T

Breast

-

ECD

p.E350K

350

Malignant melanoma

c.1048G>A

Skin

-

ECD

p.E350K

350

Carcinoma

c.1048G>A

Skin

25303977

ECD

p.E350K

350

Malignant melanoma

c.1048G>A

NS

24265153

ECD

p.E350K

350

Carcinoma

c.1048G>A

Skin

25759019

ECD

p.E350V

350

Carcinoma

c.1049A>T

Lung

-

ECD

F351V

351

FHH

ECD

p.W352fs*6

352

Carcinoma

c.1050_1051
insT

Large intestine

24755471

ECD

W352X

352

FHH

ECD

p.E353K

353

Malignant melanoma

c.1057G>A

Skin

-

ECD

p.E353K

353

Malignant melanoma

c.1057G>A

Skin

26214590

ECD

E354A

354

ADH

ECD

p.E362K

362

Malignant melanoma

c.1084G>A

Skin

-

ECD

p.G366R

366

Malignant melanoma

c.1096G>A

Skin

-

ECD

p.G376D

376

Carcinoma

c.1127G>A

Liver

-

ECD

p.E378K

378

Malignant melanoma

c.1132G>A

Skin

22842228

ECD

p.E378K

378

Carcinoma

c.1132G>A

Skin

25303977

ECD

p.E378K

378

Malignant melanoma

c.1132G>A

Skin

26214590
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ECD

p.E378K

378

Lymphoid neoplasm

c.1132G>A

Hematopoietic
and lymphoid

24531327

ECD

p.E379K

379

Malignant melanoma

c.1135G>A

Skin

-

ECD

p.G381V

381

Carcinoma

c.1142G>T

Prostate

26000489

ECD

p.G381G

381

Adenoma

c.1143C>T

Large intestine

23204322

ECD

p.G381G

381

Carcinoma

c.1143C>T

Large intestine

25957691

ECD

p.G381G

381

Carcinoma

c.1143C>T

Large intestine

25957691

ECD

p.D382N

382

Malignant melanoma

c.1144G>A

NS

24265153

ECD

p.S385R

385

Carcinoma

c.1155C>A

Breast

-

ECD

p.S387N

387

Malignant melanoma

c.1160G>A

Skin

-

ECD

p.S388*

388

Carcinoma

c.1163C>A

Large intestine

24755471

ECD

p.S388L

388

Malignant melanoma

c.1163C>T

Skin

-

ECD

p.S388L

388

Carcinoma

c.1163C>T

Large intestine

24755471

ECD

p.A390V

390

Malignant melanoma

c.1169C>T

Skin

22842228

ECD

p.R392*

392

Carcinoma

c.1174C>T

Ovary

-

ECD

p.R392*

392

Carcinoma

c.1174C>T

Stomach

-

ECD

p.R392*

392

Carcinoma

c.1174C>T

Stomach

-

ECD

p.R392Q

392

Malignant melanoma

c.1175G>A

Skin

-

ECD

p.R392Q

392

Carcinoma

c.1175G>A

Stomach

-

ECD

R392X

392

FHH

ECD

p.P393S

393

Malignant melanoma

c.1177C>T

Skin

-

ECD

p.P393L

393

Malignant melanoma

c.1178C>T

Skin

-

ECD

p.C395F

395

Lymphoid neoplasm

c.1184G>T

Hematopoietic
and lymphoid

26608593
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ECD

C395R

395

FHH

ECD

G397R

397

FHH

ECD

p.E399D

399

Malignant melanoma

c.1197G>C

Soft tissue

26168399

ECD

p.V404V

404

Carcinoma

c.1212C>T

Endometrium

-

ECD

p.V404V

404

Malignant melanoma

c.1212C>T

Skin

-

ECD

p.V404V

404

Malignant melanoma

c.1212C>T

Skin

-

ECD

p.T406>?

406

Carcinoma

c.1218_1219
CC>AG

Lung

22980975

ECD

p.R415W

415

Carcinoma

c.1243C>T

Endometrium

-

ECD

p.S417F

417

Malignant melanoma

c.1250C>T

Skin

-

ECD

N419S

419

ADH

ECD

A423K

423

FHH

ECD

p.V424I

424

Carcinoma

c.1270G>A

Stomach

-

ECD

I427S

427

FHH

ECD

p.H429Y

429

Ewings sarcoma

c.1285C>T

Bone

25186949

ECD

p.H429H

429

Carcinoma

c.1287C>T

Large intestine

25344691

ECD

p.A430T

430

Carcinoma

c.1288G>A

Large intestine

-

ECD

p.Q432*

432

Carcinoma

c.1294C>T

Stomach

-

ECD

D433H

433

FHH

ECD

p.Y435F

435

Ewings sarcoma

c.1304A>T

Bone

25186949

ECD

p.P439T

439

Glioma

c.1315C>A

Central nervous
system

-

ECD

p.G440E

440

Carcinoma

c.1319G>A

Skin

25303977

ECD

p.R441fs*21

441

Carcinoma

c.1318delG

Lung

22980975
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ECD

p.L443I

443

Carcinoma

c.1327C>A

Lung

22980975

ECD

T445A

445

FHH/Polymorphisms

ECD

p.G447D

447

Carcinoma

c.1340G>A

Large intestine

22895193

ECD

p.G447G

447

Carcinoma

c.1341C>T

Endometrium

-

ECD

p.S448S

448

Malignant melanoma

c.1344C>T

Skin

-

ECD

p.E456K

456

Malignant melanoma

c.1366G>A

Skin

-

ECD

p.A457V

457

Carcinoma

c.1370C>T

Pancreas

-

ECD

p.A457V

457

Carcinoma

c.1370C>T

Pancreas

-

ECD

p.A457A

457

Carcinoma

c.1371G>A

Large intestine

24755471

ECD

p.R465W

465

Carcinoma

c.1393C>T

Prostate

22722839

ECD

R465W

465

FHH

ECD

R465Q

465

FHH

ECD

p.G474V

474

Carcinoma

c.1421G>T

Lung

23856246

ECD

p.G474G

474

Carcinoma

c.1422G>A

Skin

25303977

ECD

p.E475fs*3

475

Carcinoma

c.1419delG

Large intestine

25344691

ECD

p.E475K

475

Carcinoma

c.1423G>A

Breast

22722193

ECD

p.E475D

475

Carcinoma

c.1425G>C

Ovary

21720365

ECD

V477A

477

FHH

ECD

p.L485L

485

Carcinoma

c.1455G>C

Urinary tract

-

ECD

p.V486E

486

Malignant melanoma

c.1457T>A

Soft tissue

26168399

ECD

p.G487G

487

Malignant melanoma

c.1461G>A

Skin

-

ECD

p.S490F

490

Malignant melanoma

c.1469C>T

Skin

-

216

ECD

p.I491V

491

Carcinoma

c.1471A>G

Liver

-

ECD

p.P498L

498

Malignant melanoma

c.1493C>T

Skin

22842228

ECD

p.D500N

500

Malignant melanoma

c.1498G>A

Skin

-

ECD

p.I503I

503

Malignant melanoma

c.1509C>T

Skin

-

ECD

p.I503I

503

Malignant melanoma

c.1509C>T

Skin

-

ECD

p.G509G

509

Carcinoma

c.1527G>A

Lung

22941188

ECD

G509R

509

FHH

ECD

p.V513I

513

Carcinoma

c.1537G>A

Large intestine

22810696

ECD

p.G518E

518

Malignant melanoma

c.1553G>A

Skin

-

ECD

p.I528I

528

Malignant melanoma

c.1584C>T

Skin

-

ECD

W530G

530

FHH

ECD

p.R535K

535

Carcinoma

c.1604G>A

Breast

-

ECD

p.R535M

535

Carcinoma

c.1604G>T

Large intestine

-

ECD

p.R535M

535

Carcinoma

c.1604G>T

Skin

25303977

ECD

p.P538H

538

Other

c.1613C>A

Liver

-

ECD

p.D545Y

545

Carcinoma

c.1633G>T

Large intestine

23856246

ECD

p.D545Y

545

Carcinoma

c.1633G>T

Large intestine

24755471

ECD

p.D545Y

545

Carcinoma

c.1633G>T

Large intestine

24755471

ECD

p.D545Y

545

Carcinoma

c.1633G>T

Large intestine

24755471

ECD

G549R

549

FHH

ECD

p.T550T

550

Carcinoma

c.1650C>T

Skin

25303977

ECD

p.R551K

551

Malignant melanoma

c.1652G>A

Skin

-
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ECD

R551K

551

FHH

ECD

G553R

553

FHH

ECD

I555V

555

FHH

ECD

E556K

556

ADH

ECD

p.G557E

557

Carcinoma

ECD

G557E

557

FHH

ECD

p.E558K

558

ECD

p.E558*

ECD

c.1670_1671
GG>AA

Skin

25303977

Malignant melanoma

c.1672G>A

Skin

24838835

558

Carcinoma

c.1672G>T

Lung

22980975

p.E558G

558

Carcinoma

c.1673A>G

Large intestine

25344691

ECD

p.E558E

558

Malignant melanoma

c.1674G>A

Skin

26286987

ECD

p.E558E

558

Malignant melanoma

c.1674G>A

Skin

26286987

ECD

p.E558E

558

Malignant melanoma

c.1674G>A

Skin

26286987

ECD

p.P559A

559

Carcinoma

c.1675C>G

Large intestine

25344691

ECD

C562Y

562

FHH

ECD

p.E564K

564

Malignant melanoma

c.1690G>A

Skin

-

ECD

p.E564G

564

Carcinoma

c.1691A>G

Large intestine

25344691

ECD

p.C565R

565

Carcinoma

c.1693T>C

Liver

-

ECD

p.C565R

565

Carcinoma

c.1693T>C

Liver

-

ECD

C565G

565

FHH

ECD

C568Y

568

FHH

ECD

p.P569S

569

Malignant melanoma

c.1705C>T

Skin

-

ECD

p.P569L

569

Malignant melanoma

c.1706C>T

Skin

-
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ECD

p.G571E

571

Malignant melanoma

c.1712G>A

NS

23890154

ECD

p.G571G

571

Malignant melanoma

c.1713G>A

Skin

-

ECD

p.E572V

572

Malignant melanoma

c.1715A>T

Skin

-

ECD

Y573X

573

FHH

ECD

p.D575N

575

Malignant melanoma

c.1723G>A

Skin

-

ECD

p.D578N

578

Carcinoma

c.1732G>A

Skin

25303977

ECD

p.A581A

581

Carcinoma

c.1743C>T

Skin

25303977

ECD

C582Y

582

FHH

ECD

C582F

582

FHH

ECD

p.N583D

583

Malignant melanoma

c.1747A>G

Skin

-

ECD

N583X

583

FHH

ECD

p.C585F

585

Carcinoma

c.1754G>T

Ovary

-

ECD

F589L

589

ADH

ECD

p.W590fs*37

590

Carcinoma

c.1769delG

Large intestine

25344691

ECD

S591C

591

FHH

ECD

H595Y

595

FHH

ECD

p.S597S

597

Malignant melanoma

c.1791C>T

Skin

26214590

ECD

p.K601K

601

Malignant melanoma

c.1803G>A

Skin

-

ECD

p.E602D

602

Carcinoma

c.1806G>C

Lung

22980975

ECD

p.I603T

603

Carcinoma

c.1808T>C

Lung

-

ECD

p.I603I

603

Malignant melanoma

c.1809C>T

Skin

-

ECD

p.E604K

604

Glioma

c.1810G>A

Central nervous
system

-
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ECD

E604K

604

ADH

ECD

S607X

607

FHH

ECD

p.T609T

609

Malignant melanoma

c.1827G>A

Skin

-

ECD

p.E610K

610

Adenoma

c.1828G>A

Prostate

23265383

ECD

p.E610K

610

Malignant melanoma

c.1828G>A

Skin

22842228

ECD

p.E610K

610

Malignant melanoma

c.1828G>A

Skin

-

ECD

p.E610E

610

Malignant melanoma

c.1830G>A

Skin

-

ECD

E610G

610

ADH

ECD

F612S

612

ADH

TMD

p.G613R

613

Malignant melanoma

c.1837G>A

Skin

22842228

TMD

p.G613E

613

Carcinoma

c.1838_1839
GG>AA

Skin

25303977

TMD

p.G613G

613

Malignant melanoma

c.1839G>A

Skin

26343386

TMD

p.I614I

614

Malignant melanoma

c.1842C>T

Skin

-

TMD

p.I614I

614

Malignant melanoma

c.1842C>T

Skin

-

TMD

p.I614I

614

Malignant melanoma

c.1842C>T

NS

23890154

TMD

p.A615T

615

Osteosarcoma

c.1843G>A

Bone

25512523

TMD

L616V

616

ADH

TMD

p.L618F

618

Malignant melanoma

c.1852C>T

Skin

-

TMD

p.L618F

618

Carcinoma

c.1852C>T

Liver

-

TMD

p.L618F

618

Carcinoma

c.1852C>T

Liver

25822088

TMD

p.F619S

619

Malignant melanoma

c.1856T>C

Skin

-

TMD

p.F619S

619

Malignant melanoma

c.1856T>C

Skin

-
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TMD

p.V621fs*6

621

Carcinoma

c.1861delG

Large intestine

-

TMD

p.V621M

621

Hematopoietic neoplasm

c.1861G>A

Hematopoietic
and lymphoid

21909114

TMD

p.V621M

621

Glioma

c.1861G>A

Central nervous
system

24140581

TMD

G623D

623

FHH

TMD

p.F625F

625

Malignant melanoma

c.1875C>T

Skin

-

TMD

p.F625F

625

Malignant melanoma

c.1875C>T

Skin

-

TMD

p.F625F

625

Malignant melanoma

c.1875C>T

Skin

-

ICL

p.F637F

637

Carcinoma

c.1911C>T

Endometrium

-

ICL

p.F637F

637

Malignant melanoma

c.1911C>T

Skin

-

ICL

p.R638C

638

Malignant melanoma

c.1912C>T

Skin

-

ICL

p.R638C

638

Carcinoma

c.1912C>T

Large intestine

-

ICL

R638L

638

FHH

ICL

p.N639K

639

Carcinoma

c.1917C>A

Breast

-

ICL

p.V643I

643

Carcinoma

c.1927G>A

Prostate

-

ICL

p.V643A

643

Malignant melanoma

c.1928T>C

Skin

22842228

ICL

R648X

648

FHH

ICL

p.E649Q

649

Carcinoma

c.1945G>C

Ovary

-

TMD

L650P

650

FHH

TMD

p.L653F

653

Carcinoma

c.1957C>T

Large intestine

22895193

TMD

p.L654L

654

Malignant melanoma

c.1962C>T

Skin

-

TMD

p.L655H

655

Carcinoma

c.1964T>A

Kidney

23856246

TMD

S657Y

657

FHH
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TMD

C661Y

661

FHH

TMD

p.S665F

665

Carcinoma

c.1994C>T

TMD

p.S665F

665

Carcinoma

c.1994C>T

TMD

L666ins/fsX7
07

666

FHH

TMD

L666P

666

FHH

TMD

p.I669I

669

Carcinoma

c.2007C>T

Large intestine

22810696

TMD

p.G670W

670

Carcinoma

c.2008G>T

Prostate

-

TMD

G670E

670

FHH

TMD

G670R

670

FHH

ECL

p.E671K

671

Carcinoma

c.2011G>A

Skin

-

ECL

p.P672T

672

Carcinoma

c.2014C>A

Lung

-

ECL

p.W675*

675

Malignant melanoma

c.2024G>A

Skin

-

ECL

p.W675*

675

Carcinoma

c.2024G>A

Skin

25303977

ECL

p.R678H

678

Carcinoma

c.2033G>A

Ovary

21720365

ECL

p.L679M

679

Carcinoma

c.2035C>A

Endometrium

-

ECL

R680H

680

FHH

ECL

R680C

680

FHH

ECL

Q681H

681

ADH

TMD

p.P682L

682

Carcinoma

c.2045C>T

Large intestine

-

TMD

p.A683V

683

Malignant melanoma

c.2048C>T

Skin

22842228

TMD

p.G685D

685

Malignant melanoma

c.2054G>A

Skin

-

Upper
aerodigestive
tract
Upper
aerodigestive
tract

-

24292195
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TMD

I686V

686

ADH

TMD

p.S687G

687

Carcinoma

c.2059A>G

Stomach

-

TMD

p.F688F

688

Malignant melanoma

c.2064C>T

Skin

-

TMD

p.F688F

688

Malignant melanoma

c.2064C>T

Skin

-

TMD

p.V689M

689

Carcinoma

c.2065G>A

Large intestine

-

TMD

V689M

689

FHH

TMD

p.L690F

690

Carcinoma

c.2068C>T

Stomach

-

TMD

p.L696L

696

Carcinoma

c.2086C>T

Lung

22980975

TMD

p.N700S

700

Malignant melanoma

c.2099A>G

Skin

22842228

ICL

p.N700N

700

Malignant melanoma

c.2100C>T

Skin

-

ICL

p.R701C

701

Malignant melanoma

c.2101C>T

Skin

-

ICL

p.R701L

701

Carcinoma

c.2102G>T

Endometrium

-

ICL

p.A708A

708

Carcinoma

c.2124C>A

Lung

-

ICL

p.K709N

709

Carcinoma

c.2127G>T

Stomach

-

ICL

p.T712I

712

Carcinoma

c.2135C>T

Kidney

-

ICL

W718X

718

FHH

ICL

p.W719C

719

Carcinoma

c.2157G>C

Liver

-

ICL

p.G720R

720

Malignant melanoma

c.2158G>A

Skin

-

ICL

p.G720G

720

Malignant melanoma

c.2160G>A

Skin

-

ICL

p.L723M

723

Carcinoma

c.2167C>A

Breast

-

TMD

p.F725F

725

Carcinoma

c.2175C>T

Large intestine

-

TMD

p.F725F

725

Malignant melanoma

c.2175C>T

Skin

-
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TMD

p.L726L

726

Carcinoma

c.2178G>A

Endometrium

-

TMD

L727Q

727

ADH

TMD

V728I

728

FHH

TMD

p.T732A

732

Carcinoma

c.2194A>G

Breast

-

TMD

p.F733F

733

Malignant melanoma

c.2199C>T

Skin

-

TMD

M734R

734

FHH

TMD

p.I738I

738

Carcinoma

c.2214C>A

Endometrium

-

TMD

W742R

742

FHH

ECL

p.A746A

746

Carcinoma

c.2238G>A

Stomach

-

ECL

p.P747L

747

Malignant melanoma

c.2240C>T

Skin

-

ECL

P747ins/fsX7
76

747

FHH

ECL

p.P748S

748

Malignant melanoma

c.2242C>T

Skin

-

ECL

P748L

748

FHH

ECL

P748H

748

FHH

ECL

P748R

748

FHH

ECL

p.S749fs*28

749

Carcinoma

c.2244delG

Large intestine

-

ECL

p.Y751C

751

Carcinoma

c.2252A>G

Pancreas

26806338

ECL

p.R752H

752

Carcinoma

c.2255G>A

Prostate

26000489

ECL

E755D

755

FHH/Polymorphisms

ECL

p.I760I

760

Malignant melanoma

c.2280C>T

Skin

-

ECL

p.I760I

760

Malignant melanoma

c.2280C>T

Skin

-

ECL

p.I761S

761

Malignant melanoma

c.2282T>G

Skin

22622578

224

ECL

I761del

761

FHH

ECL

p.I763F

763

Carcinoma

ECL

C765W

765

FHH

ECL

p.E767K

767

ECL

p.E767K

ECL

c.2287A>T

Lung

22510280

Carcinoma

c.2299G>A

Endometrium

-

767

Carcinoma

c.2299G>A

Cervix

-

E767K

767

ADH

TMD

p.A772T

772

Malignant melanoma

c.2314G>A

Skin

24838835

TMD

p.A772A

772

Carcinoma

c.2316C>T

Lung

22980975

TMD

L773R

773

ADH

TMD

p.F775F

775

Malignant melanoma

c.2325C>T

Skin

-

TMD

p.I777I

777

Glioma

c.2331C>T

Central nervous
system

-

TMD

F788C

778

ADH

TMD

G778D

778

FHH

TMD

p.T780T

780

Malignant melanoma

c.2340C>A

Soft tissue

26168399

TMD

p.L782L

782

Carcinoma

c.2346G>A

Large intestine

24755471

TMD

p.A784S

784

Carcinoma

c.2350G>T

Cervix

-

TMD

p.I786I

786

Carcinoma

c.2358C>A

Biliary tract

-

TMD

p.I786M

786

Carcinoma

c.2358C>G

Esophagus

26873401

TMD

p.F788Y

788

Carcinoma

c.2363T>A

Kidney

-

TMD

F788L

788

TMD

p.A791D

791

Carcinoma

c.2372C>A

Upper
aerodigestive
tract

-

225

ICL

p.R795Q

795

Carcinoma

c.2384G>A

Endometrium

-

ICL

R795del/fsX8
36

795

FHH

ICL

R795W

795

FHH/Dominant Neg

ICL

p.K796*

796

Malignant melanoma

c.2386A>T

Skin

-

ICL

p.P798L

798

Glioma

c.2393C>T

Central nervous
system

-

ICL

p.P798L

798

Carcinoma

c.2393C>T

Esophagus

-

ICL

P798T

798

FHH

ICL

p.E799K

799

Malignant melanoma

c.2395G>A

Skin

-

ICL

E799K

799

ADH

ICL

p.N800N

800

Carcinoma

c.2400C>T

Pancreas

-

ICL

N802I

802

ADH

ICL

p.A804A

804

Carcinoma

c.2412C>A

Stomach

24308032

ICL

A804D

804

FHH

TMD

F806S

806

ADH

TMD

p.I807T

807

Adenoma

c.2420T>C

Small intestine

26806338

TMD

p.T808A

808

Carcinoma

c.2422A>G

Breast

-

TMD

F809L

809

FHH

TMD

M811V

811

ADH

TMD

p.I813V

813

Carcinoma

c.2437A>G

Endometrium

-

TMD

p.I816I

816

Malignant melanoma

c.2448C>T

Skin

-

TMD

p.V817I

817

Glioma

c.2449G>A

Central nervous
system

-

TMD

p.V817I

817

Malignant melanoma

c.2449G>A

NS

24265153

226

TMD

V817I

817

FHH

TMD

p.W818L

818

Carcinoma

c.2453G>T

Prostate

-

TMD

p.S820F

820

Malignant melanoma

c.2459C>T

Skin

-

TMD

S820F

820

ADH

TMD

F821L

821

ADH

TMD

p.P823S

823

Malignant melanoma

c.2467C>T

Skin

-

TMD

p.A824T

824

Carcinoma

c.2470G>A

Large intestine

-

TMD

p.A824A

824

Malignant melanoma

c.2472C>T

Skin

-

TMD

A824S

824

ADH

TMD

A826T

826

FHH/Polymorphisms

TMD

T828N

828

ADH

ECL

p.G830D

830

Carcinoma

c.2489G>A

Endometrium

22923510

ECL

G830S

830

ADH

ECL

F832L

830

ADH

ECL

F832S

832

ADH

ECL

S834del/fsX8
36

834

FHH

ECL

A835T

835

ADH

ECL

p.V836I

836

Malignant melanoma

c.2506G>A

Skin

-

ECL

V836L

836

ADH

TMD

A843E

843

ADH

TMD

A844T

844

ADH

TMD

S845N

845

ADH

227

TMD

L849P

849

FHH

TMD

p.A850V

850

Carcinoma

TMD

A850ins/fsX9
81

850

FHH

TMD

p.C851G

851

Malignant melanoma

TMD

C851S

851

FHH/Polymorphisms

TMD

p.K856K

856

ICD

p.P864S

ICD

c.2549C>T

Large intestine

22895193

c.2551T>G

Skin

-

Malignant melanoma

c.2568G>A

Skin

-

864

Carcinoma

c.2590C>T

Kidney

25401301

p.P864L

864

Carcinoma

c.2591C>T

Skin

25303977

ICD

p.R866H

866

Carcinoma

c.2597G>A

Large intestine

24755471

ICD

p.E870K

870

Carcinoma

c.2608G>A

Breast

22722193

ICD

p.E870E

870

Carcinoma

c.2610G>A

Lung

22980975

ICD

p.E871K

871

Malignant melanoma

c.2611G>A

Skin

-

ICD

p.E871E

871

Malignant melanoma

c.2613G>A

Skin

26214590

ICD

p.R873C

873

Carcinoma

c.2617C>T

Lung

22941188

ICD

p.R873H

873

Carcinoma

c.2618G>A

Large intestine

25344691

ICD

p.R873H

873

Carcinoma

c.2618G>A

Large intestine

24755471

ICD

p.T876T

876

Carcinoma

c.2628C>T

Large intestine

24755471

ICD

T876 Alu ins

876

FHH

ICD

p.H879Y

879

Malignant melanoma

c.2635C>T

Skin

26343386

ICD

p.A880T

880

Carcinoma

c.2638G>A

Endometrium

-

ICD

p.F881F

881

Malignant melanoma

c.2643C>T

Skin

-

ICD

F881L

881

FHH/Dominant Neg

228

ICD

p.A884V

884

Malignant melanoma

c.2651C>T

NS

23890154

ICD

p.R886W

886

Glioma

c.2656C>T

Central nervous
system

-

ICD

p.R886Q

886

Carcinoma

c.2657G>A

Breast

-

ICD

R886W

886

FHH

ICD

R886P

886

FHH

ICD

p.A887V

887

Carcinoma

c.2660C>T

Lung

22941189

ICD

p.T888T

888

Malignant melanoma

c.2664G>T

Soft tissue

26168399

ICD

p.R890C

890

Carcinoma

c.2668C>T

Ovary

-

ICD

p.R890H

890

Carcinoma

c.2669G>A

Stomach

-

ICD

p.R890R

890

Carcinoma

c.2670C>T

Lung

-

ICD

p.R891G

891

Carcinoma

c.2671C>G

Lung

-

ICD

p.R891H

891

Carcinoma

c.2672G>A

Endometrium

-

ICD

p.R891P

891

Carcinoma

c.2672G>C

Lung

-

ICD

p.N893N

893

Carcinoma

c.2679C>T

Large intestine

24755471

ICD

p.V894I

894

Carcinoma

c.2680G>A

Breast

-

ICD

p.V894V

894

Malignant melanoma

c.2682C>T

Skin

-

ICD

p.S895S

895

Malignant melanoma

c.2685C>T

Skin

26343386

ICD

S895V1075del

895

ADH

ICD

p.R896C

896

Carcinoma

c.2686C>T

Large intestine

-

ICD

R896H

896

FHH

ICD

K897ins/fsX9
79

897

ADH

ICD

p.R898W

898

Carcinoma

c.2692C>T

Large intestine

25344691
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ICD

p.R898Q

898

Carcinoma

c.2693G>A

Lung

22980975

ICD

p.R898R

898

Carcinoma

c.2694G>T

Lung

-

ICD

R898Q

898

ADH

ICD

p.L902V

902

Carcinoma

c.2704C>G

Lung

-

ICD

p.G903R

903

Malignant melanoma

c.2707G>A

Skin

-

ICD

p.G907E

907

Malignant melanoma

c.2720G>A

Skin

-

ICD

p.P910T

910

Carcinoma

c.2728C>A

Endometrium

-

ICD

p.S911fs*28

911

Carcinoma

c.2726delC

Large intestine

-

ICD

p.S911fs*28

911

Carcinoma

c.2726delC

Large intestine

25344691

ICD

p.S911fs*28

911

Carcinoma

c.2726delC

Large intestine

24755471

ICD

p.S912F

912

Malignant melanoma

c.2735C>T

Skin

22842228

ICD

p.S912F

912

Carcinoma

c.2735C>T

Skin

25303977

ICD

p.P923L

923

Carcinoma

c.2767_2768
CC>TT

Skin

21984974

ICD

p.P923L

923

Carcinoma

c.2768C>T

Large intestine

-

ICD

p.Q926Q

926

Glioma

c.2778G>A

Central nervous
system

-

ICD

Q926R

926

FHH

ICD

p.P927P

927

Carcinoma

c.2781C>T

Large intestine

22810696

ICD

Q930del/fsX9
38

930

ADH

ICD

p.P935S

935

Carcinoma

c.2803C>T

Large intestine

-

ICD

p.P935S

935

Carcinoma

c.2803C>T

Biliary tract

-

ICD

p.P935L

935

Carcinoma

c.2804C>T

Large intestine

-

ICD

p.Q940K

940

Carcinoma

c.2818C>A

Skin

25303977
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ICD

E942K

942

ADH

ICD

p.R955Q

955

Malignant melanoma

c.2864G>A

Skin

22842228

ICD

p.R955Q

955

Lymphoid neoplasm

c.2864G>A

Hematopoietic
and lymphoid

26189108

ICD

p.R955Q

955

Carcinoma

c.2864G>A

Large intestine

-

ICD

p.R955L

955

Malignant melanoma

c.2864G>T

Soft tissue

26168399

ICD

p.Q958L

958

Carcinoma

c.2873A>T

Stomach

23525077

ICD

p.R961K

961

Carcinoma

c.2882G>A

Lung

22980975

ICD

p.I967V

967

Carcinoma

c.2899A>G

Liver

-

ICD

p.S970S

970

Carcinoma

c.2910C>T

Prostate

22722839

ICD

p.S970S

970

Carcinoma

c.2910C>T

Stomach

25042771

ICD

p.G971S

971

Carcinoma

c.2911G>A

Esophagus

-

ICD

p.G971S

971

Carcinoma

c.2911G>A

Stomach

-

ICD

p.T972M

972

Carcinoma

c.2915C>T

Stomach

-

ICD

p.T974T

974

Malignant melanoma

c.2922C>T

Skin

-

ICD

p.F979S

979

Carcinoma

c.2936T>C

Endometrium

-

ICD

p.D980H

980

Carcinoma

c.2938G>C

Lung

-

ICD

p.Q983E

983

Carcinoma

c.2947C>G

Breast

-

ICD

p.Q983R

983

Carcinoma

c.2948A>G

Large intestine

25344691

ICD

A986S

986

FHH/Polymorphisms

ICD

A988V

988

ADH

ICD

A988G

988

ADH

ICD

p.R990R

990

Malignant melanoma

c.2970G>A

Skin

-
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ICD

p.R990R

990

Malignant melanoma

c.2970G>A

Skin

-

ICD

p.R990R

990

Malignant melanoma

c.2970G>A

NS

23890154

ICD

p.R990R

990

Malignant melanoma

c.2970G>A

Skin

26343386

ICD

R990G

990

ADH/Polymorphisms

ICD

p.N991S

991

Carcinoma

c.2972A>G

Skin

25303977

ICD

p.T993M

993

Carcinoma

c.2978C>T

Esophagus

25839328

ICD

p.T993M

993

Carcinoma

c.2978C>T

Biliary tract

-

ICD

H994Y

994

ADH

ICD

p.S997F

997

Carcinoma

c.2990C>T

Skin

25303977

ICD

p.S997S

997

Malignant melanoma

c.2991C>T

Skin

21499247

ICD

p.S997S

997

Malignant melanoma

c.2991C>T

Skin

-

ICD

D1005N

1005

FHH

ICD

p.T1006M

1006

Carcinoma

c.3017C>T

Large intestine

24755471

ICD

p.T1006M

1006

Carcinoma

c.3017C>T

Esophagus

26873401

ICD

Q1011E

1011

FHH/Polymorphisms

ICD

p.P1015L

1015

Carcinoma

c.3044C>T

Endometrium

-

ICD

p.C1018C

1018

Carcinoma

c.3054C>T

Large intestine

-

ICD

p.E1020K

1020

Malignant melanoma

c.3058G>A

Skin

-

ICD

p.D1022N

1022

Malignant melanoma

c.3064G>A

Skin

-

ICD

p.L1025M

1025

Glioma

c.3073C>A

Central nervous
system

-

ICD

p.T1026T

1026

Carcinoma

c.3078C>T

Stomach

-

ICD

p.V1027I

1027

Osteosarcoma

c.3079G>A

Bone

25512523
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ICD

p.E1029K

1029

Malignant melanoma

c.3085G>A

NS

23890154

ICD

p.L1032R

1032

Carcinoma

c.3095T>G

Lung

22980975

ICD

p.G1034E

1034

Malignant melanoma

c.3101G>A

Skin

-

ICD

p.R1041W

1041

Carcinoma

c.3121C>T

Ovary

21720365

ICD

p.R1041W

1041

Adenoma

c.3121C>T

Prostate

23265383

ICD

p.R1041W

1041

Carcinoma

c.3121C>T

Prostate

22502944

ICD

p.R1041Q

1041

Carcinoma

c.3122G>A

Prostate

26000489

ICD

p.P1042L

1042

Malignant melanoma

c.3125C>T

NS

23890154

ICD

p.V1044V

1044

Malignant melanoma

c.3132G>A

Skin

-

ICD

p.E1045K

1045

Carcinoma

c.3133G>A

Liver

-

ICD

p.E1045K

1045

Carcinoma

c.3133G>A

Liver

25822088

ICD

p.E1048*

1048

Carcinoma

c.3142G>T

Small intestine

27900363

ICD

p.L1050*

1050

Carcinoma

c.3149T>A

Stomach

22037554

ICD

p.S1051P

1051

Carcinoma

c.3151T>C

Large intestine

-

ICD

p.P1052S

1052

Malignant melanoma

c.3154C>T

Skin

-

ICD

p.V1056M

1056

Carcinoma

c.3166G>A

Large intestine

23856246

ICD

p.V1056M

1056

Carcinoma

c.3166G>A

Large intestine

24755471

ICD

p.S1061G

1061

Carcinoma

c.3181A>G

Liver

-

ICD

p.V1063A

1063

Carcinoma

c.3188T>C

Large intestine

22895193

ICD

p.G1066R

1066

Carcinoma

c.3196G>C

Urinary tract

-

ICD

p.G1066D

1066

Carcinoma

c.3197G>A

Upper
aerodigestive
tract

26934577

ICD

p.S1069N

1069

Carcinoma

c.3206G>A

Large intestine

25344691
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ICD

p.N1074N

1074

Glioma

c.3222C>T

Central nervous
system

-

ICD

p.V1076V

1076

Malignant melanoma

c.3228G>A

Skin

-

ICD

p.N1077D

1077

Carcinoma

c.3229A>G

Lung

22980975

ICD

X1079QextX
1087

1079

FHH

ICD

p.?

Carcinoma

c.13781G>T

Large intestine

25344691

ICD

p.?

Carcinoma

c.17331G>C

ICD

p.?

Carcinoma

c.17331G>C

ICD

p.?

Lymphoid neoplasm

c.186-1G>A

Upper
aerodigestive
tract
Upper
aerodigestive
tract
Hematopoietic
and lymphoid

21798897

23619168
26437031

ECD – Extracellular domain (dark purple), TMD – Transmembrane domain (brown), ICD –
Intracellular domain (red), ECL – Extracellular loops (light purple), ICL – Intracellular loops
(pink), AA – Amino acids, FHH – Familial hypocalciuric hypercalcemia or NSHPT mutations
(cyan), ADH – Autosomal dominant hypocalcemia mutations (magenta), COSMIC cancer
missense mutations (light blue) and non-missense mutations (dark blue). No data in gray.

PCR of CaSR Mutations
To begin in making the disease mutation of bCaSR and hCaSR we designed the primers for the
mutations we were interested in creating (Figure 3.5). Our CaSR structure competitor did many
mutations previously for the analysis of their binding site locations. The Geng et al. mutations are
as follows; for the dimerization site L159P, W458A, R172G, D215G, R227L, R551K, and
G557E[284]. For the binding Sites, T145I, S147A, S170A, Y218S, E297K, I81M, T100I, N102I,
R66H, R69E, and S417L[284]. We have also analyzed S170, Y218, E297 for the TNCA/proposed
Ca2+ binding site I pocket, as well as now looking into I81M for the Mg2+ binding site I pocket .
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Figure 8.3– CaSR disease mutations for ECD.
Green are mutations already done previously. Purple are planned mutations and if
they have disease relevance they are noted in parentheses.

Initially we made these mutations with the noted Tm based on previous primer design methods.
After running PCR there were little to no colonies after transformation into Dh5α. The colonies
that did present were not correct once amplified using miniprep and run for sequencing. We
investigated further how to optimize the primer design. We found that primers should be between
14-28 bp long, the previous primers are too long since the previous method was 25-45 bp. The
GC content should be 40-60%, ideally around 50% GC. The Tm should be between 55-65°C,
where the previous protocol was a Tm ≥ 78°C . Therefore, the primers were redesigned to meet
these parameters for our planned mutation sites (Figure 3.5).
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Of the new primers ordered all had colony growth on their plates this time around. All of these
PCR were done using the pfu kit for PCR. There seems to be a double band pattern showing for
all the samples in the DNA gel. After running sequencing, we confirmed that the reason was that
the samples were contaminated with template DNA as all the sequencing matched the template
and no mutations were successful. Next time the DNA needs to be treated with newly ordered
PNK in order to remove the template DNA before running the DNA gel and doing miniprep, since
the old PNK seems to be expired. We repeated the PCR again exactly as before, but all samples
were either too low of a concentration to sequence or the sequence had no mutation present.
Further, repeated with only 5 mutations to simplify the protocol and using the KOD Hot Start that
others use. For those 5 mutations, all of them had colonies on their plates to did miniprep and sent
to sequencing. Again, the mutations either did not have enough DNA sample or no mutation was
seen. With the lack of successful mutations once again, we turned to different primer approach of
not having the primers be complementary. Since complementary primers have a higher risk of
binding to each other instead of the parent DNA leading to a failed PCR reaction .
Initially we just did 5 mutations with the new primers to keep it simple; R69L (Anion site), I81M
(FHH Mg2+ top site), E228Q (ADH Dimer Site), E241K (ADH Dimer Site), D275N (Hinge Site).
First did phosphorylation of primers using T4 PNK. Then did PCR using pfu DNA polymerase
protocol with 20 ng/µL of CaSR pcDNA at 30 cycles with an 8.5 minute extension time. After
PCR did DpnI parent DNA digestion followed by transformation into XL10 Gold competent cells
using 20 µL of PCR product. The next day only 1 plate grew colonies out of 5. So, we repeated
mutation on D275N and R69L, for D275N did 4 different temperatures than before. Initially did
Ta of 60.8°C for D275N and this time did 65, 55, 50, and 45°C. For R69L did one at 50°C versus
55°C before.

Same protocol as before besides temperature change.

Additionally, did
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transformation with 2 µL and 20 µL of PCR product to see which was most effective. Still no
correct mutations after doing miniprep and sequencing on these colonies. Also saw no apparent
difference in using 2 or 20 µL of PCR product for transformation, will continue to use 2 µL for
saving of product and reduction of salts.
Since the new primers saw no success, we decided to go back to the last time we were able to get
a successful point mutation on CaSR pcDNA to look at the protocol differences. Back then we
used KOD DNA polymerase versus pfu DNA polymerase and the primers we used were around
35-45 bp long. So, we decided to look up which polymerase is better for larger plasmids such as
CaSR pcDNA which is 8662 bp long. In the PCR paper by Munteanu et al. has a comparison of
pfu and KOD Hot Start DNA Polymerase on large plasmids for site-directed mutagenesis[411].
Their plasmid total size to test which is better is 16 kbp, which is relevant to our CaSR mutagenesis
since the CaSR plasmid is 6.8 kb for bCaSR and 8.7 kb for hCaSR. Pfu DNA polymerase can do
up to 10 kb but loses efficacy the larger the plasmid, while KOD can do up to 21 kb plasmids.
They found that KOD was able to give results at just 8 cycles of PCR, with more cycles up to 30
give even better results. Pfu, on the other hand, was unable to give results for their large plasmid.
Table 8.2 – hCaSR disease mutation primers designed.
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They also referenced a 2009 paper by Laible and Boonrod for primer design[412]. This paper
recommends primers of 25-45 bp with more than 40% GC content where the primer ends in a G
or C on both ends.
We used this method of primer design to design new primers to continue the mutations of CaSR
pcDNA using KOD DNA polymerase (Table 8.2). Next, we choose 3 mutations to initially try
these primers and the KOD DNA polymerase technique; S272A (hinge site), D275N (hinge site),
and E297D (hinge site, ADH). We did two temperatures for each primer with one being the
temperature listed on the IDT primer sheets and the other being 5 degrees lower than the T m.
Phosphorylation of primers using T4 PNK as before per protocol. Then we did PCR using KOD
DNA Polymerase following their protocol which has 5 µL of 10x KOD buffer, 5 µL of 1x 2 mM
dNTPs each, 5 µL of 10 mM MgCl2, 30.6 µL filtered water, 1.5 µL of 10 µM Sense (5’) Primer
(5 pmol/µL), 1.5 µL of 10 µM Antisense (3’) Primer (5 pmol/µL), 1 µL of 200 ng/ µL template
DNA, and 0.4 µL of KOD DNA polymerase (2.5 U/µL) with a total volume of 50 µL. Then we
did thermocycling conditions per the KOD protocol slightly increased to 30 cycles for the larger
plasmid size.
After PCR we did DpnI parent DNA digestion using 0.5 µL DpnI enzyme and 5 µM cutsmart
buffer added directly to PCR product and incubated at 37°C for 1 hour then heat inactivated at
80°C for 20 mins. Finally, we took 2 µL of the PCR product for transformation into XL10 Gold
cells. We were able to get 18 colonies on the 6 plates and used those for miniprep and sent the
DNA for sequencing. So far for hCaSR S272A, E297K, and R66H have been successfully cloned.
Unfortunately, our microscope was having issues, so we temporarily switched gears to bCaSR
mutations while the microscope was being repaired. We designed the bCaSR primers using the
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same method we had found to be successful for the hCaSR mutations and ordered them as outlined
in Table 8.3.
Table 8.3 – bCaSR ECD disease mutation primers designed.

We made mutations for bCaSR so far of R66H (Anion/pH for FHH), D216N (Anion/pH for
disrupt/cancer), E241K (Dimer for ADH), S272A (Hinge Mg for disruption), E297K (Hinge for
FHH/NSHPT), H254A (pH for disrupt), E228Q (Dimer for ADH), and E228K (Dimer for ADH),
these mutations were successfully made using the primers in Table 8.3 and the KOD DNA
Polymerase protocol as described earlier. For large plasmids we have found KOD works
effectually but for smaller plasmids pfu works more efficiently.
The successful mutations made for bCaSR and hCaSR are outlined in Table 3.1, where planned
mutations to be made indicated in the third column in black, successfully made hCaSR mutations
are shown in blue, made bCaSR mutations are in red, and mutations made for hCaSR and bCaSR
are in green.
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Previously the mutations have been unsuccessful but with research we found the correct primer
formation and PCR protocols to successfully produce bCaSR and hCaSR mutants. Using the
correct DNA polymerase for the size of the plasmid and protein for site-directed mutagenesis is
critical. Although the primers and protocol are optimized this does not necessitate that the
mutations will effectively work during PCR. There are many factors influencing primers and PCR,
most notably temperature, cycles of run, and primer design. Thus, looking at alternative reasons
and going back to protocols when we were successful is key. By doing this we have found out the
KOD DNA polymerase is better for larger plasmids and that primer design can also matter for
plasmid size. Using the new primers and KOD polymerase resulted in a successful mutation.
We were able to PCR three mutations for hCaSR and bCaSR of E297K (FHH), S272A, R66H
(FHH). With the maintenance of our epifluorescence microscope for almost a year we focused on
bCaSR mutation binding assays. We were able to purify each mutant and the WT for bCaSR,
although R66H both times had such a low concentration of protein through purification that
binding studies were not possible. The WT bCaSR and E297K and S272A mutants went forward
with binding studies. We first optimized our binding study protocols where we did not utilize
EGTA since the Ca2+ present was negligible and adding EGTA can lead to saturation or pH
changes. Also increasing the amount of titration added from 1-2 µL to ~4 µL helped to
significantly reduce error, by keeping the volume closer to 4-5 µL we can also reduce dilution
effects of the bCaSR.
These tables outline the primers and mutations as well as the results for our CaSR mutations and
the Geng at al. mutations for comparison of mutations made and the results (Table 8.4-Table 8.5).
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Table 8.4 – bCaSR and hCaSR ECD disease mutations and primers made.
Disease Mutations (bCaSR/hCaSR/primers to be
Binding Sites
Binding Residues
PCR)
New Site

I81, S84, L87, L88,
L91

TNCA Site

S147, A168, S170,
Y218, E297

Hinge Site

A214, D216, Y218,
S272, D275

FHH/NSHPT: I81M
Disruption: S84A
FHH/NSHPT: Y218S, Y218C, E297K (reduced bCaSR
expression)
Disruption: Y218K (loss of all function), Y218Q
(reduced activity), E297I (loss of all function)
Disruption: S272I (loss of all function), D275I (loss of
all function), S272A (LOF Ca2+ binding Trp and loss of
cooperativity and LOF Tb3+/Trp)
Cancer: D275N
FHH/NSHPT: R66C, R66H (loss of bCaSR expression)

Anion Site

Dimer Site

pH/pKa
Effects

R66, R69, W70,
R415, I416, S417

E228, E229, E231,
E232, S240, E241

N/A

Disruption: R69L
ADH: E228Q (loss of bCaSR expression), E228K (loss
of bCaSR expression), E241K (reduced bCaSR
expression)
Disruption: E224I (to be tested), E228I (reduced Mg
function TNCA recovers)
Disrupt pH/pKa: R69L, D215I (to be tested), D215G
(FHH), H254A (reduced bCaSR expression), S296A
Cancer: D216N (LOF of Ca2+ Trp binding), S296A

Geng et al. showed that Trp acts as agonist shifting EC50 to 1 mM IP1 accumulation and that at
higher Ca2+ higher Trp induced Ca2+ release with 2.5 mM being much higher than 0.5 and 1.5 mM
showing that basal Ca2+ first activates similar to what we observed with TNCA. Geng et al. showed
that Trp induces oscillation in the presence of 1.5 mM Ca2+ at 2-20 mM Trp. They also showed
that SO4 leads to less sensitive CaSR to [Ca2+]o from 2.2 to 2.7 mM for IP1 accumulation.
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Table 8.5 –hCaSR ECD disease mutation made by Geng et al. and observations.
Binding
Geng et al Mutations (hCaSR) (WT IP1 100% & EC50 1.5 mM
Binding Sites
Residues
and [Ca2+]i oscillation EC50 1.6 mM) (LOF = loss of function)
New Site

I81, S84, L87,
L88, L91

FHH/NSHPT: I81M ([Ca2+]i oscillation EC50 2.5 mM and IP1
20% & EC50 2.5 mM)

TNCA Site

S147, A168,
S170, Y218,
E297

FHH/NSHPT: Y218S (IP1 20% & EC50 4.5 mM), E297K (IP1 10%
& EC50 5.5 mM)
Disruption: S170A (IP1 LOF 0% & EC50 none), S147A (IP1 LOF
50% & EC50 5 mM)

Hinge Site

A214, D216,
Y218, S272,
D275

FHH/NSHPT: Y218S (IP1 20% & EC50 4.5 mM)

Anion Site

R66, R69,
W70, R415,
I416, S417

FHH/NSHPT: R66H (40% IP1 & EC50 4.5 mM and [Ca2+]i
oscillation EC50 4 mM)
Disruption: R69E (LOF 20% IP1 & EC50 3.5 mM and [Ca2+]i
oscillation EC50 4 mM) and S417L (LOF 10% IP1 & EC50 4.5
mM and [Ca2+]i oscillation EC50 2.5 mM).

Dimer Site

E228, E229,
E231, E232,
S240, E241

FHH/cancer: G557E (lower dimer Ca2+ site, IP1 85% & EC50
3.2 mM, [Ca2+]i oscillation EC50 3 mM LOF), R227L (IP1 75% &
EC50 5 mM)

pH/pKa
Effects

N/A

FHH/NSHPT: D215G (dimer interface LOF IP1 50% & EC50 5.5
mM)
FHH/NSHPT: L159P (IP1 50% & EC50 4 mM), R172G (IP1 60%
& EC50 4 mM), R551K (IP1 80% & EC50 4 mM)

Homodimer
Interface
Internal
Inactive Ca2+
site
Glycosylation
Mutations

Disruption: W458A (LOF IP1 50% & EC50 2.3 mM)
T100, N102,
T145, G146

FHH/NSHPT: T100I (LOF IP1 0% & EC50 1 mM)
Disruption: T145I (IP1 LOF 20% & EC50 4.2 mM), N102I (LOF
[Ca2+]i oscillation EC50 3.1 mM and IP1 25% & EC50 4 mM)
N386Q, S402N and/or N468Q says does not change IP1
function
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Perifusion Drug Treatment Over Small Volume Diffusion Method
Since the ATP ΔF change for Cos-7, and other cell lines, was relatively weaker than other drugs
such as 4-cmc and CPA we wanted to investigate different methods of adding the drug as well as
increasing concentrations. So, in and we tried three different methods. First, 100 μM ATP small
volume addition which is 60 µL of 1.25 mM ATP added on to cells, 200 μM ATP perifusion large
volume, and lastly 5 mM perifusion of ATP. There is a low response, around 10-20%, to the small
volume 100 μM ATP and a similar response to 200 μM ATP perifusion large volume, but there
was a much greater response to 5 mM perifusion of ATP, around 25-30%. In we replaced the 200
μM ATP perifusion with 2.5 mM ATP perifusion, but unfortunately the signal constantly decreases
the whole trial telling us the cells were not good and therefore null. The next three dishes were
done just with the 100 μM ATP small volume and then with 5 mM ATP perifusion in order to
compare the differences between the concentrations (Figure 8.4). Doing this technique, over 10
dishes, we were able to see that the small volume addition of 60 µL of 1.25 mM ATP only caused
a release of around 5-15% whereas the 5 mM ATP perifusion led to a 25-35% release. Thus using
0.5-5 mM perifusion would be more ideal for future trials in order to see the release better for
analysis and then we would know if the recovery curve was from true change as opposed to a
reaction to diffusion of the small volume technique as previously used. This perifusion technique
can be used for future cell imaging experiments.
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Figure 8.4 -CatchER+ in Cos-7 cells small volume versus perifusion systems.
Cos-7 cells transfected with CatchER+ are treated with 100 μM small volume (sv)
ATP at 60 uL of 1.25 mM ATP then washed with buffer. Next the cells are treated
with perifusion of 3-5 mL large volume (lv) of 5 mM ATP to mimic the concentrations
actually added using sv of ≥1.25 mM then washed with buffer.

The results were repeated in C2C12 myoblast cells but some of the cells had issues compared to
the previous results where they elicited no response, this is probably due to do the perifusion
method of 200 μM 4-cmc over the small volume method which adds a small amount of higher
concentrated compound (2-100 µL of ~1-20 mM) depending on the volume adding and the volume
of the chamber estimating the amount being added directly on the cells can be anywhere from 120 mM in actuality. This is further confirmed by the fact the doing perifusion large volume method
elicited almost no response compared to the concentrated small volume method, for what should
be the same ending concentration of 200 μM 4-cmc. When the small volume method was returned,
we see a typical response of between 15-35% change. Based on our previous epifluorescence test
of ATP perifusion concentrations we just need to increase the perifusion concentration to see the
same response as the small volume since the actual concentration being added to the cells in much
higher before diffusion.
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Neuron Imaging
We were able to image one transfected neuron with CatchER+ and 3 dishes with transfected glial
cells. Since we were not initially experienced in identifying neurons, we often accidentally
imaged glial cells that we thought were neurons but weren’t. The neuron we circled the soma
(center) versus dendrites (extended parts) to compare the signaling difference between the two
since the ER spans the soma and dendrites but being so far translocated might respond differently.
We circled both soma and full dendrites to observe if there were any differences in the ER signaling
in the different regions. We did see a difference between the soma and dendrites here, but multiple
trials need to be performed with multiple compounds and control to confirm if results are true.
Initially we used DHPG an mGluR1/5 agonist which activates ER Ca2+ release through the IP3R,
the decrease in response was seen after addition of DHPG with the soma being slower than the
dendrites to respond with about a 10-20% release, much higher then what we see for ATP release
of around 5-15%.
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Figure 8.5 – CatchER+ in mouse hippocampal neurons.
Top – 50 μM DHPG and 200 μM of 4-cmc was added to initiate a release of Ca2+ from
the ER through the IP3R/mGluR1 and RyR, respectively. Bottom – Min/Max of
neurons. 0.005% saponin was added to permeabalize the cells, followed by 1 mM
EGTA with 10 μM ionomycin (min) and 100 mM – 2M Ca2+ with 10 μM ionomycin
(max). Far Right – Neuron at 488 nM excitation showing CatchER+, the same cell
showing circles of soma and dendrites, overlay of 550 nm and 488 nm, and then bright
field.
We also tested 4-cmc for comparison to our other CatchER+ imaging, and then min/max at the end
to try and get a basal Ca2+ level for calibration. The 4-cmc response was similar to 4-cmc release
in other cell types with around 20-30% release. The soma was able to recover the max signal past
the baseline for the min/max experiment while the dendrites were not able to achieve a maximum
signal higher than the basal signal indicating a high starting Ca2+ concentration in neurons.The
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glial cells responded similarly to other cell lines in response to 4-cmc and min/max, with the basal
Ca2+ levels still being much higher than other cell lines. This could be because the cells were too
stressed after 2 drugs and permeabilization to achieve a maximum signal, or it could be because
the ER basal Ca2+ levels in glial cells and neurons are substantially higher. More studies need to
be done to confirm.
A second batch of neurons was plated and transfected with CatchER+ for 9 dishes, and then one
dish was transfected with GFP as a control. We decided to do 4 trials with 50 μM DHPG wash
and 200 μM 4-cmc and the other 5 trials with 15 μM CPA and then 10 mM Caffeine all done in
the basal media that the neurons are cultured in to prevent shock of Ringer’s buffer.
Unfortunately, this time the soma and dendrites did not respond differentially like in the previous
neuron imaging we did. We were able to better identify neurons though, so no glial cells were
imaged and only neurons. The response to the 50 μM DHPG was very small and in some cases
negligible with the average being 5-10% release (Figure 8.6). 4-cmc release shows a very quick
response for release in 0-10 seconds releasing 25-35% (Figure 8.6). Initially, the release of CPA
and Caffeine seemed very large, but after subtracting the background there was no change at all.
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Figure 8.6 – CatchER+ in mouse hippocampal neurons.
A – 50 μM DHPG (blue), 200 μM of 4-cmc (red) was added to initiate a release of Ca2+
from the ER through the IP3R/mGluR1 and RyR, respectively. The neurons were
washed between with neurobasal medium (black) to equilibrate. B – 15 μM CPA
(green), and 10 mM Caffeine (purple) was added to initiate a release of Ca2+ from the
ER through inhibiting SERCA pump and activating the IP3R/mGluR1, respectively.
The neurons were washed between with neurobasal medium (black) to equilibrate.

We noticed when doing the imaging there was a high background coming from the basal media
where the background and dendrite fluorescence intensity were both near 20,000 and soma was
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40,000-60,000. This led to not being able to visualize the dendrite signal and barely being able to
differentiate the soma signal. The GFP transfected neuron was done also with 50 μM DHPG, 200
μM 4-cmc, 15 μM CPA, and 10 mM Caffeine in basal media the whole time (Figure 8.7).

Figure 8.7 – GFP in mouse hippocampal neurons.
A&B – 50 μM DHPG (blue), 200 μM of 4-cmc (red), 15 μM CPA (green), and 10 mM
Caffeine (purple) was added to initiate a release of Ca2+ from the ER through the
IP3R/mGluR1 and RyR, SERCA pump, and IP3R, respectively. The neurons were
washed between with neurobasal medium (black) to equilibrate. Data is shown as
raw (A) or normalized with background signal subtracted (B).
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It was during this trial that the background fluorescence was very apparent because while there
was no change in fluorescence with DHPG and 4-cmc additions there was a change in fluorescence
in CPA and Caffeine responses (Figure 8.7). This led us to see that the basal media was
contributing to the background fluorescence and causing false results. This led us to further
investigate the reason for this background fluorescence in the basal media (NEUROBASAL
medium, ThermoFisher Cat# 21103049) and what buffers others use for cell imaging neurons. We
found an article by Samtleben et al. which specifically talking about imaging ER Ca2+ in
hippocampal neurons[413]. They use a buffer called artificial cerebrospinal fluid buffer (ACSF) for
their imaging[413]. When we consulted with Dr. Mabb on using this buffer she said that the lab she
was in previously had used an ACSF buffer they called E4 (124 mM NaCl, 3 mM KCl, 1.8 mM
CaCl2, 2 mM MgCl2, 10 mM HEPES, 10 mM D-Glucose, pH=7.4). The basal media has many
components needed for growth several of which could be contributing to the fluorescence at 488
nm, most notably riboflavin which is excitable at 488 nm (Table 8.6).
Table 8.6 – Components of NEUROBASAL medium.
Components

Concentration (mM)

Glycine

0.4

L-Alanine

0.02247191

L-Arginine hydrochloride

0.39810428

L-Asparagine-H2O

0.005533333

L-Cysteine

0.2603306

L-Histidine hydrochloride-H2O

0.2

L-Isoleucine

0.8015267
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L-Leucine

0.8015267

L-Lysine hydrochloride

0.7978142

L-Methionine

0.20134228

L-Phenylalanine

0.4

L-Proline

0.06747826

L-Serine

0.4

L-Threonine

0.79831934

L-Tryptophan

0.078431375

L-Tyrosine

0.39779004

L-Valine

0.8034188

Choline chloride

0.028571429

D-Calcium pantothenate

0.008385744

Folic Acid

0.009070295

Niacinamide

0.032786883

Pyridoxal hydrochloride

0.019607844

Riboflavin

0.00106383

Thiamine hydrochloride

0.011869436

Vitamin B12

5.02E-06

i-Inositol

0.04

Calcium Chloride (CaCl2) (anhyd.)

1.8018018

Ferric Nitrate (Fe(NO3)3"9H2O)

2.48E-04

Magnesium Chloride (anhydrous)

0.8136842
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Potassium Chloride (KCl)

5.3333335

Sodium Bicarbonate (NaHCO3)

26.190475

Sodium Chloride (NaCl)

51.724136

Sodium Phosphate monobasic (NaH2PO40.9057971
H2O)
Zinc sulfate (ZnSO4-7H2O)

6.74E-04

D-Glucose (Dextrose)
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HEPES

10.92437

Phenol Red

0.021519661

Sodium Pyruvate

0.22727273

Thus, for our next batch we decided to use the ACSF buffer over the neurobasal media for cell
imaging to prevent background fluorescence contributing to signal change disturbances. We
additionally decided to use an inline buffer heater to heat the ACSF buffer to 37°C so that the
temperature change of buffers doesn’t also affect the neurons during imaging. We received
neurons but unfortunately the plates had no viable individual transfected neurons after an hour of
searching so we used an area on the plate which had clumps of cells to test the buffer exchange
between neurobasal media and ACSF buffer to make sure the ACSF buffer didn’t affect the cell
quality and to not waste a dish of neurons for imaging (Figure 8.8). We can see upon addition of
the ACSF buffer the background fluorescence decreases dramatically but the cell quality is not
affected (Figure 8.8). Thus, we can do our future trials in ACSF without risk to the neurons.
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Figure 8.8 – ACSF buffer on mouse hippocampal neurons.
An area of neurons transfected with CatchER+ (insert left) were imaged in neurobasal
media and then washed with ACSF buffer leading to a large decrease in fluorescence
signal from the removal of background fluorescence in neurobasal media. The
decrease in background fluorescence can also be seen in cell image of ACSF buffer
(insert right) where the background is notably darker than the neurobasal media.
The next batch of neurons can be successfully done using the inline heater and ACSF buffer so we
may get concrete results and push forward on the neuron imaging with CatchER+. Simultaneously,
the development of the HILO imaging technique on CatchER+ in other cells types has been
thoroughly investigated and perfected opening up the possibility of trying neurons in the HILO
imaging methodology. Since neurons present with a vast and dynamic ER structure with differing
signaling possibly occurring throughout the neuron body and dendrites the HILO imaging system
could help to investigate microdomains of Ca2+ signaling present.
We were able to see a response to all of the compounds but had a multitude of issues which had to
be remedied until the results could be confirmed as accurate. Firstly, the neurobasal media had
fluorescent compounds in the media which excited at 488 nm, the same wavelength of CatchER+,
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and caused high background signal which disrupted the accuracy of the treatment signals. This
background fluorescence was corrected by instead utilizing ACSF media for imaging which we
showed decreases the fluorescence without disruption to neuron quality. We also used small
volume addition of the reagents and buffers instead of utilizing an inline heated perifusion system,
so we switched to that methodology for future experiments.
We were able to successfully image hippocampal neurons which were obtained from post-natal
mice using our fluorescence ER Ca2+ sensor, CatchER+, in epifluorescence, HILO, confocal, and
STORM imaging systems. We initially imaged CatchER+ in neurons on an epifluorescence 40x
Leica microscope in neurobasal media activating the ER response using 200 µM 4-cmc to activate
the RyR Ca2+ release, 50 µM DHPG or 10 mM Caffeine to activate mGluR1/5 to indirectly activate
the IP3R Ca2+ release, and lastly with 15 µM CPA to inhibit SERCA pump refilling (Figure 8.5Figure 8.7). We were able to see a response to all of these compounds but had a multitude of issues
which had to be remedied until the results could be confirmed as accurate. Firstly, the neurobasal
media had fluorescent compounds in the media which excited at 488 nm, the same wavelength of
CatchER+, and caused high background signal which disrupted the accuracy of the treatment
signals (Table 8.6). This background fluorescence was corrected by instead utilizing ACSF media
for imaging which we showed decreases the fluorescence without disruption to neuron quality
(Figure 8.8). We also used small volume addition of the reagents and buffers instead of utilizing
an inline heated perifusion system, so we switched to that methodology for future experiments.
Additionally, the resolution of our 40x objective and the overall fluorescence overlap of
epifluorescence led us to change to HILO imaging technique with a 100x objective on a Nikon
microscope in order to see micro changes throughout the neuron and be able to visualize the soma,
dendrites, and dendritic spines accurately.
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CatchER+ STORM Imaging in Neurons
In order to analyze the microdomain area differences we see through our HILO imaging and
correlate these differences to protein expression, whether it be ER or PM proteins, we needed to
be able to confirm the protein expression in these areas with the signals we are seeing. Ideally, we
would want to first image the single neuron on the HILO microscope and then treat the same
sample with fixing and antibody staining in order to see the protein expression on that same exact
neuron. We are currently optimizing the protocol in order to not only treat the same sample for
staining after HILO imaging, but also the best way to find the exact same neuron. In order to
implement this eventually optimized procedure we first needed to optimize the best staining and
imaging technique to visualize these proteins along the neuron such as mGluR1/5, IP3R, RyR
and/or CatchER+.
We have previously shown the staining and imaging of fixed cells transfected with CatchER+ using
confocal microscopy as well as direct STORM (dSTORM) imaging. Both of these techniques can
visualize the protein expression but in order to imaging staining accurately in smaller regions of
interest, such as neuron dendrites and dendritic spines, the dSTORM method will be more accurate
since the dSTORM method images based on photon by photon response as opposed to confocal
imaging the full fluorescence signal and helps to reduce the background noise over confocal
imaging. Currently our STORM imaging can only do one probe at a time, unfortunately, but the
system is being improved to include a two-color imaging system. Thus, confocal currently holds
the benefit of multicolor imaging but with lower accuracy and resolution, as well as higher S/N
ratio of STORM.
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Before optimizing the STORM imaging technique for CatchER+ in other cell types and eventually
neurons we begun imaging neurons with epifluorescence and confocal imaging (Figure 8.9).

Figure 8.9 – Confocal imaging of hippocampal neurons with mGluR1 and CatchER+.
Neurons were transfected with CatchER+ (B) and stained with mGluR1 antibody (A)
and the two signals were merged together (C&D) and then a dendritic region with
dendritic spines were enlarged (E) for further in dept visualization.

As mentioned, we are able to see the neuron soma, dendrites, and dendritic spines but the resolution
at the dendritic spine level gets more difficult to discern from background signal. We can see the
red staining of mGluR1 (Figure 8.9A), the green color of the CatchER+ transfected into the neurons
(Figure 8.9B) and the merging of these two channels to see the ER signal versus mGluR1 signal
(Figure 8.9C&D). We further zoomed in on the merge channel to a region of the dendrite with
visible dendritic spines and are able to see one spine has CatchER+ ER expression and mGluR1
expression seen by the orange color overlap of red and green in Figure 8.9E and further along the
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dendrite we see another spine with ER expression but no mGluR1 present. This implies that one
of the spines is having mGluR1 and IP3R activation present while the other spine has no mGluR1
signaling occurring since there is no expression.
We can see the dendrite and dendritic spines in Figure 8.9E but there are also background mGluR1
staining signal shown by the red points away from the dendrites. These red points could be
mGluR1 signal from other neurons not transfected with CatchER+ but is more likely just
background signal. The issue with this background signal is that the red areas are not much smaller
than the dendritic spine staining we observed and brings forth the issue of if the red signal seen in
Figure 8.9E on the left spine is true signal or background signal.
This is where the advantages of STORM imaging can come into play over confocal imaging. Since
STORM imaging is photon by photon signal from photo switchable fluorescence probes with the
brighter the photon signal being further from the background and multiple photons measured in
the same region over a length of time, we can then eliminate background signal and visualize the
true signal versus background signal.

This technique would eliminate the possibility of

background signal being interpreted as true signal.
We first tested C2C12 cells with CatchER+ using dSTORM, conjugated secondary antibody in the
lab, and the standard STORM fixing protocol which worked seamlessly (Figure 5.21). Therefore,
we attempted the same protocol on the next batch of neurons plated on the 18x18 mm slides for
STORM imaging and were able to obtain five dishes. We planned to use two dishes for control
staining with GFP primary antibody (Figure 8.10) as a control compared to CatchER+ signal, the
next dishes were one each of mGluR1 (Figure 8.11A-C), mGluR5 (Figure 8.11D-F), and IP3R
(Figure 8.12) primary antibodies.
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Figure 8.10 – STORM imaging of mouse hippocampal neurons with CatchER+.
Neurons were transfected with CatchER+ (488 nm, B&E, green) and stained with
GFP antibody (647 nm, A&D, blue and magenta). The CatchER+ signal was first
imaged using fluorescence at 488 nm and then the corresponding STORM signal was
collected at 647 nm with the merged image (C&F) where 488 nm signal is green, and
647 nm signal is magenta. All samples were done with 647 secondary antibodies
conjugated in lab (non-commercial).
The main difference in our CatchER+ STORM imaging in C2C12 cells versus our first batch of
neurons is our permeabilization method in which we utilized 0.005% saponin instead of 0.1%
Triton-X100. We first washed each dish with 1 mL of PBS once and then fixed the with 400 µL
of fixing solution (3% paraformaldehyde (PFA), 0.1% glutaraldehyde (GA) in PBS) at RT for 10
mins, no shaking. The sample is reduced with 2 mL of 0.1% NaBH4, prepared immediately before
use, and shaking for 7 mins at RT. The sample is then washed 3 times with 1.5 mL of PBS for 7
mins each time while shaking at RT. Before adding antibody, the sample is blocked using 1.5 mL
of blocking buffer (3% BSA and 0.1% Triton-X100 (0.005% saponin for neurons)) for 20 mins
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while shaking at RT. Then add 1.5 mL of primary antibody (2 ug/mL) in blocking buffer, incubate
for 30 mins at RT or O/N at 4°C (while shaking for at least 30 mins). Then wash 3 times with 1.5
mL of washing buffer (0.2% BSA and 0.05% Triton-X100 (no Triton-X100 or saponin for
neurons)) for 15 mins each time while shaking at RT.

Figure 8.11 – STORM imaging of neurons with mGluR1/5 and CatchER+.
Neurons were transfected with CatchER+ (488 nm, A&D, green) and stained with
either mGluR1 (B&C) or mGluR5 (E&F) antibody (647 nm, blue and magenta). The
CatchER+ signal was first imaged using fluorescence at 488 nm and then the
corresponding STORM signal was collected at 647 nm with the merged image (C&F)
where 488 nm signal is green, and 647 nm signal is magenta. All samples were done
with 647 secondary antibodies conjugated in lab (non-commercial).

Next, add 1.5 mL of secondary antibody (2 ug/mL) dilution in blocking buffer and incubate for 30
mins at RT while shaking and covered with foil to protect fluorophore from light. Wash 3 times
with 1.5 mL of washing buffer for 10 mins each time while shaking at RT and covered with foil
to protect fluorophore from light. Wash once with 1.5 mL of PBS for 5 mins and covered with
foil to protect fluorophore from light.
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We saw for the CatchER+ signal at 488 nm (Figure 8.10A&D) versus the GFP antibody with
secondary STORM antibody at 647 nm (Figure 8.10B&E) had almost exact overlap when merged
together (Figure 8.10C&F) showing that the STORM technique accurately stains the antibody we
are interested in observing. The mGluR1 primary antibody (Figure 8.11B) had a strong STORM
signal and when overlapped (Figure 8.11C) with the CatchER+ 488 nm signal (Figure 8.11A) we
can see that the expression of mGluR1 seems to be highly expressed throughout the ER of the
neuron. While this data may be the true signal change, we did find it unusual that there would be
such high expression.

Figure 8.12 – STORM imaging of mouse hippocampal neurons with IP3R and
CatchER+.
Neurons were transfected with CatchER+ (488 nm, A, green) and stained with IP3R
antibody (647 nm, B&C, blue and magenta). The CatchER+ signal was first imaged
using fluorescence at 488 nm and then the corresponding STORM signal was
collected at 647 nm with the merged image (C) where 488 nm signal is green, and 647
nm signal is magenta. All samples were done with 647 secondary antibodies
conjugated in lab (non-commercial).

mGluR5, on the other hand, had much lower expression when stained with primary antibody with
the STORM secondary antibody at 647 nm (Figure 8.11E) in comparison to the CatchER+ 488 nm
signal (Figure 8.11D) image and is even more apparent when merged together (Figure 8.11F).
Lastly, IP3R expression is lower similar to mGluR5 expression (Figure 8.12). The CatchER+ 488
nm image shows expected ER expression (Figure 8.12A) while the IP3R primary antibody with
secondary 647 nm antibody (Figure 8.12B) has much lighter expression as seen in the merged
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image (Figure 8.12C). These data suggests that the IP3R expression is much lower than mGluR1/5
and actually more expressed evenly throughout the dendrites and soma.
The issue we came upon with our first batch of neuronal STORM imaging was that the negative
control (not shown) had high background fluorescence for the secondary antibody even though no
primary antibody was present. We did not know if this was an issue with our permeabilization
method (0.005% saponin) or due to using in lab conjugated secondary antibody as opposed to
commercially purchased secondary antibody.
Our STORM imaging of mouse hippocampal post-natal neurons in order to correlate the protein
expression on these neurons to the responses we see in the HILO imaging are so far inconclusive.
The first batch of STORM imaging were promising but with only a small field of view and only
one color of STORM imaging available these results are not very telling in that they show that the
mGluR1/5 and IP3R proteins are present but without the dual color system as in confocal imaging
cannot quantify pertinent information (Figure 8.10-Figure 8.12). The next batch of neurons for
STORM was too confluent to see any expression of the antibodies without background disruption
and was therefore unsuccessful. Further trials of dual color STORM or confocal imaging need to
be performed so we can correlate the protein expression to the signaling response we see in
response to compound treatment.

Appendix B – ArcKR Neuron Mutation
Since we have been able to consistently get neuron imaging results using HILO microscopy, ACSF
buffer, and CatchER+ transfected using WT hippocampal neurons then we are perfectly placed to
try our methodology on mutant post-natal mouse hippocampal neurons. The activity-regulated
cytoskeleton-associated (Arc) protein is thought to be master regulator of synaptic plasticity in the
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brain as well as through regulation of endocytosis of AMPA receptors[414-418]. Arc protein synthesis
dysfunction has been shown to be a factor in such neurological disorders as Alzheimer's disease
(AD), autism, amnesia and fragile X syndrome (FXS)[419]. mGluR type I activation with DHPG to
induce long term depression (LTD) of the neuron synaptic plasticity leads to increase in Arc
translation and a decrease in postsynaptic AMPA receptors expression. Therefore, increased levels
of Arc could lead to sustained LTD. Arc is degraded by ubiquitination pathway by the K267/268
ubiquitination site, so disruption of the Arc degradation could lead to enhanced sustained LTD
upon DHPG activation of mGluR1/5. To test this hypothesis the Mabb lab designed an Arc protein
mutation at residues K268/269 to 268R (ArcKR mutant) which disrupts the ubiquitination site on
the Arc protein. This ArcKR mutant can be compared to the WT Arc for the effects on disrupted
ubiquitination on long term depression effects in hippocampal neurons. We are interested in the
effect that this mutant ArcKR will have in response to DHPG activation of mGluR1/5 and ER Ca2+
signaling differences.
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Figure 8.13 – ArcKR and WT mouse hippocampal neurons 4-cmc responses.
The response to the perifusion of 1 mM 4-cmc is shown through the ΔF/F0 plot with a
heat map of CatchER+ transfected into the mouse hippocampal neuron WT (A) and
ArcKR mutant (B). The color of the lines correspond with the regions higlighted by
boxes in the heat map.

We looked at 5 trials of WT Arc with CatchER+ with four trials being 100 μM DHPG (Figure
8.14) and one trial being 1 mM 4-cmc for a control (Figure 8.13). Then we also investigated 9
trials of ArcKR transfected with CatchER+ with eight trials being 100 μM DHPG (Figure 8.15Figure 8.16) and one trial being 1 mM 4-cmc for a control of the ER response (Figure 8.13).
The 4-cmc response between the WT and ArcKR mutant were similar with a release between 1050%, there was a slight difference in the rate of release, the ArcKR mutant seemed to reach a
plateau of signal for the lower release (~20%) whereas the WT has a more consistent decrease
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without a plateau effect seen (Figure 8.13). More trials need to be done with 4-cmc on the WT and
ArcKR mutant on the same conditions and time course to confirm these differences.

Figure 8.14 – WT mouse hippocampal neurons DHPG respresentative responses.
A-D – The response to the perifusion of 100 μM DHPG is shown through the ΔF/F0
plot with a heat map of CatchER+ transfected into the WT mouse hippocampal
neuron. The color of the lines correspond with the regions higlighted by boxes in the
heat map.

WT Arc is what all of our previous neuron trials have been under since WT Arc is naturally
occurring in the mouse hippocampal neurons. We still repeated 4 trials of WT with CatchER+
treated with 100 μM DHPG (Figure 8.14) the same day as our ArcKR mutant trials to confirm that
any signal differences between WT and ArcKR are directly correlated by the mutant of ArcKR
and not because the sample batch of neurons, mice, or CatchER+ transfection had an effect on the
signaling. We see a similar response as we have seen with 100 μM DHPG treatments in our past
experiments (Figure 8.14). The 100 μM DHPG leads to a release in Ca2+ from the ER, shown by
a decrease in the CatchER+ signal, in a majority of regions of the neuron and that some regions of
the neurons actually exhibit an increase in the ER Ca2+ response implicating an influx of Ca2+ into
the ER (Figure 8.14). Additionally, we again see the effect of the washing with ACSF buffer leads
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to the same response as DHPG as previously discussed (Figure 8.14). After the DHPG and wash
treatments the WT neurons are able to fully recover in most regions and mostly recover in the
others, rarely do we see a neuron, dendrites or dendritic spines have no recovery at all since most
have at least a partial recovery (Figure 8.14).

Figure 8.15 – ArcKR neurons DHPG responses for trials 3, 4, 6, and 8.
A-D – The response to the perifusion of 100 μM DHPG is shown through the ΔF/F0
plot with a heat map of CatchER+ transfected into the ArcKR mutant mouse
hippocampal neuron. The color of the lines correspond with the regions higlighted by
boxes in the heat map. Eight trials were done trial 3 (A), 4 (B), 6 (C), 8 (D), 9, and 1113.
We did 8 trials of ArcKR mutant mouse hippocampal neurons with CatchER+ transfection and 100
μM DHPG treatment (Figure 8.15-Figure 8.16). Only one of the trials had an obvious out of
character response and that was trial 3 (Figure 8.15A) midway through the DHPG treatment when
the sample is not being disturbed in any way with buffer or DHPG some regions the neurons saw
~20% curved release similar to what we see with 4-cmc. None of the other 7 trials saw this effect
so was probably an issue in this particular dish sample. The video of the experiment shows the
issue might be from focus changes although that would hypothetically affect all of the regions and
not just a few. Besides this outlier on some regions in trial 3 the rest of the trials were all similar

265

to each other with some similarities and differences to the WT neurons. The main similarities seen
between the WT and ArcKR experiments was, firstly, the trend we see of a release of Ca2+ from
the ER and an uptake of Ca2+ to the ER in different regions of the neurons and, secondly, the
response to DHPG and to ACSF buffer wash (Figure 8.14-Figure 8.16).

Figure 8.16 – ArcKR neurons DHPG respresentative responses for trials 9 and 11-13.
A-D – The response to the perifusion of 100 μM DHPG is shown through the ΔF/F0
plot with a heat map of CatchER+ transfected into the ArcKR mutant mouse
hippocampal neuron. The color of the lines correspond with the regions higlighted by
boxes in the heat map. Eight trials were done trial 3, 4, 6, 8, 9 (A), 11 (B), 12 (D), and
13 (C).

The most striking response difference was the lack of recovery in the ArcKR mutant neurons in
compared to the WT neurons (Figure 8.15-Figure 8.16). Where the WT neurons had a complete or
mostly complete recovery to the baseline after DHPG treatment, the ArcKR neurons only saw a
very minor recovery or a complete plateau with little to no recovery of signal. Then when the
ACSF buffer was added to wash away the DHPG the neurons were much more differential with
some of the washes having recovery to the DHPG plateau before wash or some also having little
to no recovery and leading to another signal plateau (Figure 8.15-Figure 8.16). Additionally, many
of the trials had a progressive overall decrease in signal throughout the whole experiment, this
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trend is generally not seen for the WT neurons which mostly stay flat in comparison (Figure 8.14Figure 8.16).
Further research needs to be done on mutant hippocampal neurons of interest in comparison to the
WT using CatchER+ with 50 µM and 100 µM DHPG, 4-cmc, and CPA to confirm that the DHPG
mediated mGluR1/5 activation is the cause of upregulation of Arc transcription as well as the cause
of LTD. CPA and 4-cmc can show that the ER release is not effected by Arc except from the
DHPG activation of mGluR1/5.
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